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ABSTRACT 
AIvIL1 long splice isoform regulates transcription of many hematopoietic 
specific genes and may act as both transcriptional activator and repressor. 
The AMLI short isoform which lacks the transactivation domain can bind DNA 
but is not capable of activating transcription; suggesting that it acts in a 
dominant-negative manner. Thus, if the long AMLI isoform induces 
differentiation of hematopoietic progenitors, the short isoform may promote 
their self-renewal. This hypothesis may be tested using an engineered ES 
cell differentiation system overexpressing individual AMLI isoforms. 
Therefore, we aimed here to generate ES cell lines overexpressing individual 
AIvIL1 isoforms constitutively or in a regulatable fashion in order to test 
their biological functions. Both, long and short AIv1IL1 isoforms demonstrated 
cytotoxic effect when overexpressed constitutively in ES cells. In order to 
overcome the toxicity problem, these isoforms have been expressed 
conditionally in an inducible fashion using the tetracycline gene expression 
system. Different experimental designs were tried to conditionally 
overexpress the isoforms in ES cells. Finally, the AMLI isoforms were 
targeted into the HPRT homing site of Ainvl5 ES cells which harbour both 
regulatory and responsive elements of the tetracycline gene expression 
system. Since AMLI isoforms were linked to a fluorescent EGFP reporter the 
expression of AMLI could be readily monitored following induction with 
doxycycline. Upon doxycycline induction reduction in size and number of 
undifferentiated colonies was observed that has not been associated with 
obvious apoptotic events. AMLI induction has also been initiated during the 
putative haemangioblast differentiation stage. However, no obvious deviation 
in clonogenic haematopoietic activity has been observed in induced and 
non-induced differentiating embryoid bodies. 
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Chapter 1; INTRODUCTION 
1.1. General introduction 
The AMILI/Runxl/CBFa2IPEBP2a gene was described in the t(8; 21) 
chromosomal translocation in a patient with acute Myeloid leukaemia (AML) 
(Miyoshi et al. 1991). Simultaneously, the mouse AML  protein was purified by two 
research groups independently. It was found to be capable of binding to (i) the 
polyomavirus enhancer (therefore, the protein was called PEBP2 (polyomavirus 
enhancer binding protein)) (Kamachi et al. 1990) and (ii) the core site of the 
Moloney murine leukaemia virus (MoMLV) enhancer (the protein was called CBF 
(core binding factor)) (Wang and Speck 1992). The PEBP2/CBF protein was initially 
reported to be consisted of two subunits, designated as a and 13 (Wang and Speck 
1992). The PEBP2a/CBFci subunit binds DNA, whereas PEBP2I3/CBFI3 does not 
bind DNA but significantly enhances DNA binding ability of the a subunit (Ogawa 
et al. 1993; Wang et al. 1993). The mouse PEBP2aICBFa subunit is highly 
homologous to human AML I. It contains 128 amino acid Runt domain homologous 
to Drosophila runt genes (Ogawa et al. 1993; Wang et al. 1993). It has been shown 
that the Runt domain is responsible for both DNA binding and heteromerisation 
abilities of the AML 1 protein. Later, two novel Runt homology domain containing 
genes, AML2/Runx3 and AML3/Runx2, were also described (Levanon et al. 1994; 
Wijmenga et al. 1995). They both bind DNA and heterodimerisation with the CBFI3 
protein enhances their DNA-binding ability. According to modern nomenclature, 
AML I, AML2 and AML3 constitute the Runx gene family (Westendorf and Hiebert 
1999), 
The involvement of AML1 in Ieukaemogenesis has been extensively studied 
(reviewed by Perry et al. 2002; Asou 2003). A few types of chromosomal 
translocations that involve AML I are associated with different types of leukaemia. 
The t(8; 21) translocation has been found in 10-15% of all AML cases (Bitter et al. 
1987). The t(3; 21) translocation is associated with chrome myeloid leukaemia 
(Mitani et al. 1994). The t(12; 21) translocation is common in the childhood B-cell 
leukaemia (Golub et al. 1995). The t(16; 21) translocation is associated with therapy-
related myeloid leukaemia (Gamou et al. 1998). Of note, The CBFI3 gene 
involvement in chromosomal aberrations associated with acute myeloid leukaemia 
has also been shown (Liu et al. 1993). 
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It has also been shown that AML1 plays an important role in normal 
haematopoiesis. It has been shown to be a transcription factor (Zaiman et al. 1995). 
A number of haematopoiesis related genes are targets of AML 1 (Hernandez-Munain 
and Krangel 1994; Nuchprayoon et al. 1994; Zhang et al. 1996). AIVIIL1 is an 
important regulator of haematopoietic development in embryogenesis (reviewed by 
Tracey and Speck 2000; Speck 2001). It is indispensable in embryonic generation of 
the definitive haematopoietic cells. This chapter reviews current knowledge of 
AML  biology during embryonic development and in the adult organism. 
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1.2. AML1 structure and expression 
1.2.1. The AML1 gene structure 
The AMLI gene is located on chromosome 21 in the human genome 
(Miyoshi et al. 1991; Levanon et al. 1994) and on homologous chromosome 16 in the 
mouse genome (Bae et al. 1994). It has a complex structure (see Figure 1). The 
human AML1 gene spans 260 kb (çi1oase pairs) and contains 12 exons (Levanon et 
al. 2001). Only partial data about the mouse AML 1 gene structure is available, but it 
appears to be similar to the human one (Bae et al. 1994; Telfer and Rothenberg 
2001). 12 different alternatively spliced variants of the human cDNA (Levanon et al. 
2001) and 9 variants of the mouse cDNA (Levanon et al. 1996; Telfer and 
Rothenberg 2001) have been described (see Figure 1). These alternatively spliced 
variants of the AML 1 cDNA encode a large repertoire of proteins ranging in size 
from 20 to 52 kilodaltons (Miyoshi et al. 1991; Bae et al. 1993; Bae et al. 1994; 
Zhang et al. 1997; Tsuji and Noda 2000; Fujita et al. 2001; Levanon et al. 2001; 
Telfer and Rothenberg 2001). Functional roles of individual isoforms of AML  will 
be discussed below. 
AML1 protein contains two major domains: the Runt domain and the 
transactivation (TA) domain. The Runt domain consists of 128 amino acids and is 
located in the N-terminal part of the molecule. Two functions of the Runt domain 
have been described: (i) DNA binding and (ii) heterodimerisation with the CBFI3 
protein (Ogawa et al. 1993). Crystal structure analysis of the Runt domain showed 
that it consists mostly of antiparallel 13-sheets forming a 13-barrel with an S-type 
immunoglobulin fold (Berardi et al. 1999; Nagata et al. 1999). Interestingly, several 
other transcription factors (p53, NF-icB etc.) have the same fold (reviewed by Bork et 
al. 1994; Rudolph and Gergen 2001). The TA domain is located at the C-terminus of 
the protein and presumably interacts with other transcriptional factors (Ogawa et al. 
1993; Bae et al. 1994; Miyoshi et al. 1995). 
1.2.2. Regulation of the AML1 transcription and translation 
Two different promoters (distal and proximal) drive transcription of AML 1 
(Ghozi et al. 1996). The distance between the promoters is about 160 kb in human 
genome. The length of the longest primary transcripts is 260 kb (distal transcripts) 
and 100 kb (proximal transcripts) (Levanon et al. 2001). Several polyadenylation 
signals are interspersed in the gene locus. The alternative polyadenylation signals 
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	 Fl AML1A 
Figure 1. Exon-intron structure of the AML1 gene locus and several 
alternatively splice isoforms 
The upper diagram shows the exon-intron structure of the AML 1 gene locus. The 
distal (Pd) and proximal (Pp) promoters are designated by yellow ovals. Red boxes 
represent coding regions of exons, while white boxes show untranslated regions 
(UTRs). The exons numbers are shown below the diagram. Vertical arrows designate 
polyadenylation signals. The exons 3, 4 and 5 encode the Runt domain and the exons 
7B and 8 encode the transactivation (TA) domain. The structure of the four most well 
studied AML1 isoforms is shown below the AMLI gene locus diagram. The 5' end 
part of the exon 4 is translating in all transcripts apart from AML1AN where the 
initiator ATG is located at the middle of the exon (see Chapters 1.2 and 1.6). 
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provide a mechanism for the generation of a set of transcripts of different lengths 
(Miyoshi et al. 1995). The regulation of activation and termination of the AML1 
transcription as well as the spatiotemporal pattern of proximal and distal promoter 
activities is important for understanding various aspects of the AML1 biology. 
However, this issue remains poorly investigated. Only one attempt has been made to 
investigate the role of the promoter switch in cell fate decision (Telfer and 
Rothenberg 2001). To this end the activity of the AIvILI promoters during lymphoid 
differentiation was studied. It was found that lymphoid progenitors, differentiated B-
and T-cells preferentially use the AML 1 distal promoter, whereas the switch onto the 
AML 1 proximal promoter is strongly associated with the natural killer cell fate 
decision (Telfer and Rothenberg 2001). 
The distal and proximal transcripts differ in structure and size of their 5' 
untranslated regions (UTR). 5' UTRs of the AML 1 distal transcripts are rather short 
whereas 5' proximal UTRs are very long (more than 1.6 kb), GC-rich and may form 
the stable stem-loop structures (Levanon et al. 1996). 15 ATG codons upstream of 
the initiator ATG (uATG5) were found in the proximal 5' UTR. Many of the uATGs 
were followed by a short open reading frame (ORF). These short ORFs may have an 
inhibitory influence on the initiation of translation at the downstream initiator ATG 
(Kozak 1991). Interestingly, these features are characteristic for internal ribosomal 
entry sites (IRES) (reviewed by van der Velden and Thomas 1999). Indeed, IRES 
mediated initiation of the proximal transcripts translation was confirmed 
experimentally (Pozner et al. 2000). At the same time, the translation of distal 
transcripts is initiated via the usual cap-dependent mechanism. It is conceivable that 
IRES-mediated translation may be an important tool in regulation of the AML1 
activity, since it has been shown that IRES located within the proximal 5' UTR has 
different levels of activity in different cell lines (Pozner et al. 2000). The IRES 
activity is very low in nonhematopoietic cell lines, but is high in such cells as Jurkat 
T-cells and K562 erythro-megakaryocytic progenitor cells. Induction of 
megakaryocytic differentiation in K562 cells is associated with upregulation of IRES 
activity whereas erythroid differentiation of the cells causes downregulation of the 
IRES-mediated translation (Pozner et al. 2000). 
1.2.3. AML1 expression pattern 
Expression of AML1 was studied by Northern analysis and different results 
have been obtained for mouse and human tissues. In adult mouse the AML1 
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expresses at highest level in the thymus and at lower level in the lung, the heart and 
the spleen (Satake et al. 1995). In human tissues the thymus and the spleen also show 
high level of AML1 expression. In addition, expression of AML1 has also been 
revealed in the lung, the liver, the skeletal muscles, the kidney, the pancreas, the 
genital glands, the peripheral blood but not in the heart (Miyoshi et al. 1995). 
Generation of the AMILI reporter mice provided a tool for more precise analysis of 
the AM1L1 expression pattern. A reporter mouse strain with the LacZ reporter 
targeted into the AMLI gene locus was used for the analysis of the AML1 
expression during embryonic development (North et al. 1999). AML  expression has 
been found in all major hematopoietic sites in an embryo (dorsal aorta, yolk sac, 
vitelline and umbilical arteries and foetal liver) as well as in some non-hematopoietic 
sites such as the olfactory epithelium, the spinal ganglia and the maxillary processes. 
The mouse line with the enhanced green fluorescent protein (EGFP) reporter targeted 
into the AML 1 gene locus has been used for the analysis of the AML 1 expression in 
the mouse adult haematopoietic system (Lorsbach et al. 2004; North et al. 2004). The 
immature hematopoietic progenitors and more mature cells of myeloid, B- and T-
lymphoid lineages have high levels of AML  expression. There is no/low expression 
of AML1 in erythroid cells. These reports confirm the earlier data obtained using 
immunochemistry and in situ hybridisation methods (Simeone et al. 1995; Corsetti 
and Calabi 1997). 
1.2.4. Subcellular localization of the AML1 protein 
Immunofluorescence labeling experiments demonstrated that AML I is a 
nuclear protein, It contains the nuclear localization signal (NL S) which has been 
mapped within the Runt domain (Lu et al. 1995). Furthermore, the AML  protein is 
associated with nuclear matrix. AML I contains the nuclear matrix targeting signal 
(NMTS) which is physically distinct from NLS; NIMTS resides within the TA 
domain (Zeng et al. 1997). AML I and transcriptionally active DNA polymerase II 
are colocalized in a nucleus and linked to the nuclear matrix (Zeng et al. 1998). 
Furthermore, experiments with the fluorescent AML1-EGFP fusion protein have 
shown that the protein is colocalized with nascent transcripts (Harrington et al. 
2002). These findings suggest that NIMTS directs AML1 to the nuclear matrix 
associated with subnuclear transcriptionally active sites. Targeting of a 
transcriptional factor to a specific subnuclear domain may be essential for 
transcription regulation, since it may facilitate transcriptional complex assembling. 
Mislocalization of a transcriptional factor in the nucleus may perturb expression of 
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target genes (reviewed by Stein et al. 1998). For instance, AML1/ETO is a chimeric 
protein, which is generated as a result of translocation t(8; 21). The AML1/ETO 
chimeric protein contains the N-terminal part of AML 1 and almost entire ETO 
protein (Kozu et al. 1993). Therefore, AML1/ETO lacks the AMIL1 NMTS. As a 
result AMIL1/ETO is directed to the sites which do not coincide with AML1 
subnuclear localization (McNeil et al. 1999). This is one of the mechanisms, which 
presumably compromise gene expression in AML 1/ETO transformed cells. 
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1.3. AML1 function: AMLI as a transcriptional regulator 
AML1 is a site-specific DNA binding protein which recognizes the 
nucleotide sequence 5'-TGPyGGTPy-3' (Py: pyrimidine) (Kamachi et al. 1990; 
Melnikova et al. 1993). Transcriptional activity of AMLI has been demonstrated 
(Zaiman et al. 1995). Subsequent studies have shown that AMLI acts as a 
transcriptional organizer facilitating an assembly of an active transcriptional complex 
on the promoter of a target gene. Close and sometimes overlapping localization of 
transcription factors binding sites are usual for many promoters. By this mutual 
cooperation of transcriptional factors an assembly of a transcription factor complex is 
ensured and results in promoter activation. On its own AML 1 is a weak transcription 
activator, but cooperation with other DNA binding transcription factors enhances its 
transcriptional activity. For example, (i) AMLI and c-Myb functional cooperation is 
necessary for the I  cell receptor (TCR) 8 enhancer activation (Hemandez-Munain 
and Krangel 1994), (ii) AMLI functionally interacts with the PU.1 and C/EBP 
proteins in order to activate transcription from the macrophagecolony-timulating 
factor (M-CSF) receptor promoter (Zhang et al. 1994; Zhang et al. 1996; Petrovick et 
al. 1998), (iii) AMLI and ETS-1 functionally cooperate on the TCRa, TCRI and 
MoMLV enhancer, B-cell specific i.t enhancer and la  promoter (Wotton et al. 1994; 
Giese et al. 1995; Sun et al. 1995; Erman et al. 1998; Me et al. 1999) and (iv) the 
LEF- 1 (lymphocyte enhancer binding factor) protein enhances the DNA-binding 
abilities of AMLI and ETS on the TCRci enhancer (Giese et al. 1995; Mayall et al. 
1997). The mechanism of the AML  and ETS cooperation has been most extensively 
studied and will be discussed below. 
AMLI interacts with DNA via its DNA binding Runt domain. However, 
subsequent studies have demonstrated that AMLI contains auto-inhibitory domains 
which form a complex with the Runt domain preventing DNA binding (Kanno et al. 
1998; Gu et al. 2000). ETS-1 (E26 transformation pecific) is a member of a large 
family of transcriptional regulators sharing the common DNA binding ETS domain 
(reviewed by Oikawa and Yamada 2003). As AMLI, ETS-1 also contains auto-
inhibitory domains interacting with the ETS DNA binding domain (Jonsen et al. 
1996). Experiments have shown that AMLI and ETS interact via their auto-
inhibitory domains and these protein-protein interaction activates their DNA binding 
abilities (Kim et al. 1999; Goetz et al. 2000). According to the model proposed, 
AMLI and ETS interact via their auto-inhibitory domains. As a result DNA binding 
domains release from negative regulatory complexes and may interact with DNA. 
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Several non-DNA binding proteins also enhance DNA binding ability and 
stability of AML 1. The CBFI3 protein increases the DNA binding ability of AMLI 
(Ogawa et al. 1993; Wang et al. 1993). Furthermore, the CBFf3 protein protects 
AMLI from the ubiquitylation and subsequent proteasome-mediated proteolysis 
(Huang et al. 2001). The ubiquitously expressed ALY protein also increases the 
AMLI DNA binding ability on the TCRa enhancer. Similarly, ALY interacts with 
the LEF- 1 transcription factor which is also presents in the AMLI transcriptional 
complex and increases its DNA binding ability (Bruhn et al. 1997). Furthermore, the 
YAP protein increases the AMLI mediated transcriptional activation of the 
osteocalcin promoter but the YAP influence on the AMLI DNA binding ability has 
not been studied (Yagi et al. 1999). 
An important group of non-DNA binding proteins interacting with AML  is 
histone acetyltransferases (HATs). HATs catalyze transfer of the acetyl groups onto 
lysine residues of histories. Acetylation of histories triggers conformational changes 
in chromatin, which adopts an open conformation and becomes more accessible for 
the transcriptional machinery. Acetylation is a widely used mechanism of 
transcriptional regulation (reviewed by Blobel 2000) AMLI interacts with p300 and 
CBP (cREB binding protein) (Kitabayashi et al. 1998) that are highly homologous 
proteins, possessing an intrinsic HAT activity (Ogryzko et al. 1996) and, moreover, 
bind other HATs (Yang et al. 1996). Furthermore, p300 and CBP interact with basal 
transcriptional factors (Kwok et al. 1994). AMLI physically interacts with p300 and 
CBP and p300 increases the AMLI mediated activation of the myeloperoxidase 
promoter (Kitabayashi et al. 1998; Kitabayashi et al. 2001). Moreover, p300 
acetylates AMLI. This modification enhances the AMLI DNA-binding ability and 
stimulates its transcriptional activity (Yamaguchi et al. 2004). It has also been shown 
that the proyelocytic leukemia (PML) nuclear protein stimulates functional 
cooperation between AML  and p300 (Nguyen et al. 2005). 
MOZ (monocytic leukemia zinc finger protein) is another transcription 
coactivator which possesses an intrinsic HAT activity (Champagne et al. 2001). 
MOZ physically interacts with AMLI and enhances the AMLI mediated 
transcription from the myeloperoxidase promoter (Kitabayashi et al. 2001). 
Furthermore, MOZ and AMLI cooperate to activate the macrophage inflammatory 
protein-la promoter (Bristow and Shore 2003). The acetylation of AMLI by MOZ 
has also been shown (Kitabayashi et al. 2001). Interestingly, like AMLI, the MOZ 
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gene is involved in chromosomal translocations associated with different types of 
leukemia (Borrow et al. 1996; Liang et al. 1998; Kitabayashi et al. 2001). 
For a long time, AML I has been considered exclusively as a transcriptional 
activator. However, its transcriptional repressing capacity is also established now. 
AIvIIL 1 transcription repression is firstly mediated via the Groucho/TLE corepressor 
interaction (Aronson et al. 1997; Javed et al. 2000). Members of the Groucho/TLE 
family of corepressor proteins do not interact with DNA but form transcription 
repressive complexes with DNA-binding proteins. The mechanism of the 
Groucho/TLE-mediated repression is not fully understood but it is conceivable that 
they recruit histone deçetylases (HDACs) to DNA. HDACs catalyse removing of 
the acetyl groups from lysine residues of histories what stabilizes interaction between 
histories and DNA. This restores transcriptionally inactive status of chromatin and 
shuts down transcription (reviewed by Chen and Courey 2000). The five most C-
terminal amino acids of AML 1 (VWRPY) are necessary for physical interaction 
between AMIL 1 and Groucho/TLE. The fact that this amino acid sequence is 
conserved across all 'members of the Runx family underscores their significant 
biological role (Aronson et al. 1997). Co-transfection of the AML1 and 
Groucho/TLE expressing plasmids significantly decreases the level of reporter genes 
expression whose transcription is driven by various AML1 responsive 
promoters/enhancers (TCRa and 13  enhancers, M-CSF promoter (Imai et al. 1998; 
Levanon et al. 1998)). Physical interaction between AML1 and some of the HDAC 
family members further support the model for HDAC mediated AML  repression of 
transcription (Durst et al. 2003). 
The AML 1 mutants lacking the C-terminal VWRPY amino acids cannot 
interact with Groucho/TLE. It has been found however that this prevents repression 
of transcription of several but not all target genes (Aronson et al. 1997). This finding 
suggests the existence of Groucho/TLE-independent mechanisms involved in AML 1 
mediated transcription repression. Subsequent studies confirmed that repression of 
the p21 promoter by AMLI occurs via the mSin3A corepressor interaction 
(Lutterbach et al. 2000). Physical interaction between AML1 and mSin3A has been 
demonstrated and its regulation by the AML1 phosphorylation has also been shown 
(Lutterbach et al. 2000; Imai et al. 2004). mS1n3A binds to dephosphorylated AML  
and the complex comes apart upon the AML1 phosphorylation (Imai et al. 2004). 
The C-terminal VWRPY amino acids are not necessary for the association between 
AML1 and mSin3A. The putative mechanism of the mSin3A mediating 
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transcriptional repression looks similar to the Groucho/TLE mediating one. mSin3A 
does not bind DNA, but interacts with DNA binding transcriptional factors. 
Furthermore, mS1n3A forms a complex with HDACs recruiting them to DNA that 
promotes transcriptional repression (reviewed by Knoepfler and Eisenman 1999). 
The fact that the HDACs inhibitor impairs the p21 promoter repression mediated by 
the AML1 and mSin3A interaction further supports this model (Lutterbach et al. 
2000). 
Taken together, the following model of AML1 mediated transcriptional 
regulation may be suggested (see Figure 2). AMIL1 interaction with other 
transcriptional factors facilitates the binding of the Runt domain to DNA. Depending 
on the cellular context, DNA bound AML1 interacts with different types of non-
DNA binding proteins, which may recruit either HATs or HDACs. HATs catalyze 
acetylation of histories disrupting chromosome structure and stimulating 
transcription. HDACs catalyze the reverse process of the histories deacetylation 
restoring closed chromatin structure and shutting down transcription. According to 
that, the cellular context determines whether the AMIL 1 dependent transcription is 
activated or repressed. In line with this model the AML 1 represses the p21 promoter 
in the 3T3 cells, but activates the same promoter in the K562 cells (Lutterbach et al. 











Figure 2. Transcriptional complex formation by AML1 
Schematic representation of a model of the AML1 mediated transcriptional 
activation. AML1 DNA binding is facilitated by other DNA binding transcription 
factors (for instance, ETS- 1, LEF- 1). The LEF- 1 protein induces bending of DNA 
(Giese et al, 1995). The non-DNA binding proteins either stabilize the transcriptional 
complex (ALY, CBFI3) or recruit HATs and basal transcriptional factors. p300ICBP 
interacts with the CREB/ATF transcriptional factors (Chrivia et al. 1993). 
Schematic representation of a model of the AMIL 1 mediated transcriptional 
repression. AML1 binds DNA and interacts with either mSin3A or Groucho/TLE 
corepressor which recruit HDACs. The involvement of other DNA binding 
transcriptional factors in the repressive complex is also possible but is not shown. 
The diagrams are simplified; not all proteins involved in the AML1 transcriptional 
complex are shown. 
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1.4. The role of AMLI in a mouse embryonic development 
1.4.1. Hematopoietic differentiation in viva 
Hematopoietic stem cells (HSCs) lie at the foundation of the haematopoietic 
system. These cells reside mainly in the bone marrow in the adult organism (see 
Figure 3). HSCs are capable of self-renewing and multipotent myeloid, erythroid and 
lymphoid differentiation. The HSCs population comprises only about 0.05% of the 
total number of bone marrow cells (reviewed by Morrison et al. 1995). This small 
cell population continuously supplies differentiating haematopoietic cells into the 
blood stream (reviewed by Morrison et al. 1995; Kondo et al. 2003). Markers 
expressed in HSCs are shared with other haematopoietic cells. Therefore, only a 
functional transplantation assay is the ultimate test that allows reliable identification 
of HSCs (reviewed by Domen and Weissman 1999). To determine if a given cell 
population contains HSCs the cells are transplanted into myeloablated recipient. 
Irradiation of mice at about 950 Rad causes efficient myeloablation followed by the 
death of the animal due to severe anaemia. Transplanted HSCs function in recipient 
animals over a period of more than 4-6 months and therefore can rescue the animals. 
Other in vitro assays allow identification of different mature hematopoietic 
progenitors (reviewed by Domen and Weissman 1999). 
First blood cells in the mouse appear in E7.5 yolk sac (Moore and Metcalf 
1970). This initial population mainly consists of large nucleated erythrocytes. It has 
been shown that the yolk sac before ElO is not capable of reconstitution of adult 
recipients hematopoietic systems (Harrison et al. 1979; Sonoda et al. 1983; Muller et 
al. 1994), Therefore, E7.5-E10 yolk sac does not contain definitive HSCs. It is 
suggested that first embryonic blood cells represent a transient cell population 
serving only immediate needs of an embryo (Dzierzak and Medvinsky 1995). Only 
by El 1 the first transplantable HSCs emerge in the embryo in the area of the dorsal 
Aorta, genital ridge/gonads and pro/rnesonephros region (AGM region) (Muller et al. 
1994; Medvinsky and Dzierzak 1996). Sites of HSCs generation were also found in 
vitelline and umbilical arteries in E10.5 (de Bruijn et al. 2000). Slightly later, by El 1 
definitive HSCs appear in yolk sac and the foetal liver (Muller et al. 1994). In order 
to assess the potential of various embryonic tissues to generate HSCs; an organ 
culture method was used in order to preserve intracellular interactions within 
explants. Using the method tissue explants dissected from the embryo were cultured 
for 2 or 3 days. Dissociated cells from the cultured explants were transplanted into 
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Figure 3. Schematic representation of the multilineage differentiation of 
hematopoietic stem cells in bone marrow 
(Morrison et al. 1995) 
Multipotent bone marrow HSCs have the ability to maintain themselves (self-
renewal) and differentiate into any type of blood cells. HSCs produce progenitor 
cells with restricted differentiation potential which terminally differentiate into 
mature blood cells. Hematopoietic progenitors with restricted differentiation 
potential are designated as colony-forming gnits (CFU) - granulocyte/macrophage 
(GM), - gakaryocyte (Meg) and - erythroid (E) depending on which type of blood 
cells they are commited. BFU-E (burst forming unit - erythroid) represent more 
immature erythroid progenitors than CFU-E (Stephenson et al. 1971). NK designates 
nature killer. 
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which initiated cells capable of long-term repopulation at this time (Medvinsky and 
Dzierzak 1996). Therefore, AGM has autonomous capacity to generate HSCs. The 
peak of HSC activity was detected in the AGM region on Eli, but by the next day it 
is going down (Kumaravelu et al. 2002). It is interesting that by E12 the yolk sac 
acquires capacity to expand HSCs, suggesting that it also contributes in formation of 
the definitive haematopoietic system. It is widely accepted that HSCs are not 
generated de novo in foetal liver but arrive from extra-hepatic sources (Johnson and 
Moore 1975). It has been suggested that HSCs emerging in AGM or yolk sac enter 
the circulation and colonize the foetal liver in two consecutive waves. The first wave 
of HSCs originating from the AGM region comes on E10-E12, whereas the second 
one arrives from yolk sac on E12-E13 (Kumaravelu et al. 2002) (see Figure 4). 
Simultaneously with colonisation of the foetal liver the number of HSCs is growing 
in embryonic blood. The foetal liver is the main hematopoietic site in the mouse 
foetus during E12-E16. From E16 HSCs colonise definitive haematopoietic 
territories, bone marrow and spleen (Delassus and Cumano 1996). 
Earlier investigations of embryonic haematopoietic development led to an 
observation that hematopoietic cells are closely associated with the ventral part of the 
dorsal aorta endothelium (Garcia-Porrero et al. 1995). Several independent studies 
provide evidences that hematopoietic cells bud from the hemogenic endothelium 
lining the floor of the dorsal aorta, vitelline and umbilical arteries. In order to prove 
this, endothelial cells in the chicken embryo were labelled using different methods 
(Jaffredo et al. 1998; Jaffredo et al. 2000) and their progeny were later tracked. 
Hematopoietic clusters expressing the pan-haematopoieyic marker CD45 attached to 
the floor of the dorsal aorta were found labelled with the fluorescent marker. It has 
also been shown that endothelial cells sorted on the basis of expression of the 
vascular endothelial cadherin (Breier et al. 1996) from the E9.5 mouse embryo gave 
rise to hematopoietic colonies after culturing with growth factors (Nishikawa et al. 
1998). Cumulatively these data support the hypothesis firstly proposed more than 80 
years ago that hematopoietic and endothelial cells have a common progenitor called 
"hemangioblast" (Sabin 1920; Murray 1932). 
1.4.2. AMLi is a regulator of the definitive hematopoiesis during mouse 
embryogenesis 
The AML1 knock-out mice have been independently generated by three 










Figure 4. Schematic representation of the HSCs distribution in hematopoietic 
tissues of a mouse embryo 
(from Kumaravelu et at. 2002) 
First HSCs emerge in the ElO-il AGM region. They form the first wave of a foetal 
liver colonisation during E11-E12. The second wave comes from the yolk sac (YS) 
by E12-E13. 
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die between El 1.5 and El2.5 from extensive haemorrhages in the nervous system 
and pericardium. Although the yolk sac hematopoiesis looks unaffected, 
hematopoietic progenitors are not developed in the foetal liver. Expression of a few 
hematopoietic specific genes are abolished in AMLI' embryos (Okada et al. 1998). 
CBFI3 phenotype is similar: CBFJ3' embryos die on El1.5-E13.5 due to 
haemorrhage in the central nervous system. Foetal liver hematopoiesis is also 
severely impaired (Sasaki et al. 1996; Wang et al. 1996; Niki et al. 1997). However, 
while the foetal liver cells from the E11.5 AMiL1 embryos produced no 
hematopoietic colonies in vitro, the CBFII' ones could generate a few of them 
(Wang et al. 1996). Subsequent studies have shown that AMIL 1' embryonic stem 
(ES) cells (see below) fail to develop hematopoietic colonies in vitro and do not 
contribute into hematopoietic tissues of chimeric mice (Okuda et al. 2000). 
The influence of the AML1 mutation on HSCs development was studied 
using the AML1 reporter mouse strain (North et al. 1999). The LacZ reporter gene 
was targeted into the AMIL1 locus, and the reporter was observed in all 
hematopoietic sites of the AMLl aczj+  embryos (AGM, vitelline and umbilical 
arteries, yolk sac and foetal liver). Close association between LacZ positive 
hematopoietic and endothelial cells was observed in the ventral portion of the dorsal 
aorta, umbilical and vitelline arteries. E11.5 foetal livers from AML 1'' embryos 
failed to produce hematopoietic colonies in vitro (Okuda et al. 1996; Wang et al. 
1996; Okada et al. 1998). In line with that FACS (fluorescence activated cell sorting) 
analysis demonstrated that the E1l.5 AML  1LaL foetal liver expressed significantly 
decreased level of cell surface markers associated with haernatopoietic 
differentiation. Since no LacZ positive cells were found in the blood of the 
embryos, it has been proposed that AMLI knock-out embryos fail to 
generate HSCs in the AGM region. Comparison of the LacZ expression in the dorsal 
aortas of the AML Lacl and AML Lap-"- embryos showed that both of them 
contained LacZ positive cells in the endothelial and para-aortic mesenchymal cells of 
E9.5 embryos. However, by E10.5 LacZ expression increased in the endothelium and 
was accompanied with appearance of LacZ positive haematopoietic cells in the aortic 
lumen of the AN'fl. 1 LacZI+  embryos in contrast to AML 1 ' embryos. Interestingly, 
mesenchymal but not endothelial cells express LacZ in the E11.5 dorsal aorta 
suggesting that AML1 marks a transient population of hemogenic endothelial cells. 
LacZ positive cells sorted out from the AML 1.ac  embryos reconstituted lethally 
irradiated recipients whereas LacZ negative ones failed to do this (North et al. 2002). 
Therefore, AMIL1 may be a positive regulator of the generation of definitive HSCs. 
26 
Its expression in the hemogenic endothelium may be essential for development of the 
definitive hematopoietic system. Since HSCs express AMIL1 it suggests its essential 
role in HSC functioning. Further experiments studying the role of AML in 
hemangioblast formation and differentiation are in line with this idea. 
Cells isolated from the AGM region of the E9.5 A ILl' embryos failed to 
generate hematopoietic cells in vitro whereas cells isolated from wild type embryos 
produced them successfully. However, the endothelial-like structures were generated 
in vitro from AGMs of embryos of both genotypes (Mukouyama et al. 2000). 
Endothelial cells sorted out from E10.5 AML1' embryos also failed to produce 
hematopoietic colonies in vitro. AML1 expression in the wild type endothelial cells 
was confirmed by the reverse transcription - polymerase chain reaction (RT-PCR) 
suggesting the AML1 role in acquisition of the hematopoietic potential by 
endothelial cells. Interestingly, although both AML 1' and wild type cells produced 
endothelial colonies in vitro, the number of colonies generated by the knock-out cells 
was slightly higher (Yokomizo et al. 2001). The intermediate population between 
endothelial and hematopoietic cells has been described using CD45 pan-
haematopoietic and VE-cadherin endothelial markers (Fraser et al. 2003). Both 
endothelial and hematopoietic markers are expressed in this population which is 
capable of generating VE-cadherin negative CD45 positive cells in vitro. This 
intermediate cell population was sorted out from wild type E9.5 embryos. In contrast, 
AML1 knock-out embryos lacked this population (Fraser et al. 2003). Cumulatively 
these data suggest that AML1 is one of the key regulators of development of the 
definitive haematopoietic system in the mammalian embryo. 
1.4.3. The role of AML1 in the vascular network development 
Extensive haemorrhages observed in the AMLF' embryos imply that it may 
be involved in the vascular development regulation. Blood vessels may be generated 
by either vasculogenesis or angiogenesis. Vasculogenesis implies de novo formation 
of blood vessels from angioblasts whereas during angiogenesis new vessels are 
generated from pre-existing ones (reviewed by Patan 2000). Analysis of angiogenesis 
in the AML1 embryos has shown that they contain less branches and small 
capillaries by El 1 than wild type littermates (Takakura et al. 2000). In accord with 
that AML Y' AGMs from E9.5 embryos generate less developed vascular network in 
vitro than the wild type AGMs. However, this defect can be rescued by 
supplementation of either wild type HSCs or angiopoietin-1 to the culture. Based on 
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these experiments the role of HSCs in vasculogenesis has been proposed (Takakura 
et al. 2000). Angiopoietin-1 signalling plays an essential role in vascular 
development (reviewed by Ward and Dumont 2002) Interestingly, angiopoietin-1 
expression in the HSCs has been demonstrated (Phillips et al. 2000; Takakura et al. 
2000). Since in the absence of AML1 HSCs are not generated, angiopoietin-1 is not 
provided for growing vessels, what may cause underdevelopment of the vascular 
network in AML L' embryos. 
The functional interplay between angiopoietin-1 and AML1 has been further 
shown during investigation of the angiogenic activity of MSS31 cells overexpressing 
the CBFf3-SMM1HC (Namba et al. 2000). The MSS31 cell line was established from 
spleens of newborn mice. These cells demonstrate properties of endothelial cells 
(Yanai et al. 1991). CBF-SMMI-IC is a fusion of the CBFI3 and smooth muscle 
Myosin heavy chain (SMMHC) proteins. This chimeric gene was cloned from a 
chromosomal inversion found in patients with AIVIIL (Liu et al. 1993). The CBF-
SMMHC protein acts as a dominant negative inhibitor of AML1. The CBF3-
SMMHC knock-in mice phenotype is very close to the AMIL1 knock-out one 
(Castilla et al. 1996). The level of the angiopoietin-1 expression was significantly 
decreased in the CBF-SMiMIHC overexpressing MSS31 cells suggesting again that 
AML 1 may be a positive regulator of the angiopoietin- 1 gene expression (Namba et 
al. 2000). Furthermore, the tube formation and cell migration in vitro of the MSS31 
cells were significantly reduced when CBFI3-SMMI-IC was overexpressed. 
Therefore, AML 1 is likely to be involved in vascular endothelial network formation. 
AML 1 is a putative regulator of several angiogenesis-related genes. AML 1 
activates transcription of the endothelial specific puromycin-insensitive leucyl-
specific aminopeptidase (PILSAP) gene in MSS31 cells (Niizeki et al. 2004). It is 
also a putative activator of endogenous vascular giastase (EVE) in vascular smooth 
muscle cells (Wigle et al. 1998; Mitani et al. 2000). Both PILSAP and EVE play an 
important role in angiogenesis promoting proliferation and migration of endothelial 
or vascular smooth muscle cells (reviewed by Rabinovitch 1999; Sato 2003). 
Furthermore, expression of the insulin-like growth factor-binding protein-3 (IGFBP-
3), a putative inhibitor of angiogenesis is downregulated upon AMLI expression in 
endothelial AEL-AR cells derived from E11.5 AMLL' embryos (Iwatsuki et al. 
2004). AML1 induction results in (i) enhancement of the vascular network formation 
in vitro, (ii) activation of the endothelial marker VE-cadherin expression and (iii) 
downregulation of the IGFBP-3 gene expression. Since AML i embryos contain 
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VE-cadherin positive cells (see above, Fraser et al. 2003) it is unlikely that yE-
cadherin is an AML 1 target gene. More likely upregulation of its expression may 
demonstrate the endothelial differentiation enhancement. IGFBP-3 protein belongs to 
a family of proteins acting as regulators of insulin-like growth factors (IGF) 
(reviewed by Delafontaine et al. 2004). The inhibitory influence of IGFBP-3 on 
endothelial cells proliferation was shown (Delafontaine et al. 1996; Franklin et al. 
2003). AML  interacts with the IGFBP-3 promoter and represses it. Supplementation 
of AMLI expressing AEL-AR cells with the IGFBP-3 protein inhibits vascular 
network formation in vitro (Iwatsuki et al. 2004). Taken together, all this data 
unambiguously show that AML1 is involved in the regulation of angiogenesis; 
however detailed mechanisms are yet to be investigated. 
1.4.4. Hematopoietic differentiation in vitro: ES cell model 
All experimentations with transgemc mice have essential limitations which 
may be caused by embryonic lethality, poor accessibility of early precursor cell 
populations and necessity of prolonged animal breeding. Some of these limitations 
can be circumvented by modelling of differentiation in vitro using embryonic stem 
(ES) cells. ES cell lines are derived from the inner cell mass of the E3.5 blastocysts 
(Evans and Kaufman 1981; Martin 1981). These cells are pluripotent since they can 
give rise to any cell type. Undifferentiated ES cells can be maintained continuously 
in vitro if the LIF (leukaemia inhibitory factor) cytokine is added to the medium 
(Gearing et al. 1988; Smith et al. 1988; Williams et al. 1988). If undifferentiated ES 
cells are injected back into a blastocyst they can contribute to all cell types of the 
animal (Bradley et al. 1984). Withdrawal of LIF from the ES cell culture medium 
induces differentiation. Differentiation is further enhanced in three-dimensional 
aggregates formed in suspension culture (so-called, embryoid bodies, EBs) 
(Doetschman et al. 1985). 
Molecular mechanisms governing the ES cells self-renewal and 
differentiation have being highlighted during the last years. First, the STAT3 
transcription factor has been identified as a downstream effector molecule of the 
LIF-activated signalling pathway (Niwa et al. 1998). Second, an independent ES 
self-renewal promoting signalling pathway has been discovered (Ying et al. 2003). 
This pathway is induced by the BMP (bone morphogenetic protein) ligand molecule. 
ES cells can be propagated in the serum-free medium if both LIF and BMP are 
supplied. The BMP signalling causes the Id (inhibitor of differentiation) gene 
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expression. The Id molecules role is not clarified fully yet, but it is conceivable that it 
precludes the neural differentiation factors functioning. Two intracellular proteins 
have been identified as ES cell self-renewal determinants. The Oct4 transcription 
factor is necessary for the ES cells pluripotency maintenance (Nichols et al. 1998). 
ES cells differentiation, transdifferentiation or self-renewal in vitro is Oct4 dose-
dependent (Niwa et al. 2000). Nanog is another ES cell protein which acts as the self-
renewal positive regulator. Nanog overexpressing ES cells may self-renew if the LIF 
signalling is blocked (Chambers et al. 2003). 
ES cells can differentiate into various cell types in vitro if appropriate culture 
conditions are applied (reviewed by Keller 1995; Smith 2001). Hematopoietic 
differentiation of ES cells has been performed in a semi-solid medium containing 
0.9% methylcellulose (Wiles and Keller 1991). Methylcellulose provides a three-
dimensional matrix which is supportive for developing EBs. The medium is further 
supplemented with various cytokines and growth factors promoting hematopoietic 
differentiation in vitro. Different ES cell differentiation media have been developed 
but most of them share erythropoietin, interleukins (IL-3 and IL-6), M-CSF, G-CSF 
(granulocyte colony-stimulating factor) and SCF (tem cell factor) (Wiles and Keller 
1991; Keller et al. 1993). A method of the ES cells hematopoietic differentiation in 
vitro using two-dimensional cultures has also been developed (Nishikawa et al. 1998; 
Fraser et al. 2002). The two-step method is based on fetal liver kinase-1 (FIk-1) 
expression, Flk-1 is a transmembrane tyrosine kinase which serves as a receptor for 
vascular endothelial growth factors (Matthews et al. 1991; Quinn et al. 1993). Flk-1 
is a marker of late mesodermal and early endothelial and hematopoietic cells 
(Yamaguchi et al. 1993; Shalaby et al. 1995; Eichmann et al. 1997). ES cells were 
precultured in LIF-free medium on type IV collagen-coated plates for four days. 
After that Flk- 1 positive cells were sorted out from the predifferentiated ES cells to 
eliminates inhibitory effects which other germ layers may exert on hematopoietic 
differentiation (Kessel and Fabian 1987) and plated onto 0P9 feeder cells in 
presence of erythropoietin, SCF and IL-3 (Nishikawa et al. 1998; Fraser et al. 2002; 
Fraser et al. 2003). 0P9 stromal cells established from calvaria of a newborn knock-
out mouse which lacked functional M-CSF (Nakano et al. 1994) efficiently induce 
hematopoietic differentiation in ES cells. 
AML1 expression level is rather low in undifferentiated ES cells and EBs 
during first days of differentiation. However it grows gradually from the third day of 
differentiation (Fujita et al. 2001; Lacaud et al. 2002). AML1 EBs generate fewer 
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blast colonies giving rise to both endothelial and hematopoietic cells than the wild 
type EBs (Kennedy et al. 1997; Choi et al. 1998). The blast colonies are considered 
to represent the putative hemangioblast stage. This defect of the AML 1 EBs has 
been rescued by the AMILI expressing retrovirus infection (Lacaud et al. 2002). 
Interestingly, AMIL 1 blast colonies demonstrate that they have potential to 
differentiate into endothelial and primitive erythroid lineages but not into myeloid or 
definitive erythroid cells (Okuda et al. 1996; Lacaud et al. 2002). These experiments 
suggest that AML  plays an important role in specification of the haemangioblast. 
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1.5. The role of AMIL1 in adult hematopoiesis 
1.5.1. Introduction 
Since the AML F' embryos do not survive, the conditional knock-out strategy 
has been employed in order to investigate functions of AMTL 1 in adult hematopoiesis 
(Ichikawa et al. 2004). A genetically modified mouse strain with the AML1 exon 5 
surrounded by lox? sites was generated and bred with the Mxl-Cre transgenic mice. 
The Mxl-Cre transgenic mice encode Cre recombinase driven by the inducible Mxl 
promoter and induce efficient recombination in different cell types (Kuhn et al. 
1995). The Mxl promoter is inducible by interferons (Chang et al. 1991; Finkelman 
et al. 1991). Upon endogenous interferons induction by synthetic double-stranded 
RNA, Cre catalyses excision of the lox? sites flanking DNA fragment in the AML 1 
genomic locus in double transgenic mice (see the Chapter 2.2 for the detailed 
discussion of the Cre recombinase and conditional knock-out strategies). After 
recombination the AML1 allele encodes the protein whose ability to bind DNA is 
abolished. However, the TA domain remains unaffected and may exert a biological 
effect. Furthermore, this experimental design does not perturb expression of AML1 
minor isoforms lacking the exon 5. 
In addition two other transgenic mouse strains with EGFP and LacZ reporters 
targeted into the AIvIL1 locus have been instrumental for biological analysis of 
AML  (North et al. 1999; Lorsbach et al. 2004; North et al. 2004). 
1.5.2. The role of AML1 in the HSCs functioning 
The highest level of AML 1 expression is observed in the HSC enriched bone 
marrow fractions (Lorsbach et al. 2004; North et al. 2004). It has been shown using 
AMLI L" reporter mouse strain that AMIL1 marks HSCs. LacZ positive cell 
population sorted out from bone marrow of AML1 	mice reconstitutes the 
hematopoietic system of lethally irradiated recipients whereas LacZ negative 
population fails to do so. Furthermore, LacZ positive bone marrow cells from 
AML1 	animals generate many more hematopoietic colonies in vitro than the LacZ 
negative cells (North et al. 2004). The AML1 function in HSCs is not clear yet; 
however it is conceivable that AML1 may have an inhibitory influence on 
proliferation of immature hematopoietic progenitors. Bone marrow AML i cells 
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produce elevated numbers of myeloid, mixed (myeloid and erythroid) and 
megakaryocytic colonies in vitro compared to wild type cells. Similarly, the number 
of undifferentiated hematopoietic, early megakaryocytic and lymphocytic 
progenitors determined by the surface marker staining is also increased in the AML 1 
' bone marrow cells. The colony-replating capacity of the AML 1 bone marrow 
cells is also elevated (Ichikawa et al. 2004). 
1.5.3. The role of AML1 in the megakaryocytic development 
AML 1' mice have significant defects in platelet development. The number 
of platelets in the peripheral blood is significantly decreased after the knock-out 
inducer injection. The histochemical analysis of the AML1 bone marrow revealed 
no normal megakaryocytes but immature megakaryocyte-like cells instead of them 
(Ichikawa et al. 2004). The important role of AML in the megakaryocytic 
development has been further evidenced by discovering physical interaction and 
functional cooperation between AML1 and a common erythro-.megakaryocytic 
transcription factor GATA-1. However, whereas the GATA-1 expression is detected 
in both erythroid and megakaryocytic cells, AML1 displays significant levels of 
expression in megakaryocytes only (Elagib et al. 2003). The levels of the GATA-1 
expression in human hematopoietic progenitor undergoing erythroid or 
megakaryocytic differentiation in vitro are increased. In contrast, AIVIL1 expression 
is elevated only during megakaryocytic differentiation. The human leukemic cell line 
K562 recognized as common erythro-megakaryocytic progenitors (reviewed by 
Alitalo 1990) shows elevated levels of the AML 1 protein expression upon induction 
of the megakaryocytic differentiation (Elagib et al. 2003). Interestingly, the activity 
of an IRES in the AML1 proximal 5' UTR in the K562 cells is enhanced upon the 
megakaryocytic differentiation induction (Pozner et al. 2000). Furthermore, the 
AML1 overexpression induces the K562 cells to the megakaryocytic differentiation 
(Elagib et al. 2003). These results suggest that AML  may act at a level of a common 
erythro-megakaryocytic progenitor as a positive regulator of the megakaryocytic 
differentiation. It is conceivable that at early steps of differentiation it may not be 
essential since the megakaryocyte-like cells have been found in the AML1 bone 
marrow. However, the AIvILI gene seems to be indispensable during the later stages 
of the megakaryocytic differentiation, since the platelet generation is impaired and 
immature megakaryocytic progenitors accumulate in the AML1 bone marrow 
(Ichikawa et al. 2004). Interestingly, mutations in the AML1 gene have been found 
in patients affected with the familial platelet disorder, an autosomal dominant 
hereditary disease characterised by the platelet defects (Song et al. 1999; Michaud et 
al. 2002). 
1.5.4. The role of AML1 in the erythrocytes development 
It seems that AML1 is only marginally involved in the erythroid cells 
differentiation. The AML I expression in differentiating erythrocytes is very weak or 
undetectable (Lorsbach et al. 2004; North et al. 2004). There is no difference in the 
number of erythroid colonies generated from A1v1t1 and wild type bone marrow 
cells in vitro. Furthermore, the haemoglobin level has not been changed in the mouse 
peripheral blood upon the excision in the AML 1 gene locus (Ichikawa et al. 2004). 
However, the AML1 expression has been detected in early erythroid progenitors 
(Lorsbach et al. 2004; North et al. 2004). Furthermore, the downregulation of an 
erythroid specific gene HERF1 in the AMLL' ES cells has been shown (Harada et 
al. 1999). The possible involvement of AML1 in the early erythroid differentiation 
needs further investigations. 
1.5.5. The role of AML1 in the granulocytes and monocytes development 
The role of AML1 in granulocyte and monocyte development has not been 
fully investigated so far. Presumably, AML1 may play a role in development of these 
cells, but its role is not crucial. There is no significant difference in the peripheral 
blood neutrophil counts between the AMLl and wild type mice. The AML1 bone 
marrow cells could reconstitute properly the granulocytic and monocytic 
compartments of the lethally irradiated recipients (Ichikawa et al. 2004). At the same 
time, several research groups demonstrated the possible involvement of AML 1 in the 
granulocytes and monocytes differentiation in vitro. The 32D munne myeloid 
progenitor cell line grows in presence of IL-3 and differentiates into neutrophils upon 
the G-CSF addition (Migliaccio et al. 1989). The AMLIB isoform overexpressed in 
the 32D (clone 3) cells enhanced proliferation of the immature neutrophil progenitors 
in the presence of G-CSF whereas the AML 1 C isoform overexpress ion had no effect 
on the 32D cells (Telfer and Rothenberg 2001). However, there is a contradiction 
between these data and an earlier publication reporting no influence of the 
overexpressed AMLIB isoform on the 32D (clone 3) cells proliferation or 
differentiation (Tanaka et al. 1995). U937 human lymphoma cells differentiate into 
monocyte-like cells upon retinoid acid treatment (Olsson and Breitman 1982), which 
is accompanied by increased expression of AML1 (Tanaka et al. 1995). However, 
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functional significance of this has not been studied. Furthermore, AMLI regulates 
transcription of the neutrophil elastase and myeloperoxidase gene which are the early 
markers of granulopoiesis (Nuchprayoon et al. 1994; Li et al. 2004). The promoter of 
the monocyte specific M-CSF receptor is also can be activated by AMLI (Zhang et 
al. 1994; Zhang et al. 1996; Petrovick et al. 1998). 
1.5.6. The role of AMLI in lymphocyte development 
AIv1IL 1 is involved in the lymphocyte development, since the lymphocyte 
count in blood of the AML I -1- mice is decreased. Furthermore, the AMLI-1-  bone 
marrow cells in contrast to wild type cells do not repopulate B- and T-cell 
compartments of lethally irradiated recipients (Ichikawa et al. 2004). 
1.5.6.1. The role of AML1 in the B-cells development 
AMLI-mediated activation of a few B-cell specific promoters has been 
reported: (i) AMLI cooperates with the early B-cell factor protein and activates the 
early B-cell specific promoter mb-i (Maier et al. 2004), (ii) AMLI activates 
transcription of the B-cell specific protein kinase BLK (Liberrnann et al. 1999). The 
AIvliLl physical interaction and functional cooperation with the B-cell specific 
transcriptional factor PAX5 in the BLK promoter activation has been also reported 
(Libermann et al. 1999). Furthermore, AMLI binds to the B-cell specific t enhancer 
(Erman et al. 1998). 
It has been shown that the AMLI is capable of activation of transcription of 
the B-cell specific lcd germ line promoter. The expression of immunoglobulin heavy 
chains may be switched in mature B-cells upon antigen activation. The switch occurs 
via site-specific recombination between so-called switch regions in the 
immunoglobulin heavy chain locus. Transcription from heavy chain promoters is 
necessary and precedes recombination between switch regions in the gene. The 
accessibility of chromatin to the recombination machinery associated with changes in 
its structure is a mechanism controlling the time and site of recombination. The 
promoter/enhancer regions activating transcription of germ line transcripts are 
designated as I (intervening) (reviewed by Stavnezer 2000). 
The transforming growth factor (TGF)-131 induces transcription from the lcd 
germ line promoter that precedes the immunoglobulin class A heavy chain switch. 
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TGF-t3 1 interacts with extracellular domains of the transmembrane receptor 
serine/threonine protein kinase, what triggers conformational changes in the 
receptors and phosphorylation of the Smad intracellular signalling molecules. Upon 
phosphorylation, Smads tnmerize and translocate into the nucleus where they 
interact with DNA and promote formation of active transcriptional complexes 
(reviewed by Moustakas et al. 2001; Derynck and Zhang 2003). The Jul promoter 
contains both the Runt domain and Smads binding sites (Zhang and Derynck 2000). 
AML1 activates the Jul promoter in the lymphoid DG75 and erythro-
megakaryocytic K562 cell lines (Xie et al. 1999). AML1 physically interacts with 
Smad proteins that enhances transcription from the Jul promoter in K562 and HepG2 
cells (Hanai et al. 1999; Pardali et al. 2000; Zhang and Derynck 2000). Functional 
cooperation between AML1 and Smads increases responsiveness of cells to TGF-131 
(Pardali et al. 2000; Zhang and Derynck 2000). In line with that subnuclear 
colocalization of the AIvIL1 and Smads proteins has been shown (Zaidi et al. 2002). 
Interestingly, the AML2 protein exerts the similar effect on the Jul promoter (Shi 
and Stavnezer 1998; Hanai et al. 1999; Zhang and Derynck 2000). Thus further 
investigations are required to clarify the specific role of individual members of the 
AIvIIL family in the lal promoter regulation. 
1.5.6.2. The role of AML1 in the T-cells development 
Thymus is an organ where the level of AML1 expression is highest in adult 
mice (Satake et al. 1995), suggesting its important role in T-cells development. Most 
of T-cells belongs to either cytotoxic or helper subclass distinguished by their 
specific coreceptors expressed on the cell surface. Cytotoxic cells express the CD8 
coreceptor whereas helper cells express the CD4 molecule. T-cell development can 
be divided in three major stages. The most immature thymocytes are CD4 CDW 
oub1e negative (DN) cells. According to expression of CD44 and CD25 surface 
molecules development of DN cells is further subdivided into double-negative stages 
1 to 4 (DN1, 2, 3, 4) (Pearse et al. 1989; Godfrey et al. 1993). During the CD44 
CD25 DN1 and CD44 CD25 DN2 stages thyrnocytes gradually restrict their 
differentiation potential becoming irreversibly committed to the T-cell lineage at the 
CD44 CD25 DN3 stage. At the DN3 stage TCRI3 locus rearrangement starts. The 
cells in which in-frame TCRI3 rearrangement has occurred are selected for further 
maturation (f3-selection) (Dudley et al. 1994; Hoffman et al. 1996). At the CD44 
CD25 DN4 stage TCRQ rearrangement starts and finishes at the CD4
+  CD8+  double 
positive (DP) stage (Godfrey et al. 1994). If the DP cells express the TCRQI3 
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heterodimer, they undergo subsequent rounds of positive and negative selection and 
only cells with intermediate affinity to the MHC (major  histocombatibility omplex) 
class I or II molecules survive. T-cells selected with the MT-IC class I molecules 
differentiate into mature CD8 single positive (SP) cytotoxic cells, whereas cells 
selected with the MI-IC class II molecules differentiate into CD4 SP helper cells. 
Thus, the interaction with the Ivil-IC molecule governs the lineage choice in the DN 
thymocytes; however details of this mechanism remain unclear (reviewed by 
Rothenberg 2002; Gill et al. 2003). 
The transition from the DN2 to DN3 stage is blocked in AML I -1-  thymocytes 
generated by the chemically induced Cre-mediated excision in the AML 1 locus 
(Ichikawa et al. 2004). Furthermore, in other research the excision in the AML1 
locus has been catalysed by Cre driven by the T-cell specific Lck promoter (Taniuchi 
et al. 2002). The Lck gene encodes a tyrosine protein kinase belonging to the Src 
family. Lck is involved in signal transduction in thymocytes (reviewed by Zamoyska 
et al. 2003). The transition from the DN3 to DN4 stage in AML  thymocytes is 
blocked if Cre is driven by the Lck promoter (Taniuchi et al. 2002). The difference in 
the stage of the T-cell maturation block may be explained by delayed Cre expression 
in the Lck-Cre mice. Several important regulatory genes acting at the DN and DP 
stages are targets of AML1. First, AML1 is a regulator of TCRct, 0, y and 6 
enhancers activity (Redondo et al. 1991; Hsiang et al. 1993; Hernandez-Munain and 
Krangel 1994; Wotton et al. 1994; Giese et al. 1995; Sun et al. 1995; Bruhn et al. 
1997). As in the case with the immunoglobulin heavy chain rearrangement, 
transcription from TCR promoters is necessary and precedes TCR rearrangement. It 
has been shown that mutations in the TCR6 enhancer preventing the AML 1 binding 
significantly impaired TCR rearrangement (Lauzurica et al. 1997). Rag-i and 2 
(recombination activation genes) catalyse rearrangements in the TCR loci. It has 
been shown that native Runt domain binding sites in the Rag-1, 2 silencer are 
essential for proper regulation of Rag-I and 2 genes expression (Yannoutsos et al. 
2004) Further investigations are necessary to understand which of three AML 
proteins is involved in regulation of RAGs. CD4 is expressed at low level in most 
immature thymocytes. The CD4 expression is controlled by the CD4 
promoter/enhancer and silencer. AML 1 binding sites have been found in the silencer. 
Experiments with knock-out mice showed that AML1 (but not AML2 or 3) is 
necessary for the CD4 gene repression at the DN stage (Taniuchi et al. 2002). CD4 
may be repressed via the Oroucho/TLE dependent mechanism since the AML 1 
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cDNA lacking the C-terminal VWRPY amino acids causes expansion of CD4 
positive cells (Nishimura et al. 2004). 
The mechanism of CD4 repression may be different in the DN and CD8 SP 
cells. It is thought that in contrast to active repression in the DP cells CD4 becomes 
epigenetically and therefore irreversibly silenced in CD8 SP cells. The same Runt 
domain binding sites in the CD4 silencer are responsible for silencing in both DN 
and CD8 SP cells. However, it is AIvIIL2 which is required for silencing of CD4 in 
CD8 SP cells and further maturation of cytotoxic T-cells. It has been shown that CD4 
in the AML2' mature thymocytes is partially derepressed (Taniuchi et at. 2002). 
CD4 is fully derepressed in the thymocytes of the compound AML  AML2' mice 
and therefore these both genes cooperate in differentiation of CD8 SP cells (Woolf et 
al. 2003). 
Terminally differentiated SP CD4 and CD8 cells enter bloodstream and leave 
thymus becoming naïve peripheral T-cells. Further differentiation steps are necessary 
for the generation of mature I-helper (Tb) and cytotoxic cells. The AML 1 
involvement in the naïve CD4 cells differentiation was shown (Komine et al. 2003). 
Naïve CD4 cells may differentiate towards either Thi or Th2 subclass. Thi and Th2 
cells produce different cytokines and act on different types of effector cells 
(reviewed by Grogan and Locksley 2002). AMIL1 inhibit the Th2 cell lineage 
differentiation, promoting maturation of the Th 1 cells. AML 1 is a negative regulator 
of GATA-3 which is a key transcription factor in Th2 cells (reviewed by Murphy and 
Reiner 2002). 
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1.6. Functional role of individual isoforms of AML1 
The AML1 gene locus encodes a number of alternatively spliced isoforms. 
The expression pattern, functional significance and regulation of expression of 
individual isoforms are not well understood. The available data on this issue arrived 
mainly from the analysis of the four individual isoforms: AML IA, AML IB, AML 1C 
and AML IAN (see Figure 1). 
The AML lB and C isoforms belong to the long isoforms subgroup. They 
have both Runt and TA domains and may activate and repress transcription of target 
genes. These isoforms differ in their N-termini since A1'vIILlB is transcribed from the 
proximal promoter whereas AML 1C is transcribed from the distal promoter (Miyoshi 
et al. 1995; Ghozi et al. 1996). Proximal transcripts are initiated from exon 3; 
whereas the distal ones are initiated from exon I followed by exon 2 and the 3' 
segment of exon 3. The splice acceptor site of the exon 3 is located 13 nucleotides 
downstream of the initiator ATG codon of the proximal transcripts. Therefore, the 5 
most N-terminal amino acids of the exon 3 are missing in the AML 1C protein but the 
whole protein is longer than the AML 1 B, since the AML IC translation is initiated by 
an ATG codon located in the exon 1. AML 1 C contains 27 extra amino acids as 
compared to AML 1B (Miyoshi et al. 1995). Functional significance of this difference 
is not clear. However, different influence of AML1B and C isoforms on the 
neutrophilic differentiation has been shown by overexpression in 32D cells (Telfer 
and Rothenberg 2001). 
The AML IA and AN isoforms are the short isoform s. They contain either 
Runt (AML 1 A) or TA (AML IAN) domains. Both of them cannot activate 
transcription of target genes (Meyers et al. 1995; Zhang et al. 1997). The AML1AN 
isoform is transcribed from the distal promoter, therefore it encodes exon 1. There is 
an internal splice donor site within the exon 1 which is joined to a splice acceptor site 
within exon 4 during the AML1AN transcript splicing. Translation of the AML1AN 
protein is initiated by an ATG located within the exon 4. Therefore, the AML IAN 
protein does not contain the functional Runt domain and represents an N-truncated 
short isoforms. Accordingly, AML IAN neither bind DNA nor interacts with the 
CBFf3 protein. The AML1AN coexpression interferes with reporter gene activation 
mediated by AML1B in a few cell lines presumably by sequestering co-factors 
forming active transcription complex with long AML1 isoforms. AML1AN 
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expression has been found in a hematopoietic cell line at the level lower than long 
isoforms (Zhang et al. 1997). 
The polyadenylation signal for the short AMLIA isoform termination of 
transcription is located within the exon 7A, whereas polyadenylation signals 
involved in the termination of long isoforms transcription are located within the exon 
8 (Miyoshi et al. 1995). Therefore, AML 1A isoform does not contain the TA domain 
encoded by exons 7B and 8 which are located downstream exon 7A. Of note, exon 
7A is spliced out from the long isoforms transcripts. This exon encodes nine C-
terminal amino acids of the AML1A protein (Miyoshi et al. 1995). Whether this 
sequence play any functional role is unknown. Since AML1A encodes the Runt 
domain it binds DNA and heterodimerizes with the CBFI3 protein, but it is not 
capable of activating transcription of target genes due to absence of the TA domain 
(Bae et al. 1994; Meyers et al. 1995; Tanaka et al. 1995; Aziz-Aloya et al. 1998). 
Interestingly, the AML1A isoform shows higher affinity to the AML1 binding site 
than AML1B (Tanaka et al. 1995). AM1L1A is a minor isoform which expression 
could not be detected by the Northern blot hybridization using exon 7A as a probe 
(Miyoshi et al. 1995). As a result there is virtually no data on expression analysis of 
the AML 1A isoform. 
Experiments aiming to investigate the functional role of the AML1A short 
isoform suggest that it may act as a dominant negative inhibitor of the long isoforms. 
It has been shown that the long AMLIB isoform transfected into the P19 murine 
embryonal carcinoma (EC) cell line activated transcription of a reporter gene but the 
AML 1 A isoform cotransfection reduced the levels of the TepOrteT gene expression 
(Tanaka et al. 1995). Similar results have been shown in C33A human cervical 
carcinoma cells. Activation of a reporter gene by long AIvIL1C isoform has been 
reduced by cotransfection with the short AML 1A isoform (Meyers et al. 1995). 
Therefore it is conceivable that AML1 long isoforms which have both Runt 
and TA domains and are capable of activating transcription of hematopoietic specific 
genes may act as positive regulators of hematopoietic differentiation. The AIVIL 1 
short isoforms (especially, the AML1A isoform) may act as dominant negative 
regulators promoting self-renewal. I set out to test this hypothesis by generating a 
system in which overexpression of AML 1 individual isoforms can be achieved in ES 
cells. Since these ES cells may be differentiated into hematopoietic cells, 
overexpression of various AML isoforms will allow me to study their roles in 
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haematopoietic development. Various experimental systems for gene overexpression 
are discussed in the next chapter. 
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Chapter 2: INTRODUCTION 
Experimental systems for gene expression in ES cells 
2.1. Constitutive gene expression 
Constitutive expression of a gene of interest in ES cells is normally achieved 
by stable DNA transfection. The cDNA of interest is usually followed by a drug 
resistance gene for the stable transfectants selection. However, each stable 
transfectant is generated by a unique random integration event that entails significant 
variations in the levels of expression between clones which depends on surrounding 
genetic context. Furthermore, exogenous DNA may create insertional mutations 
resulting in unpredictable expression of endogenous genes. Both of these problems 
may be by-passed by using extrachromosomal (episomal) vectors for cDNA 
expression. Episomal vectors are circular double-stranded DNA molecules which are 
maintained in cells by extrachromosomal replication. Both cis and trans acting 
regulatory elements are necessary for the episomal vectors replication. The vector 
bears cis acting elements, whereas trans regulatory element(s) is usually integrated 
into genome of a host cell line (reviewed by Van Craenenbroeck et al. 2000). 
Transfection of the episomal vector in such cell line is called "supertransfection". 
Usually, episomal vectors encode a drug resistance gene ensuring the drug selection 
of supertransfectants. An episomal molecule can be maintained indefinitely in cells if 
the appropriate drug selection is applied (Gassmann et al. 1995). Transfection of 
episomal vectors is highly efficient and generates supertransfectants homogenous in 
the levels of cDNA expression. This accounts for successful application of these 
vectors in gain-of-function expression studies and functional screens (Aubert et al. 
2002; Chambers et al. 2003). 
2.2. Conditional gene expression 
2.2.1. Conditional gene activation using Cre recombinase 
Conditional gene expression systems have had a profound impact on gene 
function studies during the last decade. They proved invaluable in modelling various 
disease and research related to developmental biology and functional genetics. A 
significant disadvantage of a conventional gene targeting technology is that no 
research on adult animals can be done in the case of embryonic lethality. One way of 
avoiding this is to ablate (or to induce) gene expression in a specific tissue or at a 
definite developmental stage. Cre/ioxP technology proved to be a useful tool for this. 
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Cre (causes recombination) is the phage P1 site-specific recombinase (Sternberg and 
Hamilton 1981). It catalyses recombination between two 34 bp (base pairs) sites 
called lox? (locus of crossingover). Each loxP site consists of two 13 bp inverted 
repeats separated by an 8 bp spacer region. The spacer region confers directionality 
to a lox? site. Co-orientation of two lox? sites before recombination determines the 
structure of the recombination product. Cre does not require any ancillary phage or 
bacterial proteins for its function. Therefore, it has been successfully used in 
eukaryotic cells to mediate recombination between lox? sites incorporated both into 
chromosomal and extrachromosomal DNA (Sauer and Henderson 1988; Gu et al. 
1994). When two lox? sites are introduced into the genome in direct (head-to-tail) 
orientation and flank a genomic sequence, Cre expression causes excision of the 
foxed (flanking by loxP sites) fragment. The excised DNA fragment contains one 
lox? site and forms a circle. At the place of excision remains a single lox? site. The 
circular fragment lacks centromeres and quickly disappears since it cannot be 
maintained in the cells. If lox? sites have inverted (head-to-head or tail-to-tail) 
orientation, Cre catalyses inversion of the foxed fragment without excision. 
Conditional gene activation is achieved by placing a foxed stop cassette 
between a promoter and a coding sequence. As a result the transgene remains 
dormant. However, its expression can be achieved by Cre-mediated excision. 
Differential temporal and spatial expression of Cre predetermines time and place of 
activation of the dormant transgene. In the simplest case, Cre is driven by a tissue-
specific promoter making the transgene active in a particular cellular compartment 
only (Lakso et al. 1992). Other strategies employ chemical induction of either the 
Cre transgene transcription (Schneider et al. 2003) or translocation of Cre protein 
from the cytoplasm to the nucleus (Brocard et al. 1997; Kel!endonk et al. 1999). Cre-
mediated activation of the transgene has been successfully employed in a large 
number of studies. 
2.2.2. Conditional gene activation using chemical induction 
The Cre/lox? system allows conditional activation or inactivation of the gene 
of interest; however its further expression cannot be controlled. Other systems such 
as tetracycline-inducible systems offer more flexible control of regulation of gene 
expression. Such systems may also be useful for gene therapy applications. 
Currently, three systems (RU486, ecdysone and tetracycline gene inducible systems) 
are most widely used. All three systems contain two distinct genetic elements 
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incorporated into the cell. Such binary inducible systems contain a transcription 
activator driven by a tissue-specific promoter which is functional only in presence of 
an externally added small inducing molecule. Upon chemical induction active 
transcription activator binds to the second (responsive) element within the promoter 
which drives a gene of interest. The optimal inducible system must fulfil the 
following requirements (i) no expression of a reporter gene unless an inducer is 
added, (ii) high concentration-dependent magnitude in levels of expression of the 
gene of interest, (iii) no interference with cellular metabolic pathways. 
2.2.2.1. RU486 (mifepristone) gene expression system 
The RU486 (mifepristone) gene inducible system is based on the mutated 
human progesterone receptor (see Figure 5A). Progesterone is a steroid hormone 
which is involved in various biological functions. It is a lipophilic molecule which 
crosses the cell membrane and binds to the progesterone receptor in cytoplasm. Upon 
progesterone binding, the receptor undergoes conformational changes, enters the 
nucleus, homodimerizes and activates transcription of the promoter which contains 
the progesterone responsive element (PRE) (reviewed by Leonhardt et al. 2003). 
Progesterone antagonist RU486 (or mifepristone) acts as an inducer in this system. In 
addition this system uses a human progesterone receptor deletion mutant called PR-
891. The PR-891 mutant does not bind the endogenous progesterone, but becomes 
active upon interaction with RU486 (Vegeto et al. 1992). Since the PR-891 mutant 
receptor may activate any PRE-containing promoter it has been modified (Wang et 
al. 1994). The modified receptor contains only the PR-891 ligand binding (LB) 
domain fused to non-mammalian DNA-binding (DB) and transctivation (TA) 
domains (see Figure 5A). For that, yeast DB Gal4 domain which binds the 17 bp 
upstream activation sequence (UAS) (Giniger et al. 1985) and the herpes simplex 
virus (HSV) VPI6 TA domain (Triezenberg et al. 1988) were used. Since the UAS-
containing mammalian promoters are not known, the activation is expected to be 
specific. The functionality of the new chimeric transactivator called GLVP (a14 - 
LBD - VP16) was tested by cotransfection with a CAT (chloramphenicol acetyl 
transferase) reporter plasmid containing a promoter with four UAS. A little or no 
CAT activity was observed in the absence of RU486; however, its administration 
induced 10-20 fold reporter activity. Since RU486 is clinically used as a 
progesterone antagonist a concern was raised about its possible antiprogestin effect 
in vivo. However, it has been shown than RU486 upregulates a reporter at 
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Figure 5. Schematic representation of RU486 and ecdysone gene inducible 
systems 
RU486 gene inducible system. Transcriptional transactivator GLVP consists of 
the GAL4 DB (green circle), VP16 TA (red rectangle) and PR-891 LB (cyan 
triangle) domains. Upon the RU486 (blue star) addition, GLVP dimerizes, binds to 
the UAS (green rectangle) containing promoter and activates transcription of a 
reporter gene. 
Ecdysone gene inducible system. Ecdysone receptor (EcR) contains DB (orange 
circle), LB (pink triangle) and heterologous VP 16 TA (red rectangle) domains. Upon 
the ecdysone (yellow star) binding, EcR heterodimerizes with the RXR protein 
(violet oval). The heterodimer interacts with the EcRE containing promoter (orange 
rectangle) and activates transcription of a reporter gene. 
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concentration considerably lower than required for its physiological antagonistic 
activity (Wang et al. 1994). 
Since the first publication by Wang et al, the RU486 gene expression system 
was further improved and tested both in vivo and in vitro (Wang et al. 1997; Wang et 
al. 1997; Burcin et al. 1999). The goal of these studies was to modify GLVP in the 
way that it would gain lower background activity, higher fold activation and 
responsiveness to lower concentration of RU486. A more potent version of GLVP 
was generated by making use of a further deletion in the LB domain. Simultaneously, 
it is active at lower concentration of RU486 (Wang et al. 1997). A very high level of 
a reporter induction was achieved in vivo. The human growth hormone reporter gene 
was upregulated 33000 fold by RU486 in compound transgemc mice with the liver-
specific expression of GLVP (Wang et al. 1997). RU486 working concentrations are 
significantly lower than those that can cause physiological antiprogestin effect in 
vivo. Furthermore, RU486 is quickly metabolised in vivo and as a result the level of a 
reporter expression decreases significantly over 3-5 days (Wang et al. 1997; Burcin 
etal. 1999). 
2.2.2.2. Ecdysone gene expression system 
The ecdysone gene expression system (see Figure SB) is based on the insect 
hormone ecdysone which is a steroid hormone controlling critical developmental 
stages in Drosophila melanogaster (reviewed by Koziova and Thummel 2000). Like 
RU486, ecdysone crosses the cytoplamic membrane and binds to the cognate 
cdysone receptor (EcR). Upon the ecdysone binding EcR forms a heterodimer with 
a co-factor the Ultraspiracle (USP) protein. The EcR/USP heterodimer interacts with 
the ecdysone responsive element (EcRE) containing promoters and activates 
transcription of appropriate genes. Ecdysone is transcriptionally active only in 
complex with the USP protein (reviewed by Mangelsdorf and Evans 1995; Buszczak 
and Segraves 1998). An advantage of the ecdysone inducer is that it is not known as 
a transcriptional regulator of mammalian genes. Early experiments showed that 
contransfection of EcR and USP rendered the ecdysone responsiveness to monkey 
cells, although only 3 fold activation of a reporter gene was obtained (Yao et al. 
1992). The system was further improved, by replacement of the EcR TA domain 
with VP16 TA domain that provided better interaction between the receptor and the 
mammalian transcriptional machinery (No et al. 1996). The USP mammalian 
homologue RXR (retinoid X receptor) was also tested. Upon induction with 
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muristerone A (ecdysone analogue), the EcR/RXR heterodimer upregulated reporter 
activity by 212 fold. This system has also been tested in vivo and reporter induction 
was observed (No et al. 1996). Due to poor availability of the muristerone A, a large 
number of ecdysteroids was screened in order to identify a suitable inducer (Saez et 
al. 2000). As a result ponasterone A isolated from leaves of a widespread tree was 
found to be as a potent inducer of the ecdysone responsive genes both in vivo and in 
vitro. It induces genes specifically and fast (Albanese et al. 2000; Saez et al. 2000). A 
luciferase reporter was upregulated 100 fold by ponasterone A in the mouse skin 
(Saez et al. 2000). Therefore the ecdysone inducible system is characterised by low 
basal activity and non-interference with mammalian cellular metabolic pathways. 
Although the system may be very useful in gene expression studies; it has not been 
used a lot so far. Further studies on characterisation of the system are required. 
2.2.2.3. Tetracycline gene expression system 
The most widespread gene inducible system was generated by the Prof. 
Bujard group on the basis of the E. coil tetracycline resistance operon TnlO (see 
Figure 6A). The operon consists of two oppositely directed genes TetA and TetR. 
The regulatory sequence encoding promoters and operators is located between 5' 
ends of the genes. TetR is a transcriptional repressor controlling the tetracycline 
resistance operon while TetA is a membrane pump exporting tetracycline from cells 
(reviewed by Hillen and Berens 1994). TetR binds to the tetracycline resistance 
operator sequences 01 and 02 and shuts down transcription of both TetA and TetR 
genes in the absence of tetracycline. Once tetracycline has penetrated into the cell, it 
acts as an inducer of the tetracycline resistance genes. Tetracycline interacts with the 
TetR protein inducing its conformational changes and dissociation from the operator 
DNA thereby triggering transcription of both TetA and TetR genes 
The initial tetracycline regulatory (Tet-Off) system was generated for 
inducible repression of genes (Gossen and Bujard 1992) (see Figure 613). The TetR 
repressor was converted to a transcriptional activator by fusing to the VP16 TA 
domain. This chimaeric regulator called tetracycline transactivator (tTA) was tested 
in contransfection assays with a plasmid encoding the artificial tetracycline 
responsive promoter (TRP). TRP is composed of 7 repeats of the 19 bp 02 operator 
sequence upstream the minimal cytornegalovirus immediate early (CMV IE) 
promoter. Interaction with tetracycline induces conformational changes of tTA 
triggering its dissociation from a promoter and therefore the gene of interest remains 
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TetR-tet 











Figure 6. Schematic representation of natural and artificial tetracycline 
responsive systems 
The tetracycline resistance operon. The TetR repressor (violet circle) binds to 
operator sequences (blue rectangles) and shuts down transcription of the TetR and 
ThA genes, Once tetracycline (blue star) is added, it complexes with TetR 
preventing its interaction with DNA and activating transcription. 
Tet-Off system. tTA (the TetR repressor (violet circle) fused to the VP16 TA 
domain (orange rectangle)) activates transcription of a reporter gene driven by the 
tetracycline-responsive promoter (TRP) (blue arrows). TRP consists of the 7 repeats 
of the 02 operator sequence followed by the CMV IE minimal promoter. 
Tetracycline (cyan star) impedes the tTA binding with TRP thereby preventing the 
reporter gene transcription. 
Tet-On system. Reverse tTA (rtTA) is transcriptionally inactive unless 
tetracycline (or doxycycline) is added. Therefore, there is no reporter expression in 
the absence of doxycycline; however it is induced once doxycycline is added. 
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inactive. Both regulatory and responsive plasmids were stably transfected into human 
HeLa cells. However, the levels of the luciferase reporter gene expression in the 
presence of tetracycline differed significantly between clones probably due to 
position effect. The withdrawal of tetracycline upregulated the luciferase activity in 
all clones up to 5 orders of magnitude. Expression of a reporter gene decreased in a 
dose-dependent manner upon the addition of tetracycline (Gossen and Bujard 1992). 
Further development of the system led to generation of its Tet-On version 
with tetracycline acting as an inducer of the reporter gene transcription (see Figure 
6C). The mutant reverse TetR (rTetR) which binds to DNA upon addition of 
tetracycline was fused to the VP 16 TA domain. As a result a reverse transcriptional 
transactivator (rtTA) has been generated (Gossen et al. 1995). rtTA binds TRP and 
activates transcription only in the presence of tetracycline or its analogue 
doxycycline. Doxycycline induces a reporter gene more effectively than tetracycline 
and therefore has been used in all subsequent studies. However, rtTA tends to have 
background activity and furthermore, induces responsive promoters weaker than 
tTA. Accordingly, research aimed to isolate a more potent version of rtTA was 
undertaken (Urlinger et al. 2000). Firstly, TetR was fused to three minimal VP16 TA 
domains (VP I 6) optimized for expression in human cells. VP 1 6 lacks sites that 
potentially are capable of interaction with cellular proteins that reduced its 
cytotoxicity. As a result experiments with the TetR-VP 1 6mifl  fusion showed that 
HeLa cells became capable of tolerating higher TetR-VP16n i,, concentrations (Baron 
et al. 1997). Secondly, a library of mutant TetR-VP16min has been generated and the 
mutants that showed positive regulation by tetracycline were selected. The most 
promising mutant rtTA2SM2  contained four amino acid substitutions. It had no 
background activity in the absence of doxycycline, upregulated the reporter up to 4-5 
orders of magnitude upon the doxycycline addition and activated the reporter 
expression in a dose-dependent manner. Importantly, rtTA2SM2  induced the 
reporter at the lower concentration of doxycycline than all others regulators (Urlinger 
et al. 2000). Thus, rtTA25-M2 is a new highly improved doxycycline-dependent 
reverse transactivator. 
In contrast to tTA, which underwent significant modifications since its 
generation, TRP has not been changed considerably. Two minimal promoters (CMV 
IF and HSV TK (thymidine kinase)) were tested as a the 3' end part of TRP and the 
CMV IF promoter occurred the most highly inducible (Gossen and Bujard 1992; 
Freundlieb et al. 1997). Essential modification of TRP included construction of a 
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bidirectional TRP (hTRP)  (Baron et al. 1995). bTRP consists of the 02 heptamer 
surrounded by two CMV JE minimal promoters in the head-to-head orientation. As a 
result, bTRP can activate simultaneous transcription of two independent genes 
flanking the promoter. Thus, the bTRP vectors can simultaneously drive expression 
of a gene of interest and a reporter gene (for instance, EGFP) (Hess et al. 2001; 
Krestel et al. 2001). The reporter gene provides a valuable tool to monitor expression 
of gene of interest. 
Both Tet-Off and Tet-On systems were successfully tested in vivo (Kistner et 
al. 1996). Administration of doxycycline to animals carrying both the rtTA and TRP-
reporter transgenes induced the reporter gene up to 5 orders of magnitude. Low 
background, high inducibility and using a non-toxic inducer promise successful use 
of the tetracycline gene expression system in various studies which aim to elucidate 
gene functions. The increasing number of reports further confirm versatility of the 
system (Mansuy et al. 1998; Shin et al. 1999; Legname et al. 2000). 
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Chapter 3: MATERIALS AND METHODS 
Analytical grade reagents were supplied by Sigma, Fisher and BDH 
Laboratory Supplies. Synthetic oligonucleotides were ordered from Oswell DNA 
Service (University of Southampton). dCT32P radioisotope was supplied by 
Amersham. 
3.1. Molecular biology methods 
Basic molecular biology techniques and solution preparation were carried out 
as recommended by (Sambrook et al. 1989). 
3.1.1. List of main solutions 
6x DNA loading buffer: 0.25% bromophenol blue; 30% glycerol in water 
LB: 1% (w/v) tryptone (Difco); 0.5% (w/v) yeast extract (Difco); 85mM NaCl 
PBS (phosphate buffered saline): 0.01M phosphate buffer; 0.0027M potassium 
chloride; 0.137M sodium chloride, pH 7.4 
20x SSC (saline - sodium citrate): 3M NaCl; 0.3M sodium citrate 
lx TAE: 0.04M Tris-acetate; 0.00 IM EDTA 
0.5x TBE: 0.0045M Tris-borate; 0.001M EDTA 
TE: 10mM TrisHCl (pH 8.0); 1mM EDTA (pH 8.0) 
3.1.2. Cloning 
3.1.2.1. General remarks 
Cloning procedures involved restriction digestion of plasmids, filling of 5' or 
removal of 3' protruding ends (if necessary), isolation of DNA fragments from 
agarose gel, ligation, transformation of bacterial cells and selection of desirable 
transformants. After each enzymatic treatment DNA was extracted using 
consecutively TE-saturated phenol pH 7.8 and phenol-chloroform (1:1), precipitated 
using two volumes of 96% ethanol, washed using 70% ethanol, air dryed and 
dissolved in TE. Concentration of DNA fragments was determined by comparing the 
intensities of fragments fluorescence in UV with DNA standards following 
electrophoresis in 0.5-2% agarose gel. Agarose gel electrophoreses were set up using 
Ix TAE; 0.5 mgk!mL ethidiurn bromide was to added to gel. 0.5-1 .tg of 1 kb DNA 
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ladder (Gibco BRL) was loaded on each gel as a size standard. DNA samples were 
loaded in lx DNA loading buffer. 
3.1.2.2. Restriction 
Plasmid DNA was digested using the appropriate restriction enzymes in lx 
reaction buffer at conditions recommended by a manufacturer. Restriction enzymes 
were supplied by Roche and New England Biolabs. 
3.1.2.3. 5' overhang nucleotides filling and 3' overhang nucleotides removal 
5' overhang nucleotides were filled in and 3' overhang nucleotides were 
removed using the T4 DNA Polymerase (New England Biolabs) in lx T4 DNA 
Polymerase buffer (New England Biolabs) supplemented with the 4mM dNTPs 
mixture (Roche) and 50pg/mL BSA (New England Biolabs). 1U of the enzyme was 
added per 1 pmole of 5' ends. Reaction mixture was incubated at 12° C for 20 
minutes, after that the reaction was stopped by heat inactivation at 75°C for 10 
minutes. 
3.1.2.4. Isolation of DNA fragments from agarose 
DNA samples were run in 1-2% agarose gel. A well was cut out before a 
band of interest and cast with 1% low melting temperature (LMT) agarose gel. Once 
LMT agarose gel solidified the electrophoresis was continued till the band of interest 
reached the center of the LMT agarose fragment. After that, the LMT agarose 
fragment was cut out and melted at 65°C for 10 minutes. DNA was consecutively 
extracted using TE-saturated phenol p11 7.8 (twice) and chloroform (twice), 
precipitated using one volume of isopropanol, washed using 70% ethanol, air dryed 
and dissolved in TE. 
3.1.2.5. Ligation 
Ligation was set up at the vector:insert molar ratio 1:4 using 1-5U of the T4 
DNA ligase (Roche) in lx T4 DNA ligase buffer and incubated at 4°C for 16 hours. 
A self-ligation control reaction was set up in parallel. For the oligonucleotide adaptor 
ligation, 	the 	5'-CATTCCCCTCCCCTACGTAC-3' 	and 	5'- 
GTAGGGGAGGGGAATG-3' complementary oligonucleotides were denatured at 
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95°C for 5 minutes and annealed by the slowly cooling till 45°C. The oligonucleotide 
adaptor was ligated to a vector using 5U of the T4 DNA ligase (Roche) in Ix T4 
DNA ligase buffer at 37°C for 2 hours. 
3.1.2.6. Transformation of E. coli bacterial cells 
Epicurian Coli XLI -Blue competent cells (Stratagene) were transformed with 
5-10% of the ligation reaction volume according the manufacturer's protocol and 
spread onto LB plates with 1.5% agar and 100 .ig!mL ampicillin. The plates were 
incubated at 37°C for 14-16 hours. 
3.1.2.7. Screening of recombinant clones 
If the ligation reaction transformants gave at least 5 times more colonies than 
the self-ligation transformants, the colonies were screened for the presence of an 
insert by plasmid isolation and restriction digestion. In all other cases the colonies 
were screened by colony lift and hybridisation with the radioactive labelled cloning 
insert. 
3.1.2.7.1. Colony lifts 
The positively charged nylon membrane (Roche) was placed on the plates 
with bacterial transformants (master plates) for 1 minute and punctured to mark the 
orientation. The membrane was peeled off a plate and laid colony side up onto a new 
plate with LB 1.5% agar ampicillin and 100 j.tg/mL ampicillin. The plate with 
membrane was incubated at 37°C for 6-8 hours. After that, the membrane was peeled 
off a plate and incubated colonies side up on the Whatman 3M paper soaked in the 
denaturing solution (1.5M NaCl; 0.5M NaOH) for 5 minutes followed by the paper 
soaked in the neutralisation solution (1.5M NaCl; 0.5M TrisHCl pH 7.5) two times 
per 5 minutes, rinsed in 2x SSC, air dryed and baked at 120°C for 30 minutes. 
Master plates were incubated at 37°C for 1-2 hours to let the bacteria recover. 
3.1.2.7.2. Hybridisation of the membrane with a radioactive probe 
The membrane was prehybridised in 10-15 mL of the Church-Gilbert buffer 
(0.25M sodium phosphate pH 7.2; 7% SDS) at 65°C for 1 hour in the Techne 
rotating oven. After that, 5 niL of the Church-Gilbert buffer containing the 32P 
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labelled probe was added to the membrane. Hybridisation was carried out in the 
same conditions as prehybridisation. Unbound probe was washed out by 3-5 
consecutive incubations with the washing solution (30mM sodium phosphate pH 7.2; 
0.1% SDS) at 65°C for 20 minutes. After that, the membrane was wrapped in Saran 
wrap and exposed to the Kodak film in intensifying screens at -70°C for 1-2 hours. 
Positive colonies were selected, picked up from master plates, expanded and further 
verified by restriction digestion. 
3.1.2.7.3. Radiolabelling of DNA 
DNA fragments were labelled with using the Rediprime II random prime 
labelling system (Amersham) according the manufacturer's protocol. Uncorporated 
nucleotides were removed using the ProbeQuant G-50 microcolumns (Amersham). 
Probes were denatured at 95-100°C, chilled in liquid nitrogen and added to the 
hybridisation buffer. 
3.1.2.8. Isolation of plasmid DNA 
Plasmid DNA was purified from 3-100 mL of overnight culture of a single 
bacterial colony in the LB medium with 100 j.tg!mL ampicillin. Isolation of plasmid 
DNA was performed using the minispin and maxiprep kits (Qiagen) according the 
manufacturer's protocol. Structure of isolated plasmid was verified by restriction 
digestion. 
3.1.2.9. Site-directed mutagenesis 
Site-directed mutagenesis was performed using the GeneEditor in vitro site-
directed mutagenesis system (Promega) according the manufacturer's protocol with 
the 	5' 	phosphorylated 	mutagenic 	oligonucleotide 	5'- 
pTGTGATGTGTATCCCCGTAG-3'. Mutant plasmids were screened by sequence 
using the AML  gene specific primer 5'-TGGAAGGCGGCGTGAAG-3'. 
3.1.2.10. TA cloning of PCR products 
PCR cycling was followed by the incubation at 72°C for 7 minutes for the 3' 
A-overhangs addition. After that, an aliquot of PCR products was analysed by 
electrophoresis in 1% agarose gel. The PCR products were cloned into the pCR2.1 
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vecotor using TA cloning kit (Invitrogen) according the manufacturer's protocol. 
Transformed bacteria were plated into plates with the LB 1.5% agar medium 
supplemented with 100 g/mL ampicillin and 40 mkL each of lOOniM IPTG and 40 
mg/mL X-gal spread over plates. The plates were incubated at 37°C for 16 hours. 
Plasmids isolated from three white bacterial colonies were sequenced using the T7 
primer 5?TAATACGACTCACTATAGGG3!.  
3.1.3. DNA sequencing 
Sequence was performed by David Kivlichan and Jil Lowell (The University 
of Edinburgh) using the BigDye dideoxy termination sequencing kit and a Perkin 
Elmer ABI-Prism automated DNA sequencer. Sequences were analysed using the 
ChromasPro and GeneRunner software. 
3.1.4. PCR (polymerase chain reaction) 
PCR reaction were set up using either 10 jtg of a plasmid or 100 .tg  of the 
genomic DNA template, 10 pmoles of each primer, 0.2 mM dNTPs and 2.5 U of Taq 
DNA polymerase (Qiagen) in lx PCR buffer (Qiagen). All PCR reactions were 
carried out on Biometra UNOII Thermocycler. The PCR reaction with the genomie 
DNA template was denatured at 94°C for 3 minutes before the Taq DNA polymerase 
addition. Cycling conditions and sequenced of primers were as follows. 
External hybridization probe for the AML1/rtTA regulatory ES cells and mice 
genotyping 
Template: the pAML42 plasmid 
Primers: 	5'-AAGTTGAAAGCATGGGGG-3' 	(forward) 	and 	5'- 
TAATACGACTCACTATAGGG-3' (reverse) 
25 cycles: 94°C 30 see, 51°C 30 see, 72°C 1 mm. 
Neor hybridisation probe for the regulatory ES cells genotyping 
Template: the pLNeo'L plasmid 
Primers: 	5'-CTGTGCTCGACGTTGTCAC-3' 	(forward) 	and 	5'- 
AGCTCTTCAGCAATATCACG-3' (reverse) 
25 cycles: 94°C 30 see, 59°C 30 see, 72°C 40 sec. 
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Exon 3 AML  hybridisation probe for the responsive mice genotyping 
Template: the pXba3 plasmid 
Primers: 	5'-CTTGTTGTGATGCGTATCC-3' 	(forward) 	and 	5'- 
GTCTTGTTGCAGCGCCA-3' (reverse) 
30 cycles: 94°C 30 sec, 57°C 30 sec, 72°C 40 sec. 
The reaction mixture was supplemented with lx Q-solution (Qiagen) 
238 bp fragment encoding the lox? site in AinvlS cells 
Template: genomic DNA isolated from the AinvlS cells 
Primers: 5'-TTTGACCTCCATAGAAGACACCG-3' (forward) and 5'- 
AGCCGATTGTCTGTTGTGCC-3' (reverse) 
40 cycles: 94°C 30 sec, 57°C 30 sec, 72°C 30 sec. 
PCR products were analysed on a 1% agarose gel in lx TAE. 0.5-1 .tg of 1 kb DNA 
ladder was loaded on each gel as a size standard. 
3.1.5. Isolation of DNA fragments for pronuclear microinjections 
DNA fragments for pronuclear microinjections was electroeluted from 
agarose gel using the Elutrap Electro-Separation system (Schleicher&Schuell) 
according the manufacturer's protocol, precipitated using two volumes of 96% 
ethanol, washed using 75% ethanol, air dyed and dissolved in TE. 
3.1.6. Southern blot hybridisation 
3.1.6.1. Isolation of genomic DNA from ES cells and animal tissues 
ES cells were grown to confluence into 12- or 6-well plates, rinsed with PBS 
and lysed with lysis buffer (100mM TrisHCl pH 8.5; 5mM EDTA; 0.2% SDS; 
200mM NaCl; 100 j.tg/mL proteinase K (Roche)) or the lysis buffer was added to tail 
or ear biopsies. Both cell and tissue lysates were incubated at 55°C for 16 hours. 
DNA was extracted with TE—saturated phenol-chloroform (1:1) and precipated with 
equal volume of isopropanol, washed with 75% ethanol, air dryed and dissolved in 
TE. Concentration of DNA fragments was determined by comparing the intensities 
of fragments fluorescence in UV with DNA standards following electrophoresis in 
1.5% agarose gel. 
me 
3.1.6.2. Restriction digestion of genomic DNA 
5-10 ig of genomic DNA were digested with 50U of either Afi II (NEB) or 
Eco RV (Roche) restriction enzyme in the appropriate lx restriction buffer. BSA 
(final concentration 100 tg/mL) was added to the Afi II restriction reactions. The 
reactions were incubated at 37°C for 20-24 hours. 
3.1.6.3. Electrophoresis 
Electrophoresis in 0.7% agarose gel 1xTAE pH 7.5-7.8 was performed for 16 
hours at 1 V/cm. 0.5-1 .tg of 1 kb DNA ladder was loaded on each gel as a size 
standard. lOx DNA loading buffer was added to each restriction reaction before 
loading. 
3.1.6.4. Blotting 
Genomic DNA was transferred from agarose gel onto the Hybond-N+ nylon 
membrane (Amersham) by the download transfer in the TurboBlotter apparatus 
(Schleicher&Schuell) according the manufacturer's protocol. DNA transfer was 
performed in the alkaline transfer buffer (0.4M NaOH; 0.6M NaCl) for 16 hours at 
room temperature. After transfer a membrane was rinsed 3 times for 5 minutes in 2x 
SSC and baked at 80°C for 2 hours. 
3.1.6.5. Hybridization. 
Membranes were prehybridised in 15 mL of the Church-Gilbert hybridization 
buffer (0.5M [NaiPO4 pH 7.0; 7% SDS; 2mM EDTA; 100 .tg/mL denatured 
heterologous DNA) at 65°C for 3-24 hours in the Techne rotating oven. 
Hybridisation was performed in 15 mL of the Church-Gilbert buffer with the 32P 
radiolabelled probe at 65°C for 16 hours on a rotator. Unbound probe was washed 
out by 3-5 consecutive incubations in the washing solution (0.2x SSC; 0.1% SDS) at 
65°C for 15-20 mm. After that, the membrane was wrapped in Saran wrap and either 
exposed to the Kodak film in intensifying screens at -70°C for 1-10 days or in a 
phosphoirnager cassette for 3-48 hours. 
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3.1.6.6. Labelling reaction 
DNA for labelling was obtained by either restriction digestion or PCR 
amplification and purified by the isolation from the 1% LMT agarose. Reagents for 
the labelling reactions were obtained from the DECAprime II DNA labelling kit 
(Amersham). 75 ng of DNA were dissolved in 30.5 mkL of water, 7.5 mkL of lOx 
DECAmer primer was added and the mixture was denatured by boiling for 5 minutes 
and chilled in liquid nitrogen. 15 mkL of the 5x reaction buffer —CTP, 200mkC1 of 
dCT32P and IOU of the exonuclease-free Kienow enzyme were added. The reaction 
was incubated at 37°C for 2 hours and stopped by 13.3mM EDTA. DNA was 
denatured again by boiling for 5 minutes and chilled in liquid nitrogen. Uncorporated 
nucleotides were removed using the ProbeQuant G-50 microcolumns (Amersham). 
3.1.6.7. Probe stripping 
If reprobing was planned, was membrane was incubated in the boiling 
0. 1xSSC; 0.5% SDS for 5-10 minutes. After that the membrane was exposed for 16 
hours. 
3.1.7. Isolation and reverse transcription of RNA 
Aseptic RNAase-free technique was followed during all manipulations with 
RNA. This included using RNAse free disposable plasticware (Ambion), DEPC 
treated glassware, pre-treatment of all solutions with DEPC. 
3.1.7.1. RNA isolation 
RNA was isolated using the RNeasy mini kit (Qiagen) according the 
manufacter's protocol. Concentration of RNA was determined by comparing the 
intensities of fragments fluorescence in UV with RNA standards following 
electrophoresis in 1% agarose gel in lx TBE. Contaminating genomic DNA was 
degraded by DNAse I (DNA-free, Ambion) in lx DNase I buffer (Ambion) at 37°C 
for 1 hour. After that DNAse I was inactivated using the DNAse inactivation reagent 
(Ambion) according the manufacturer's protocol. 
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3.1.7.2. Reverse transcription - Qolymerase chain reaction (RT-PCR). 
1 tg of DNA-free RNA was used as a template for the random primed 
reverse transcription reaction using the RETROscript first-strand synthesis kit for 
RT-PCR (Ambion) according the manufacturer's protocol. 10% of the reaction final 
volume was used as a template for PCR. Templates were mixed with 10 pmoles of 
each primers, dNTPs (Roche) (final concentration of each dNTP 0.2mM), lOx PCR 
buffer (Qiagen) and heat at 94°C for 3 minutes. After that 0.625 U of Taq DNA 
polymerase (Qiagen) diluted in the lx PCR buffer buffer (Qiagen) was added to each 
PCR reaction. PCR was carried out on Biometra UNOTI Thermocycler. Cycling 
conditions and sequences of PCR primers are tabulate below (Table 1): 
Table 1. PCR conditions 
Target Primers PCR conditions 
gene  
AML  Forward: 5' CCAGCAAGCTGAGGAGCGGCG 3' 35 cycles: 94°C 1 mm, 
Reverse: 5' CCGACAAACCTGAGGTCGTTG 3' 60°C 	1 mm, 72°C 	1 
mm. 
rtTA Forward: 5' AACAACGCCAAGTCATTC 3' 40 cycles: 94°C 30 sec, 
Reverse: 5' GCCGAAAAGGAAGGCAG 3' 56°C 30 sec, 72°C 40 
sec. 
actin Forward: 5' CCAGAGCAAGAGAGGTATC 3' 30 cycles: 94°C 30 sec, 
Reverse: 5' TGGAAGGTGGACAGTGAG 3' 55°C 30 sec, 72°C 1 
mm. 
PCR products were analysed on a 1% agarose gel in lx TAE. 0.5-1 tg of 1 kb DNA 
ladder was loaded on each gel as a size standard. 
3.1.8. Luciferase reporter assay 
Cells on 12- or 6-well plates were lysed using lx passive lysis buffer 
(Promega). Lysates were clarified by centrifugation at 16000xg for 30 seconds. 
Firefly and Renilla luciferase activities in the lysates were assayed using the Dual-
Luciferase Assay System (Promega). Luminescence was measured using the 
Mediators Diagnostic Systems PhL machine. 
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3.2. Cell biology methods 
Routine culture of ES cells was carried out as recommended (Smith 1991). 
All ES cell manipulations were performed in laminar flow sterile hoods using a strict 
sterile technique that included wiping the hood down and spraying all items entering 
the hood with 70% industrial methylated spirits. Cell culture plasticware was 
supplied by Iwaki and Nunc. All cell culture plates were gelatinised (0.1% gelatine in 
PBS for 20 minutes). Undifferentiated ES cells were grown in 7.5% CO2 at 37°C in 
a humidified incubator (Laboratory Supplies Ltd). All solutions were tested for 
sterility and warmed to 37°C prior to use. ES cells were examined using an inverted 
microscope (Olympus CK2). ES cells were maintained in lx GMEM ES cells culture 
medium containing 10% fetal calf serum, 0.1% MEM non-essetial amino acids, 
4mM glutamine, 2mM sodium pyruvate, 0.1 mM 3-mercaptoethanol. The medium 
was supplemented with recombinant human LIF (100u/mL). LIF conditioned 
medium was prepared by transient transfection of COS-7 cells by the LIF expression 
medium (Smith 1991). Plasmid DNA solution was sterilised before transfection. For 
that, it was precipitated using 96% ethanol, washed with 70% ethanol, air dryed in a 
hood and dissolved in sterile PBS. All solutions for tissue culture experiments 
including LIF conditioned medium were prepared by the tussue culture staff. 
3.2.1. Thawing ES cells 
A vial with frozen ES cells was taken from the liquid nitrogen storage and 
thawed in a 37°C water bath. The cell suspension was transferred to a tube with 7 
mL of pre-warmed ES cell medium and centrifuged immediately at 300xg for 3 
minutes. The cell pellet was resuspemded in ES cell medium and transferred into the 
gelatinised cell plate. The medium was changed next day in order to remove dead 
cells and traces of DMSO. 
3.2.2. Passaging and expansion of ES cells 
ES cells were usually passaged every two days. The cells were washed with 
PBS; 2-3 mL of trypsin solution was added to a 100mm Petri dish and incubated at 
37°C for 3-5 minutes. The cells were pipetted until a single cell suspension was 
obtained. After that trypsin was netralised with the ES cell medium and an aliquot of 
cells was plated onto a new gelatinised plate. 
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3.2.3. Freezing of ES cells 
The cells were trypsinised, pelleted by centrifugation, resuspended into 0.9 
mL of the ES cell medium and transferred to a cryovial (Nunc). 0.1 mL of DMSO 
was added to the cell suspension and cryovials were rapidly transferred to a -80°C 
freezer. 24 hours latter cryovial were transferred to liquid nitrogen storage. 
3.2.4. Transfection of ES cells 
3.2.4.1. Electroporation 
The cells were trypsinised and counted in a hemocytorneter. The appropriate 
number of cells was pelleted by centrifugation, resuspended in PBS, pelleted again, 
resuspended in 0.7 mL of PBS and transferred into an electroporation cuvette 
(BioRad 0.4.cm gap). DNA dissolved in 0.1 mL of PBS was added to the cuvette. 
Amount of cells and DNA used for different electroporation experiments are 
tabulated below (Table 2). 
Table 2. Conditions of electroporation 
Experiment Number of cells Amount of DNA 
AML  gene targeting lx 107  40 tg 
Cre-plasmid 	transient 
transfection  
lx 10 2 jig 
Single lox? targeting 5x 107 100 jig of each plasmid 
Electroporation was performed in GenePulser transfection apparatus (BioRad) at 
240V, 500 mkF usually giving a time constant of 6.2-7.8 msec. Electroporated cells 
were rapidly transferred to 7 mL of ES medium and plated. Drug selection was 
started 24-48 hours after electroporation. Cells were selected using 300-350 jig/mL 
of G418 12-15 days. The drug-containing medium was changed every two days. 
Drug resistant colonies were picked up with a Pasteur pipette and transferred into a 
24- or 48-well plate for further expansion. 
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3.2.4.2. Lipofection 
3.2.4.2.1. Lipofection of the E14/T cells with episomal vectors 
1x106 of E14/T cells were plated onto a well of a 6-well plate and lipofected 
using 3 tg of DNA and 3 nikL of the Lipofectamine 2000 reagent (Invitrogen) 
according the manufacturer's protocol. Two days latter the lipofected cells were 
replated onto 100 mm dishes at low density (2x103 and 5x104 cells per plate) into the 
puromycin (2 1gImL) containing medium with or without LIF. The puromycin-
containing medium was changed every two days. On the tenth day of selection the 
cells were stained using the Leishman's reagent. For this purpose, the medium was 
aspirated, the Leishman's reagent (BDH) was added and the cells were incubated for 
5 minutes ar room temperature. After that the Leishman's reagent was aspirated and 
the cells were rinsed with water. 
3.2.4.2.2. Lipofection of the regulatory and B8 ES cells with AMLllluciferase 
responsive constructs 
1.5x10' cells were plated onto a well of a 12-well plate and lipofected 16 
hours later using 0.5 jtg of DNA and 3 mkL of the FuGENE 6 reagent (Roche) 
according the manufacturer's protocol. 
3.2.5. Self-renewal assay 
450 Amy 15 cells or their derivatives were plated per well of a 6-well plate 
with the ES cell medium containing doxycycline. Concentrations of doxycycline 
ranged between 5 ng!mL and 1000 p.g/mL. The medium was changed every two 
days. After 10-14 days of cultivation the cells were washed once with PBS, fixed and 
stained using the Alkaline Phosphatase Leukocyte kit (Sigma-Aldrich) according the 
manufacturer's protocol. 
3.2.6. Differentiation of ES cells 
3.2.6.1. EB differentiation assay 
ES cells were trypsinised at room temperature till cell clumps detached from 
plastic. After that, the ES cell medium without LIF was added and the cells were 
transferred into 30 mm bacterial dishes (Sterilin). EB suspension was pipetted every 
day in order to prevent EBs from adhering to plastic. Routinely, the medium was 
changed every 2 days. For this purpose, the EB suspension was transferred to a tube 
and EBs were let to sediment by gravity. After that, the medium above the 
supernatant was aspirated and a fresh medium was added. Similarly, EBs were 
collected for lysis. 
3.2.6.2. Methylcellulose differentiation assay 
Single cell suspension was obtained from growing ES cells by trypsinisation, 
followed by centrifugation and further resuspension at concentration 30 cells/mkL in 
complete medium without LIF. 10 mkL drops were plated onto a 150-mm bacterial 
dish (Sterilin) using a multichannel pipette. Inverted dishes were incubated at 37°C 
in 5% CO2 for 48 hours. A 100-mm dish with PBS was put inside each iverted dish 
in order to prevent evaporation of the hanging drops. EBs were collected by flushing 
the dishes with PBS, transferring to a tube and letting the EBs to sediment by gravity. 
After that, EBs were suspended in a fresh ES cell medium without LIF, transferred 
into 100-mm bacterial dishes and incubated at 37°C in 5% CO2 for 6 days on a 
rotating shaker (50 rotations per minute). The medium was changed every two days 
and doxycycline (final concentration 1 pg/mL) was added when appropriate. On the 
sixth day, EBs were trypsinised, cells counted and aliquoted. 100 rnkL aliquots 
containing 2x104 - 5  X104 cells were mixed with 1.5 mL of the Methocult GF M3434 
medium (StemCell Technologies Inc) and plated onto 30-mm bacterial dishes 
(Sterilin). Plates were incubated at at 37°C in 5% CO2 for 10-15 days. 0.5 ml, of the 
fresh medium was added on the sixth day of differentiation. 
3.2.7. Flow cytometry 
3.2.7.1. Preparation of cells for flow cytometry 
Single cell suspensions were obtained by trypsinisation of cells. After that, 
the cells were counted using a hemacytometer and resuspended at 1x106 cells/mL in 
cold PBS/10% FCS solution. Flow cytometry analysis was performed on 
FACSCalibur analyser (BD Biosciences). All FACS procedures were assisted by 
FACS operator in ISCR, Jan Vrana. 
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3.2.7.2. Co-staining using annexin V-PE and 7-AAD 
Cells were prepared for staining as described above and stained using the 
Annexin V-PE apoptosis detection kit I (BD Biosciences) according to a 
manufacturer's protocol. 
3.3. Animals 
All animals were housed and bred within Biomed Unit (ISCR, The University 
of Edinburgh) according to the provisions of the Animals (Scientific Procedures) Act 
(UK) 1986. Mice were housed in a stabilised environment with a 14 hours light/10 
hours dark cycle and were provided with a constant supply of water and food. 
Routinely, litters were left with parents until 3 weeks of age when they were weaned 
by separating the offspring from their parents and tail tips were taken for genotyping. 
At 6 weeks of age mice could be used for mating. 
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Chapter 4: RESULTS 
Constitutive expression of individual isoforms of AMLI in ES 
cells 
4.1. Introduction 
The aim of the project was to generate AMIL1 overexpressing ES cell lines. 
First, an attempt to generate ES cell lines constitutively overexpressing individual 
isoforms of AML 1 was undertaken in order to (i) test putative cytotoxic effects, (ii) 
investigate influence of individual isoforms of AML1 on the development of 
hematopoietic progenitors. For this purpose, episomal vectors for expression of 
foreign cDNA in ES cells were used (Aubert et al. 2002). These vectors encode the 
polyoma virus enhancer and origin of replication (see Figure 7). The origin of 
replication carries the PyF1OI mutation. This mutation has been shown to be 
favourable for the productive infection of EC cells (Fujimura et al. 1981). The 
PyF 101 origin of replication was successfully used in episomal vectors for ES cells 
(Gassmann et al. 1995). An E14/T ES cell line constitutively expressing the polyoma 
large T antigen was used for the episomal vectors supertransfection. Large T antigen 
is necessary for the polyoma virus origin of replication activity. The E14/T cells 
showed normal self-renewal and differentiation capacities (Aubert et al. 2002). The 
episomal vector used contains a bi-cistronic gene expression cassette encoding a 
cDNA of interest. The bi-cistronic cassette is driven by a strong ubiquitous CAG 
promoter functional in many cell types including ES cells (Niwa et al. 1991). The 
first cistron encodes a cDNA of interest followed by ECMV (encephaIoyocarditis 
virus) IRES which ensures initiation of translation in the second cistron. The second 
cistron encodes the puromycin resistance gene (Puro') followed by the bovine growth 
hormone (BDH) polyadenylation (pA) signal. When puromycin is applied to 
supertransfected E14/T cells only cells harbouring the episomal vector survive. The 
vector also contains ColE 1 origin of replication and may be amplified in E. co/i in 
presence of ampicillin. 
4.2. Generation of episomal vectors 
Three novel episomal vectors were generated on the basis of an EGFP 
containing episomal vector described above which had been provided by Dr. Ian 
Chambers (University of Edinburgh). EGFP was cut out from the original vector by 








Figure 7. Diagram of episomal vectors 
Three vectors with different inserts (EGFP, AML1A and AMLIB) and a vector 
without any insert were used for supertransfection ofEl4/T cells. Py: polyoma virus. 
Intron: a chimeric intron consisting of the chicken 13-actin and rabbit 3-g1obin gene 
fragments. See text for the detailed description of other elements of the vector. 
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self-ligation, (ii) ligation of the AML1A and AML1B inserts. The self-ligation 
yielded a control vector without an insert. Plasmids with human AML1A and 
AMLIB cDNAs were kindly provided by Dr. Issay Kitabayashi (Japan). The AML  
cDNAs were tagged with epitopes at their N-termini. The 0.8 kb HA-AML IA and 
1.4 kb Flag-AML1B inserts were cut out using the Stu I and Cla I restriction 
enzymes. The CIa 1 5' protruding ends of the inserts and Eco RI 5' protruding ends 
of the vector were filled-in using T4 DNA polymerase before ligation. Recombinant 
molecules with the head-to-tail orientation of the AML1A (or B) and Puror  genes 
were selected and verified by sequence. 
4.3. Supertransfection of ES cells 
El 4/T cells for supertransfection with episomal vectors were provided by Dr. 
Ian Chambers (ISCR, University of Edinburgh). Control vectors with and without 
EGFP insert and experimental vectors containing the AML 1A and AML IB isoforms 
were supertransfected independently. These experiments were repeated three times. 
Two days after supertransfection, the cells were replated at low density in presence 
of LIF and puromycin (2 .tg/mL) was added to culture medium. Cells 
supertransfected with the EGFP episomal vector showed green fluorescence under 
the microscope during the period of observation (see Figure 8). On the day 10 of 
culture, the cells were fixed and stained with the Leishman's reagent (see Figure 9). 
A large number of colonies were observed in supertransfected cells with or without 
EGFP insert. In contrast, the AML IA supertransfectants gave few colonies, while the 
AMIL lB supertransfectants gave no colonies at all. Similar results were obtained 
when the cells were cultured in the absence of LIF after supertransfection. However 
in this case both control and AML1A supertransfectants produced fewer colonies 
which underscores the important role of LIF in the ES cells propagation. 
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Figure 8. EGFP expression in the E14/T supertransfected cells 
Microphotograph of the El 4/T cells supertransfected with a control episomal vector 
with the EGFP insert on the fifth day of the puromycine selection. The scale bar 
represents 100 gm. 
LSr 
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Figure 9. The AML1 overexpression has an inhibitory influence on the ES cell 
growth 
Supertransfected El 4/T cells were replated at low density two days after transfection 
and grown in the puromycin (2 tgImL) containing medium in the presence of LIF for 
10 days. The photographs of representative 10 days Leishman's stained cultures are 
shown. Four episomal vectors with different inserts or without an insert were 
supertransfected independently: (A) AML1A insert, (B) AML1B insert, (C) no insert 
and (D) EGFP insert. 
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Chapters: RESULTS 
Generation of AMLI/rtTA regulatory ES cells and mice 
5.1. Introduction 
High levels of expression of AIv1IL1 isoforms in ES cells have cytotoxic 
effect, whereas low levels of AML 1 expression have been reported to be toleratable 
by ES cells (Aziz-Aloya et al. 1998). Therefore an inducible gene expression system 
might be a useful alternative. A system for inducible expression of individual 
isoforms of AML  was designed on the basis of the Tet-On gene expression system. 
A new potent tetracycline-dependent transactivator rtTA2SM2  was targeted into the 
AIVIL1 locus in order to ensure its expression in hematopoietic progenitors. This 
should allow inducible expression of AMLI individual isoforms in hematopoietic 
progenitors. The level of expression is expected to be dose-dependent upon the 
doxycycline induction both in vitro and in vivo (see Figure 10). 
5.2. Generation of the regulatory construct 
The regulatory construct for the AMIL1 gene targeting has been generated on 
the basis of AML1 genomic clones. rtTA gene expression cassette was inserted 
downstream of the AMIL 1 proximal promoter. Generation of the regulatory construct 
consisted of two stages: (i) generation of the rtTA gene expression cassette and (ii) 
cloning of the rtTA gene expression cassette into the AML1 genomic clones. 
The pUHrT62-1 plasmid encoding highly inducible, low background rtTA2S 
M2 regulator (further referred as rtTA) was kindly provided by Prof Hermann 
Bujard (Germany). To generate the rtTA gene expression cassette a three-step 
cloning strategy was designed (see Figure 11). First, the 1.4 kb insert containing 
rtTA followed by the SV40 polyadenylation signal was excised from the pU}irT62-1 
plasmid using the Eco RI and Pvu II restriction enzymes and ligated into the 3 kb 
pBlueScript II SK+ vector ("Stratagene") whose multiple cloning ite (MCS) was 
digested using the Eco RI and Sma I enzymes. Since both Pvu II and Sma I enzymes 
generate blunt ends the insert was cloned directionally and recombinant molecules 







Figure 10. Schematic representation of the Tet-On gene expression system for 
conditional overexpression of the AML1 individual isoforms in hematopoietic 
progenitors 
The rtTA transactivator (violet arrow) is targeted into the AML1 gene locus and 
driven by the AML1 proximal promoter (orange oval). cDNA of an individual 
isoform of AML 1 (red arrow) downstream of the tetracycline responsive promoter 
(TRP, cyan rectangle) is integrated into the genome of the same cell. There is no 
AML  cDNA expression in the absence of doxycycline. Upon the doxycycline (cyan 
star) addition, rtTA interacts with TRP and upregulates the AMLI cDNA. 
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EcoRl 	B1I PvuII 
rtTA insert into pUHrT 62-1 plasmid 
Sail 
oI* EcoRI BglI& PtrH&aI 
rtTA insert into pBlueScript II SK+ plasmid 
pLNeorL 
Sail 	 Sail 
rtTA gene expression cassette 
Figure 11. Diagram of the three step cloning of the rtTA gene expression 
cassette 
1 - Cloning of rtTA into the pBlueScript II SK + vector. 
2 - Cloning of rtTA into the pLNeorL  vector. 
3 - Cloning of SPA into the pLNeo'L-rtTA vector. 
LoxP sites are shown as black triangles. Restriction sites marked with asterisks had 
generated 5' overhangs which were filled-in after digestion. The Bgl I restriction 
enzyme generated the 3' overhangs which were removed (marked with an 
ampersand). Ligation of the Pvu II digested rtTA-SV40pA into the Sma I digested 
vector generated no restriction site at the insert-vector junction (crossed out). 
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flanked by new cloning sites which were used during subsequent cloning steps. 
Second, the 1.1 kb rtTA-SV40pA insert was excised from the pBluesScnpt vector 
using the XhoI and Bgl I restriction enzymes. The insert was smaller than the initial 
one, because almost 0.2 kb of the vector sequence located between the Bgl I and Pvu 
II restriction sites had been left in the plasmid. The 5' protruding Xho I ends were 
filled-in whereas 3' protruding Bgl I ends were removed using the T4 DNA 
polymerase. The insert was cloned into the linearised 5.2 kb pLNeorL  plasmid vector 
(kindly provided by Dr. Igor Samokhvalov, The University of Edinburgh). The 
pLNCOrL plasmid encodes a foxed selection cassette consisting of a neomycin 
resistance gene (Neot) followed by the HSV polyadenylation signal. The vector was 
digested upstream the 5' lox? site using the Xba I restriction enzyme. The Xba 1 5' 
protruding ends were filled-in using the T4 DNA polymerase. Recombinant 
molecules with the head-to-tail orientation of the rtTA and NCOr  genes were selected. 
Third, the combined transcriptional termination sequence SPA-C2MA7_ was inserted 
between the SV40 polyadenylation signal and 5' lox? site. The SPA-C2MAZ 
termination sequence consists of a ynthetic polydenylation signal (SPA) and the 
complement gene C2 MAZ binding site. SPA is a highly efficient polyadenylation 
sequence based of the rabbit -globin gene regulatory elements (Levitt et al. 1989). 
MAZ (Myc-associated zinc finger) is a zinc finger protein interacting with DNA and 
presumably promoting its bending. It is supposed that bent DNA acts as a 
transcriptional terminator (Ashfield et al. 1994). Thus, the SPA-C2MAZ sequence 
(further referred as SPA) is a potent terminator of transcription. Its insertion into the 
rtTA gene expression cassette promotes transcriptional termination downstream of 
rtTA. The SPA containing plasmid pySPAC2+ was kindly provided by Prof Nicolas 
Proudfoot (University of Oxford). The 0.2 kb SPA insert was excised using the Bam 
HI and Eco RI enzymes. The Bam HI and Eco RI 5' protruding ends were filled-in 
using T4 DNA polymerase. The insert was cloned into the 6.3 kb pLNeorLrtTA 
vector linearised between the SV40 polyadenylation signal and 5' lox? site using the 
Xho I enzyme. The Xho I 5' protruding ends were filled-in using T4 DNA 
polymerase. Recombinant molecules with the sense orientation of the termination 
sequences were selected. Taken together, the rtTA gene expression cassette 
generated during a three step cloning procedure consists of rtTA followed by the 
SV40 and SPA polyadenylation signals and the foxed Neor  gene. The cassette may 
be released from the vector by the Sal 1 digest. Of note, the 5' Sal I site is coming 
from the pBlueScript vector MCS and has been brought by the rtTA-SV40pA insert 
while the 3' Sal I site belongs to the pLNeotL plasmid initially. 
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During the second stage of generation of the regulatory construct, the rtTA 
gene expression cassette was encompassed by the AMLI genomic DNA providing 
homology arms necessary for gene targeting. The AML I genomic DNA was isolated 
from a lambda phage genomic library and subcloned by Dr. Igor Samokhvalov in the 
laboratory (see Figure 12). The isolated genomic DNA had length of 13 kb and 
covered a region upstream exon 3, exons 3 and 4, an intron between the exons, and a 
part of an intron downstream the exon 4. Lambda genomic DNA was digested and 
subcloned into the pBlueScript H SK+ plasmid vector; namely, (i) the 3 kb fragment 
containing exon 3 and flanking intron regions was excised using the Xba I enzyme, 
(ii) the 11 kb fragment containing the major part of exon 3, exon 4 and introns 
between these exons and downstream the exon 4 was excised using the Xho I 
enzyme and (iii) the most 5' promoter/intron 1kb DNA fragment was amplified by 
PCR. 
Since I aimed to express rtTA in AML 1 positive cells it looked attractive to 
target rtTA into exon 3 which is the first coding exon of proximal transcripts. The 
initiator ATG codon of exon 3 resides within the Bsa BI restriction enzyme 
recognition site which is GATGCGTATC (the initiator codon is underlined) (see 
Figure 13). Of note, the Bsa BI enzyme recognises a discontinuous site 
GATNNNNATC and cuts it between the fifth and sixth nucleotides (fourth and fifth 
coding nucleotides of AML1) generating blunt ends. At the same time, rtTA DNA 
has a unique Xba I restriction site just downstream its initiator ATG codon. A blunt-
ended fragment with the 5' rtTA fifth coding nucleotide is generated, if rtTA is 
digested using Xba I and 5' protruding ends are filled-in using T4 DNA polymerase. 
Taken together, if AML 1 genomic DNA is digested using the Bsa BI enzyme and the 
fourth coding nucleotide of the AML 1 genomic fragment is ligated with the fifth 
coding nucleotide of the rtTA fragment, rtTA will be cloned in-frame with the 
AML1 first coding ATG. However, the rtTA fourth coding nucleotide will be 
different in the new and initial molecules, namely C will be in a new molecule, while 
T is in the initial one. Since this causes a substitution of the rtTA second amino acid, 
C was mutated to T in the AML  genomic DNA before cloning in order to avoid any 
possible complications. Of note, this mutation does not influence the Bsa BI 
digestion, because it resides in the variable part of the restriction site. 
The generation of the regulatory construct consisted of four steps (see Figure 
14). First, the fourth coding nucleotide C was substituted with T by site-directed 








exon3 	 exon4 	I 
XhoI 
5'UTRI 	 I 	 IpXholl 
exon 3 	 exon 4 
pAML42 
Figure 12. Diagram of the AML1 genomic clones 
(kindly provided by Dr. Igor Samokhvalov) 
The AML1 genomic DNA (triple line) was digested and subcloned into the 
pBluescript vector generating new pXba3 and pXhol 1 plasmids (double lines). The 
insert cloned into the pAML42 plasmid was amplified by PCR. Vector DNA is 
delineated by solid line. 
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plasmid with exon 3 of AML 1 
GTTGTGATGICGT ATC CC 






GTTGTG ATG tTGT ATC CC 
CAACAC 	ACA TAG GG 
plasmid with rtTA 
TTCACC ATG JICT AGA CT 
AAGTGG_TACAGA Ty GA 
rtTA 
restriction with Xba I 
fill-in with T4 DNA polymerase 
restriction 





CAACAC 	CA TAG GG 
TTCACC ATG FCT AG CT AGA CT 
AAGTGG TAC AGA TC GA TCT GA 
ligation with T4 DNA ligase 
GTTGTGP16k CT AGA CT 
CAACAC 	GA TCT GA 
5'UTR 	rtTA 
Figure 13. Schematic representation of the rtTA gene expression cassette 
cloning into the AML1 genomic DNA containing plasmid 
The Bsa BI restriction enzyme binds to the GATNNNNATC site and cuts it between 
fifth and sixth nucleotides. The fifth nucleotide C was substituted for T in the AML 1 
containing plasmid by site-directed mutagenesis, thus restoring the correct rtTA 
sequence upon ligation. The rtTA containing plasmid was digested using the Xba I 
restriction enzyme and the 5' protruding ends were filled-in using the T4 DNA 
polymerase. The non-variable nucleotides of the Bsa BI recognition site are in red. 
The Xba I recognition site is in blue The AML  first coding ATG is designated by a 








17 rtTA gene expression cassette 
XbI 	Nod 
4 
0 	 regulatory construct 
XbaI 	 XbaI 
I 5'UTRI 	 pXhol 
Figure 14. Diagram of the four step cloning of the regulatory construct 
Site-directed mutagenesis of the pXba3 plasmid. 
Destroying of the Xba I site (crossed out) by restriction digestion and 5' overhang 
fill-in. 
Cloning of the rtTA gene expression cassette. 
Cloning of the AML  genomic DNA fragment. 
LoxP sites are shown as black triangles. Restriction sites marked with asterisks had 
generated 5' overhangs which were filled-in after digestion. Not I is a unique 
restriction site which has been used for the construct linearization. 
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Second, an Xba I site of the mutant pXba3 plasmid was destroyed by consecutive 
linearisation using the Xba I enzyme, fill-in of 5' protruding ends using T4 DNA 
polymerase and self-ligation. Self-ligated molecules with the Xba I site destroyed at 
the 5' end of the insert were selected. The aim of the procedure was to reduce the 
number of the Xba I sites in the molecule. An extra Xba I site was brought by the 
rtTA gene expression cassette and three Xba I sites would be in the pXba3-rtTA 
plasmid unless one of them had been destroyed during previous steps. Since it had 
been planned to use the Xba I site at the 3' end of the insert in a subsequent cloning, 
the Xba I site at the 5' end of the insert was destroyed. Third, the 2.5 kb rtTA gene 
expression cassette was excised from a vector using the Xba I and Sal I digest; 5' 
protruding ends were filled-in using the T4 DNA polyrnerase and the cassette was 
ligated into the pXba3 vector undergone two rounds of modifications as discussed 
above. The 6 kb pXba3 vector was digested using the Bsa BI restriction enzyme. 
Recombinant molecules with the same orientation of the rtTA and AML 1 genes were 
selected. Fourth, the 9 kb Xba I fragment encoding the major part of an intron 
between exons 3 and 4, exon 4 and a part of an intron downstream exon 4 was 
excised from the pXhol I plasmid. This fragment was ligated into the linearised 8.5 
kb pXba3-rtTA vector. The vector encodes two Xba I sites: the first one is in rtTA 
and the second one is at the 3' end of the insert, therefore 4 variants of recombinant 
molecules were expected (two possible orientations upon ligation into each 
restriction site). Recombinant molecules with the direct oriention of the 9 kb 
fragment cloned into the Xba I site at the 3' of the insert were selected. These 
molecules are regulatory constructs for the AMLI gene targeting. They contain 
AMLI genomic DNA including exons 3, 4, surrounding introns and the rtTA gene 
expression cassette which is cloned in-frame with the AMLI first coding ATG. The 
length of homology arms is 12 kb. All functional regions of the construct (exons, 
gene expression cassette, flanking sequences) were verified by sequence. 
5.3. Targeting of the AML1 gene locus 
The regulatory construct was linearised using the Not I enzyme which 
digested a unique site locating upstream the 5' end of the insert. E14 ES cells were 
electroporated with the linearised construct. G418 (final concentration 0.3 mglmL) 
was added to the cells 48 hours after electroporation. G418 resistant clones were 
selected, expanded and screened by Southern blot hybridisation for a correctly 
targeted allele (see Figure 15). Afi II digested genomic DNA was hybridised to a 
probe external to the regulatory construct. The external probe is a 112 bp fragment 
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Figure 15. Targeting of the AMLi gene locus 
Scheme of the AML1 gene targeting. Wild type AML1 allele is shown top, 
the targeting vector is shown middle and the targeted allele is shown bottom. Lox? 
sites are shown as black triangles. All is the Afi II restriction site. External probe is 
shown as a dark red line. Internal probes are shown as green lines. Restriction 
fragments that hybridise to probes are shown as thin grey lines. 
Representative autoradiograph showing results of the Southern blot 
hybridisation. Afi II digested DNA was consecutively hybridised with external (top) 
and internal (bottom) probes. Correctly targeted clones 66, 74 and 82 gave 5.6 kb 
targeted band and 3.1 wild type band with the external probe and 5.6 kb band only 
with the internal probe. 
located upstream the 5' end of the regulatory construct. For the external probe 
preparation the 1122 bp insert into the pAML42 plasmid (see Figure 12) was 
amplified by PCR. The PCR product was digested using the Afi II restriction 
enzyme. The 112 bp restriction fragment was isolated and used as an external 
hybridization probe. The wild type allele gave a band of 3.1 kb while a correctly 
targeted allele gave a band of 5.6 kb. In order to select clones containing only one 
copy of the regulatory construct, the blots were stripped off and re-hybridised to an 
internal probe (the mixture of the rtTA and Neor  DNA fragments). The 1.1 kb rtTA-
SV4OpA cloning insert was used as an internal hybridisation probe while the Neor 
fragment was obtained by PCR. The internal probe hybridised to either the targeted 
allele of 5.6 kb in correctly targeted clones or randomly integrated construct (any 
size band) in other clones. In total, 14 out of 80 screened clones contained the 
targeted allele. 
5.4. Cre-mediated excision of the selection cassette 
Neor selection cassette may change the pattern of expression of genes of 
interest. For instance, silencing of an adjacent transgene has been previously 
described (Shin et al. 1999). Therefore, the Neor  selection cassette was excised by 
Cre-mediated recombination. The targeted clone 82 was transiently transfected with 
the pIC-Cre plasmid (kindly provided by Dr. Igor Samokhvalov, University of 
Edinburgh). This plasmid encodes Cre driven by the HSV TK promoter and polyoma 
enhancer. 48 hours after transfection the cells were replated at low density 12 days 
later, 48 individually colonies were picked up and each colony was split onto two 
wells of a 48-well plate. Medium with 0.3 mglmL of G418 was added to one of these 
wells. 11 clones which had shown the G418 sensitive phenotype after 5 days of 
growth were expanded and genotyped by Southern blot hybridization (see Figure 
16). Afi II digested DNA was hybridised to the external probe. The wild type allele 
gave a band of 3.1 kb while the targeted allele gave a band of 5.6 kb and the 
recombined allele gave a band of 4.4 kb. 10 out of 11 clones contained the 
recombined allele. The eleventh clone (clone 47) did not produce any signal. 
The targeting efficiency of the regulatory construct was high: 17.5% of 
clones were correctly targeted. Cre-mediated excision of the foxed Neor  selection 
cassette was also very efficient: 23% of clones lost the cassette upon transfection 
with the Cre-expressing cassette. Similar high efficiency of targeting of the AMIL 
locus was obtained independently by others using different constructs and slightly 
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Figure 16. Cre-mediated recombination in the AML1 gene locus 
The targeted AML 1 allele is shown top and the recombined allele is shown 
bottom. LoxP sites are shown as black triangles. All is the Afi II restriction site. 
Hybridisation (external) probe is shown as a dark red line. Restriction fragments that 
hybridise to the probe are shown as thin grey lines. 
Southern blot hybridization analysis of G418 sensitive clones. Afl II digested 
DNA was hybridised to the internal probe. Recombined clones gave bands of 3.1 kb 
(wild type) and 4.4 kb (recombined). The parental clone 82 gave bands of 3.1 kb 
(wild type) and 5.6 kb (targeted). 
different site of integration within the AML 1 locus. It will be interesting to establish 
if the structure of the AML1 gene locus favourable for artificial recombination 
observed in targeting experiments is relevant to high frequency of AMIL 1 
rearrangements in human leukaemia. 
5.5. Generation of AML1/rtTA regulatory mice 
In order to generate regulatory mice the targeted clone 14 and recombined 
clones 11 and 12 were injected into wild type mouse blastocysts by Janice Ure 
(University of Edinburgh). Male chimaeras obtained from clones 14 and 12 showed 
high levels of chimaerism and were test crossed to wild type mice. The chimaeras 
were fertile and transmitted their transgenes down the germline. Offspring from the 
test crossing were genotyped by Southern blot hybridisation (see Figures 17A and 
1713). 3 out of 6 (clone 14) and 4 out of 7 (clone 12) genotyped animals bore the 
rtTA transgene. 
Regulatory mice coming from the targeted clone 14 contained the foxed Ned 
gene. In order to excise the foxed cassette the Zp3-Cre mice which express a Cre 
transgene in oocytes were used (Lewandoski et al., 1997). Two males containing 
targeted AIVIL1 locus were crossed with Zp3-Cre females. The Crc-mediated 
excision of a foxed fragments occurred with 100% efficiency. Recombination 
occurred in 7 out of 12 genotyped offspring from the intereross while animals with 
the unrecombined transgene were not found (see Figure 17C). 
During 2 years of observation regulatory heterozygous mice have been 
phenotypically normal, healthy and fertile. As others researchers have observed, no 
obvious difference between wild type and heterozygous littermates have been 
noticed (Okuda et al. 1996). 
5.6. Analysis of the rtTA transgene expression in in vitro differentiation assay 
After that the rtTA and AML1 expression profiles in ES cells differentiating 
in vitro were compared. ES cells cultured in bacterial (low adhesive) plates in 
absence of LIF form compact aggregates of differentiating cells called embryold 
bodies (EBs) (Doetschman et al. 1985, see chapter 1.4.4). AML1/rtTA regulatory ES 
cells (clone 12) were cultured in these conditions and aliquots of EBs suspension 
were taken every 24 hours from the day 2 till 7 of differentiation. RNA was isolated 
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Figure 17. Genotyping of the AML1/rtTA regulatory mice 
A, B. Chimaeras obtained by blastocyst injections with recombined clone 12 (A) or 
targeted clone 14 (B) were test crossed to wild type mice. Genomic DNA from 
offspring was digested using the Afi II enzyme and hybridised to either the external 
probe (A) (see Legend for Figure 15) or rtTA (B). The targeted allele gave a band of 
5.6 kb, the recombined allele gave band of 4.4 kb and the wild type allele gave band 
of 3.1 kb. 
C. PTA-bearing males coming from the targeted clone 14 were crossed to Zp3-Cre 
females. Genomic DNA was digested using the Afi II restriction enzyme and 
hybridised to the external probe for genotyping. 
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from EBs. Contaminating genomic DNA was removed by the DNAse I treatment and 
RNA was used for the AML1 and rtTA-specific RT-PCR. RT-PCR for a house-
keeping 3-actin gene was set up as an internal control. Both, AML1 and -actin 
specific primers were complementary to sequences in neighbouring exons. 
Therefore, amplification of genomic DNA across intron boundaries was largely 
prevented and in any case would yield a product of a different size than from RNA. 
In contrast, the entire rtTA transgene is located within the same exon and therefore 
products of RNA and DNA amplifications would be indistinguishable. In order to 
monitor the levels of the genomic DNA contamination control PCR reactions using 
the rtTA gene specific primers were set up. The reverse transcriptase enzyme was not 
added to the appropriate reaction mixture (mock reverse transcription), therefore 
contaminating genomic DNA could only be amplified during PCR using the mock 
reverse transcription reaction "products". 
All samples used for RT-PCR contained similar amount of RNA since 
amplification using the f3-actin gene specific primers demonstrated equivalent 
amounts of the product (see Figure 18). No bands were amplified using the mock 
reverse transcribed templates and rtTA specific primers. Therefore, no contamination 
with genomic DNA was found. It has been found found that both rtTA and AML 1 
genes demonstrated similar kinetics of expression during EB differentiation. Low 
levels of expression were observed between days 2 and 4 of culture that followed by 
a gradual increase thereafter. Highest levels of expression of AML 1 and rtTA were 
observed on days 6 and 7 of differentiation. Similar results were reported by other 
researchers: low level of expression of AML1 was observed during the first days of 
ES cell in vitro differentiation, followed by significant increase in expression 
between days 4 and 8 (Fujita et al. 2001; Lacaud et al. 2002). 





mock reverse transcription 
rtTA gene specific PCR 
r~T 	- 41t 	 13-actin 
Figure 18. Kinetics of rtTA and AML1 expression during ES cells in vitro 
differentiation. 
AML 1, rtTA and -actin expression was detected by RT-PCR upon isolation of RNA 
from in vitro differentiating ES cells. Mock reverse transcribed templates were 
amplified using the rtTA gene specific primers as the genomic DNA contamination 
control. Neg designates no template control. 
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Chapter 6: RESULTS 
Generation of responsive ES cells and mice 
6.1. Introduction. 
In the previous part of my research AML I/rtTA regulatory ES cells and mice 
were generated. A further step included generation of responsive components of the 
system. Initial experiments showed that the rtTA expression follows AML I 
expression kinetics and can be detected during first days of ES cells differentiation. 
Therefore, one can expect the induction of a reporter gene in cultures of 
undifferentiated AML1/rtTA regulatory ES cells. Therefore, the regulatory ES cells 
were transiently transfected with responsive constructs in order to (i) test 
functionality of rtTA and (ii) optimize experimental conditions for efficient induction 
of a reporter gene by doxycyc line. 
6.2. Generation of responsive ES cell lines 
6.2.1. Generation of the luciferase responsive constructs 
Luciferase responsive constructs were generated on the basis of a bi-
directional tetracycline responsive vector (Baron et al. 1995) (see Figure 18). The 
vector encodes bTRP driving simultaneous transcription of two genes in opposite 
directions. Therefore, vectors with bTRP driving expression of both an individual 
AML1 isoform and the firefly luciferase reporter gene were generated. Firefly 
luciferase is a widespread genetic reporter catalyzing oxidation of the luciferin 
substrate in the presence of ATP, oxygen and magnesium cations. The reaction 
results in light emission. Since the intensity of light is proportional to the luciferase 
concentration, the intensity of the luminescent signal produced by a cell lysate is 
determined by levels of the luciferase expression. Modem methods of the firefly 
luciferase activity measurement allow detecting as little as a femtogram of the 
protein and extend over a range of eight orders of magnitude of its concentration 
(Sherfet al. 1996). 
The pBI-L tetracycline bi-directional vector ("Clontech") was used for the generation 
of the luciferase responsive constructs. The vector encodes bTRP flanked by MCS 
and the luciferase expression unit. MCS is suitable for the cloning of a gene of 
interest and therefore is followed by the rabbit -globin polyadenylation signal. 
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Figure 19. Diagram of the two step cloning of the luciferase responsive 
constructs for transient transfection assays 
Cloning of exogenous DNA into the pBI-L vector. 
Cloning of the AML  cDNA into the pBI-Le vector. 
Two responsive constructs with different isoforms of AML1 (A and B) were 
generated. Restriction sites marked with asterisks had generated 5' overhangs which 
were filled-in after digestion. A restriction site marked with an ampersand generated 
the 3' overhangs which were removed. Exogenous DNA is shown by the orange 
rectangle. 
The luciferase expression unit consists of the firefly luciferase reporter gene followed 
by the SV40 polyadenylation signal. The cloning procedure consisted of two steps 
(see Figure 18). First, the exogenous DNA fragment was cloned into the lineansed 
vector. The 2.8 kb fragment was excised from the human cDNA clone IMAGE: 
590643 using the Sca I and Xho I restriction enzymes. The protruding 5' ends 
generated by the Xho I enzyme were filled-in using the T4 DNA polymerase. The 
insert was ligated into the 6.1 kb pBI-L vector which had been lineansed 
downstream the SV40 polyadenylation signal using the Aat II restriction enzyme. 
The protruding 3' ends generated by the Aat II enzyme were removed using the T4 
DNA polymerase. The recombinant plasmid called pBI-Le carried a piece of 
exogenous DNA cloned downstream the firefly luciferase expression unit. The aim 
of this cloning was to generate a homology arm which had been planned to be used 
in the stable transfection experiments. However, later on the experimental strategy 
had been changed and the construct had never been transfected stably (see below). 
Secondly, the AML1A and AML1B cDNAs were excised from the pLNSX vector 
using the Stu I and Cia I restriction enzymes what released the 0.8 kb AML1A and 
1.4 kb AML1B inserts (see Chapter 4.2 for the AML1 cDNAs description). The 
inserts were ligated into the 9 kb pBI-Le vector subsequently treated with the Not I, 
T4 DNA polymerase and Cia I enzymes. The Not I enzyme digested the vector 
within MCS. T4 DNA polymerase filled-in protruding 5' ends of the vector 
generating blunt ends. The Cia I enzyme digested MCS just upstream the 3-globin 
polyadenylation signal. Accordingly, the linear vector carrying the blunt and 5' 
protruding Cia I compatible ends was generated and used for the directional cloning 
of the AML 1 inserts. Recombinant molecules were selected, and correct sequence of 
all functional regions of the AML 1 A/iuciferase and AML 1 B/iuciferase responsive 
the constructs was confirmed. 
6.2.2. Transfection of AMIL1/rtTA regulatory ES cells with luciferase responsive 
constructs 
The AMLI/rtTA regulatory and control wild type ES cells were transiently 
co-transfected with circular forms of the AML I B luciferase responsive construct and 
control pRL-TK piasmid ("Promega"). The pRL-TK non-reguiatable control piasmid 
encodes the Renilla luciferase driven by the HSV TK promoter while the responsive 
construct carries the firefly luciferase driven by bTRP. The Renilia and firefly 
luciferases have different structures and catalyse oxidation of different substrates 
(reviewed by Bronstein et al. 1994). Accordingly, their activities in the same cell 
all 
lysate may be measured independently by dual-luciferase reporter assay which 
allows subsequent normalisation of the inducible firefly luciferase activity to the 
control Renilia luciferase. The normalisation eliminates variability between samples 
related to different transfection efficiency and ensures more accurate interpretation of 
data. The control pRL-TK plasmid constituted 10% of total transfected DNA, 
whereas the rest consisted either entirely of the AMLIB luciferase responsive 
construct or this construct diluted with an unspecific DNA (the pBlueScript plasmid). 
Dilution of the construct is required since large amount of responsive DNA 
transfected into cells may result in high background activity (Freundlieb et al. 1999). 
AIvIL1/rtTA regulatory ES cells and control wild type cells were plated into 12-well 
plates. Each variant was plated in duplicates and transfected with mixtures of the 
control pRL-TK and AMLIB luciferase responsive plasmids. Mixtures containing 
10% and 90% of the AML 1 B luciferase responsive construct were tested. The 
control mock transfection was set up in parallel. Each transfection experiment was 
repeated three times. To achieve higher AML I /rtTA expression transfected cells 
were grown in absence of LIF to increase proportion of AML1 expressing cells. 
Doxycycline (final concentration 1 .tg/mL) was added to appropriate wells 16 hours 
after transfection. The cells were lysed 72 hours after transfection and both RenÉ/ia 
and firefly luciferase activities were quantified by the dual-luciferase reporter assay 
(see Figure 20). High levels of the Renilia luciferase expression were detected in 
lysates of cells transfected with luciferase containing constructs. In contrast, only 
background levels of both luciferases activities were determined in mock-transfected 
cell lysates. Thus, the cells were transfected successfully. However, induction with 
doxycycline did not show any significant increase in firefly luciferase expression 
above background. On occasions no more than 2 fold reporter induction was found. 
Thus, doxycycline failed to induce the luciferase reporter in the AML1/rtTA 
regulatory ES cells. This failure might be caused by the low levels of AML1/rtTA 
expression in undifferentiated ES cells. Therefore an attempt to increase the number 
of AMLI/rtTA expressing cells in order to enhance AML 1-dependent expression of 
rtTA was undertaken. For this purpose, the experiment described above was repeated 
in a modified form. Regulatory ES cells and control wild type cells were plated into 
12-well plates. The cells were co-transfected with either the AML I B responsive 
plasmid or the pBI-Le responsive intermediate construct and the pRL-TK control 
plasmid (see Figures 19 and 21). The principle of DNA composition in transfection 
mixture was the same as in previous experiments (see the paragraph above). 
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Figure 20. Doxycycline failed to induce the luciferase reporter gene expression 
in transiently transfected undifferentiated AMLI/rtTA regulatory ES cells 
E14 (wild type) and the AML1/rtTA regulatory ES cells (clones 11 and 12) were 
transiently cotransfected with the AML1B responsive construct carrying the firefly 
luciferase reporter and pRL-TK internal control plasmid. Different concentrations of 
the AML1B responsive construct in the transfection reaction mixture were assayed: 
10% (purple bars) and 90% (red bars); yellow bars represent the mock transfection 
controls. Doxycycline (1 igImL) was added to appropriate wells 16 hours after 
transfection. The cells were lysed 72 hours after transfection and both firefly and 
Renilla luciferase activities were measured in the lysates. The ratios of the 
normalised firefly luciferase activities between the doxycycline induced and 
uninduced cells are shown. Each bar represents the mean value of three independent 




transfecting DNA mixture composition: 
pRL-TK (10%), responsive construct (10%), unspecific DNA (80%) 
transfecting DNA mixture composition: 
pRL-TK (10%), responsive construct (25%), unspecific DNA (65?/o) 
transfecting DNA mixture composition: 
pRL-TK (10%), responsive construct (90%) 
Figure 21. Doxycycline failed to induce the luciferase reporter gene activation in 
the transiently transfëcted differentiated AMLI/rtTA regulatory ES cells 
The regulatory ES cells were transiently cotransfected with either the AML 1B (A) or 
pBI-Le (B) responsive construct and pRL-TK internal control plasniid. Different 
concentrations of the AMIL I B responsive construct and pBI-Le plasmid in the 
transfection reaction mixture were assayed: 10% (purple bars), 25% (orange bars) 
and 90% (red bars); yellow bars represent the mock transfection reactions. The cells 
were replated into low adhesive dishes with a medium without LIF 16 hours after 
transfection and at the same time doxycycline (1 J1g/mL) was added into dishes. The 
cells were lysed 72 hours after transfection and both firefly and Renilia luciferase 
activities were measured in the lysates. The ratios of the normalised firefly luciferase 
activities between the doxycycline induced and uninduced cells are shown. Each bar 
represents the mean value of three independent transfection experiments (n=3). Error 
bars show standards errors. 
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mass) and a responsive plasmid (10, 25 or 90% of the total DNA mass). The control 
mock transfection was set up in parallel. Each transfection experiment was repeated 
three times. Transfected cells were replated into low adhesive (bacterial) dishes with 
medium in the absence of LIT 16 hours after transfection. ES cells formed embryoid 
bodies what increased the levels of AML1/rtTA expression (see Chapter 5.6). At the 
same time the doxycycline (1 j.ig/mL) was supplemented to the culture. The cells 
were lysed 72 hours after transfection and the firefly and Renilla luciferase activities 
were measured (see Figure 21). The background levels of both Renilla and firefly 
luciferase activities were detected in mock transfected cells lysates. The transfected 
cell lysates showed the elevated levels of the Renilla luciferase activity suggesting 
that the cells had been transfected properly. However, the levels of the Renilla 
luciferase activity observed in this experiment was considerably lower than in 
previous one. Presumably, the most part of the transfected DNA had been lost during 
replating. Similar to previous experiments levels of the firefly luciferase activity 
were very low and no more than two fold reporter induction by doxycycline was 
observed. 
6.2.3. Transfection of B8 ES cells with responsive constructs 
I suppose that the failure to induce the reporter expression by doxycycline in 
the transiently transfected cells might be caused by the following: (i) rtTA was not 
working, or (ii) the responsive constructs were not working, or (iii) both of them 
were not working. I first tested if the responsive constructs are functional. For this 
purpose B8 ES cells kindly provided by Dawn Fisher and Dr. Andrew Smith 
(University of Edinburgh) were used. B8 ES cells contain the rtTA25-M2 transgene 
(see Chapter 2.2.2.3) targeted into the HPRT (ypoxantine 
phosphoribosyltransferase) gene locus. The rtTA25-M2 transgene is driven by the 
CMV promoter followed by the IRES EGFP reporter unit. The cells were plated into 
12-well plates and co-transfected with the experimental (90% of the entire 
transfected DNA) and pRL-TK control (10% of the entire transfected DNA) 
plasmids. Three experimental plasmids containing the firefly luciferase reporter 
driven by bTRP (pBT-L, pBI-Le and the AMLIB responsive construct (see Figure 
18)) were tested. The control mock transfection was set up in parallel. Each 
transfection experiment was repeated 3 times. The cells were growing in the LIF-
containing medium during entire experiment. Doxycycline (final concentration 1 
j.tglmL) was added 24 hours after transfection, the cells were lysed 48 hours after 
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Figure 22. Doxycycline induced the 40 fold luciferase reporter gene activation in 
the transiently transfected B8 cells 
The B8 ES cells were transiently cotransfected with either pBI-L (2) or pBI-Le (3) or 
the AML1B responsive construct (4) and pRL-TK internal control plasmids. 
Doxycycline (1 .tgImL) was added to cells 24 hours after transfection. The cells were 
lysed 48 hours after transfection and both firefly and Renilla luciferase activities 
were measured in the lysates. The ratios of the normalized firefly luciferase activities 
between the doxycycline induced and uninduced cells are shown. The bar (1) shows 
the mock transfected control. Each bar represents the mean value of three 
independent transfection experiments (n=3). Error bars show standards errors. 
The firefly and Renilla luciferase activities did not exceed the background levels in 
the mock transfected cells; however the high levels of the Renilla luciferase activity 
were detected in all other transfectants. The firefly luciferase activity was induced by 
doxycycline about 40 times in all cells transfected with experimental plasmids. No 
difference between luciferase activities among the cells transfected with different 
experimental plasmids was observed. 
Conditions used in transfection of B8 cells were different from those of 
AML1/rtTA regulatory cells. B8 cells were induced 24 hours after transfection and 
lysed 48 hours after transfection, whereas the AML 1 /rtTA regulatory cells were 
induced 16 hours after transfection and lysed 72 hours after tranfection. It is not 
likely that AML1/rtTA regulatory cells lost transfected plasmids during the 
prolonged incubation period since the levels of Renilla luciferase activity were 
similar in both B8 and AMLI/rtTA regulatory cells. Therefore, I concluded that the 
luciferase responsive constructs were functional and the failure to induce the 
luciferase expression by doxycycline in the AML1/rtTA regulatory ES cells had been 
caused by either the insufficient levels of the rtTA expression or by its lack of 
function. Although I have shown by RT-PCR that the knocked-in rtTA is expressed 
in a similar manner as AML1 the functional activity of the protein has not been 
proved. However, since all ways to solve this problem are very laborious I decided to 
change the strategy and generate a new responsive ES cell line (see Chapter 7). 
However, the resporter constructs have been used to generate responsive mouse 
strains. 
6.3. Generation of responsive mouse strains 
6.3.1. Generation of the EYFP responsive constructs 
The reporter constructs for the responsive mouse strains generation were 
created on the basis of the bi-directional pBI-L vector (see Figure 23). The luciferase 
reporter was substituted with the enhanced yellow fluorescent protein (EYFP). Thus 
reporter constructs encode bTRP driving both AML 1 cDNA and EYFP in opposite 
directions. EYFP allows non-invasive control of gene expression in live tissues 
providing a tool for monitoring and sorting out the AML1 overexpressing cells 
(reviewed by Naylor 1999). In order to be able to exclude a possible role of EYFP in 
the phenotype of transgenic mice the AML1 cDNA was flanked by loxP sites. This 
design allows Cre-mediated deletion of AML1 cDNA and as a result generation of 
control transgenic mice which overexpress EYFP only. This can be achieved for 
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Figure 23. Diagram of the four step cloning of the AML1IEYFP responsive 
construct 
Cloning of EYFP into the FRT sites encoding plasmid 
Replacement of luciferase with EYFP-FRT in the pBI-L vector 
Cloning of the AML  cDNA into the lox? sites encoding plasmid 
Cloning of the foxed AML  cDNA into the pBI-EYFP vector 
Two responsive constructs with different isoforms of AML1 (A and B) were 
generated. Restriction sites marked with asterisks had generated 5' overhangs which 
were filled-in after digestion. A restriction site marked with an ampersand generated 
3' overhangs which were removed. Gray arrow marks an FRT site; black triangle 
denotes a loxP site; blue left-right arrow marks bTRP. 
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example by crossing these mice with the ZP3-Cre females (Lewandoski et al., 1997). 
The responsive mouse strains are designed to be generated by pronuclear injections. 
Exogenous DNA usually forms an array at the site of integration (reviewed by 
Palmiter and Brinster 1986). The construct is designed to incorporate one frt (jIp 
recognition target) site which is the target for the yeast site-specific recombinase Fip 
(Senecoff et al. 1985; McLeod et al. 1986). Expression of Fip will excise DNA 
flanked by frt sites. Therefore, the number of copies of the transgene may be 
reducedif necessary. This can be achieved either by pronuclear injection of the Fip-
expressing plasmid or by intercrossing the AMLI/EYFP responsive and Fip 
expressing mice. 
The EYFP responsive constructs with two individual AML1 isoforms were 
generated using four step cloning procedure (see Figure 23). The first and second 
cloning steps were aimed to the pBI-EYFP vector generation. For this purpose, the 
0.7 kb EYFP insert was prepared by subsequent treatments of the pEYFP-N1 
plasmid ("Clontech") with the Not I, T4 DNA polymerase and Sac I enzymes. Not I 
linearised the plasmid downstream the EYFP insert. Protruding 5' ends were filled-in 
using the T4 DNA polymerase. Sac I digested the plasmid upstream the EYFP insert. 
Therefore, the insert with the blunt and 3' protruding Sac I compatible ends was 
generated. The EYFP insert was ligated into the 3.1 kb pdFRT vector generated by 
subsequent treatments with the Eco RI, T4 DNA polymerase and Sac I enzymes. The 
pdFRT plasmid (kindly provided by Dr. Igor Samokhvalov, The University of 
Edinburgh) encodes twofrt sites in the head-to-tail orientation. Both Eco RI and Sac 
I enzymes digest the plasmid upstream the frt sites tandem. Subsequent treatment by 
three enzymes generated the vector with the blunt and 3' protruding Sac I compatible 
ends.The recombinant molecules with the EYFP insert upstream thefrt sites tandem 
were selected and used for the second cloning step. During the second cloning step 
the 0.8 kb insert was excised from the pdFRT-EYFP plasmid by subsequent 
treatments with the Age I, T4 DNA polymerase and Spe I enzymes. The Spe I 
restriction site is located between thefrt sites while the Age I site is located upstream 
EYFP. Therefore, the EYFP-FRT insert with the 5' protruding Spe I compatible and 
blunt ends was generated. The insert was ligated into the 4.4 kb vector prepared by 
subsequent treatments of the pBI-L plasmid ("Clontech") with the Pst I, T4 DNA 
polymerase and Spe I enzymes. This treatment released the firefly luciferase insert 
from the vector generating the blunt and 5' protruding Spe I compatible ends. The 
recombinant molecules with the EYFP-FRT insert were selected. These molecules 
are the pBI-EYFP vectors which encode bTRP driving the EYFP reporter gene 
followed by the frt site and the SV40 polyadenylation signal. Furthermore, the pBI-
EYFP encodes MCS followed by the rabbit 3-globin polyadenylation signal. The 
AML1 foxed cDNA was cloned into MCS of the pBI-EYFP vector during the third 
and forth cloning steps. 
During the third cloning step the AIvIL1 foxed cassettes were generated. For 
this purpose, the AML 1A and AML 1B cDNAs were excised from the pLNSX vector 
using the Stu I and Cla I restriction enzymes (see Chapters 4.2 for the pLNSX-AML 1 
plasmids description). This released the 0.8 kb AML1A and 1.4 kb AML113 inserts. 
The 5' protruding Cla I ends were filled-in using the T4 DNA polymerase generating 
inserts with both blunt ends. Then, the inserts were ligated into the 3 kb pROSA 
vector digested with Barn HI and Xba I enzymes. Again, the vector blunt ends were 
generated by the filling-in the 5' protruding Barn HI and Xba I ends using T4 DNA 
polymerase. pROSA is a cloning vector encoding two lox? sites in the head-to-tail 
orientation (kindly provided by Dr. Igor Samokhvalov, The University of 
Edinburgh). The Barn HI and Xba I enzymes digest the pROSA vector between the 
lox? sites. Recombinant molecules with the head-to-tail orientation of the loxP sites 
and insert were selected. The rationale of this selection was that the lox? site 
antisense chain encodes two ATG codons which may act as the translation initiators 
whereby inhibiting the AIv1IL 1 initiator ATG. During the fourth cloning step, the 
foxed 0.9 kb AML1A and 1.5 kb AMLIB inserts were excised from their vectors 
using the Not I and Cla I restriction enzymes. The inserts were ligated into the 5.2 kb 
pBl-EYFP vector pretreated with the same enzymes. Not I and Cla I digested MCS 
between bTRP and the -globin polyadenylation signal. Recombinant molecules 
were selected, and correct sequence of all functional regions was confirmed. 
Therefore, I produced constructs which contain bTRP driving simultaneous 
transcription of the AML  cDNA and EYFP reporter and in which the AML  cDNA 
is foxed. 
6.3.2. Generation of the AML1IEYFF responsive mice 
For pronuclear microinjections DNA inserts that encode AML1 cDNA and 
EYFP driven by bTRP were excised from the vectors using Aat II and Ase I 
restriction enzymes (see Figure 23). The size of the AIVIILIA transgene was 4.05 kb 
and of the AML1B transgene was 4.65 kb. Pronuclear microinjections were 
performed by Mauro Tolaini (National Institute for Medical Research (NIIVIR), 
London). Founders and offsprings from further backcrossings were screened by 
Southern blot hybridisation at ISCR and NIMR. For this purpose, genomic DNA 
isolated from mouse biopsies was digested using the Eco RV enzyme and 
cosecutively hybridised with the exon 3 AML land EYFP probes. The exon 3 AML 1 
hybridisation probe was obtained by PCR while the 0.7 kb EYFP cloning insert was 
used as a hybridisation probe. The Eco RV restriction site is unique in both 
AML1/IEYFP responsive constructs. It is located between the 3' ioxP site and rabbit 
3-globin polyadenylation signal. Since usually pronuclear injected DNA forms a 
multicopy array at the site of integration (reviewed by Palmiter and Brinster 1986) 
three possible versions of integrations should be considered. These are head-to-tail, 
head-to-head and tail-to-tail tandems. The Table 2 shows the length of hybridisation 
fragments obtained by hybridisation of the Eco RV digested AML1AIEYFP or 
AMLIB/EYFP genomic DNA with either the exon 3 AMLI or EYFP probes (see 
Figures 24 and 26). 
Table 3. Length of hybridisation fragments 
Arrangement of integrants Responsive construct 
AML 1 A!EYFP AML 1 B/EYFP  
Head-to-tail 4.05 kb 4.65 kb 
Head-to-head 5.74 kb 6.94 kb 
The length of the AML1AIEYFP fragment used for pronuclear injections is 
4.05 kb. The Eco RV digestion generates two restriction fragments of 2.87 and 1.18 
kb (see Figure 24). The 1.18 kb fragment contains the rabbit (3-globin 
polyadenylation signal while the 2.87 kb fragment contains the rest of the molecule. 
Therefore, both the exon 3 AML1 and EYFP probes hybridise to the 2.87 kb 
fragment only. In the case of the head-to-tail dimerisation, the Eco RV enzyme 
generates restriction fragments of the length of the injected construct (4.05 kb) which 
bind both the exon 3 AML 1 and EYFP probes. In the case of two 2.87 kb fragments 
junction (head-to-head tandem) the probes hybridise to the 5.74 kb fragment. The 
1.18 kb fragment cannot be hybridised to the probes, therefore the tail-to-tail 
tandems give no specific hybridisation bands. 
The length of the AML1B/EYFP fragment used for the pronuclear injections is 4.65 
kb (see Figure 26). The Eco RV enzyme digestes it upstream the rabbit -globin 
polyadenylation signal generating two fragments: 1.18 kb (rabbit 13-globin 
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Figure 24. Possible arrangements of AML1AIEYFP integrants in the genome 
The 4.05 kb AMLIAIEYFP fragment used for pronuclear injections generates the 
1.18 and 2.87 kb restriction fragments upon the Eco RV (EV) enzyme digest (A). 
Three possible arrangements of the transgene DNA in the genome are shown: head-
to-tail (B), head-to-head (C) and tail-to-tail (D) tandems. Hybridisation probes are 
designated by red (exon 3 of AML 1) and yellow (EYFP) lines. Lengthes of 
hybridisation fragments are shown in red while lenghtes of the initial restriction 
fragements are designated by black. Gray arrow marks an FRT site; black triangle 
denotes a loxP site; blue left-right arrow marks bTRP. 
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Figure 25. Southern blot hybridisation of genomic DNA isolated from the 
AML1AIEYFP transgenic mice biopsies 
Genomic DNA was digested using the Eco RV restriction enzyme. The blot was 
hybridised with the exon 3 AML I probe (A), stripped off and rehybridised with the 
EYFP probe (B). 
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Figure 26. Possible arrangements of the AML1B/EYFP integrants in genome 
The 4.65 kb AML1B/EYFP fragment used for pronuclear injections generates the 
1.18 and 3.47 kb restriction fragments upon the Eco RV (EV) enzyme digest (A). 
Three possible arrangements of the transgene DNA in the genome are shown: head-
to-tail (B), head-to-head (C) and tail-to-tail (D) tandems. Hybridisation probes are 
designated by brown (exon 3 of AML 1) and yellow (EYFP) lines. Lengthes of 
hybridisation fragments are shown in red while lenghtes of the initial restriction 
fragements are designated by black. Gray arrow marks an ft/ site; black triangle 
denotes a loxP site; blue left-right arrow marks bTRP. 
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Figure 27. Southern blot hybridisation of genomic DNA isolated from the 
AML1BIEYFP transgenic mice biopsies 
Genornic DNA was digested using the Eco RV restriction enzyme. The blot was 
hybridised with the exon 3 AML 1 probe (A), stripped off and rehybridised with the 
EYFP probe (B). 
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polyadenylation signal) and 3.47 kb (the rest of the molecule). Both exon 3 AML  
and EYFP probes hybridise to the 4.65 kb fragment in the case of head-to-tail 
dimerisation and 6.94 kb fragment in the case of head-to-head dimerisation. No 
specific bands can be produced in the case of tail-to-tail dimerisation. 
Representative results of the AML/EYFP mice genotyping are shown at Figures 25 
and 27. All samples of the Eco RV digested genomic DNA gave bands of 6.5-7 kb 
and 10-11 kb when hybridised with the exon 3 AML  probe. The 10-11 kb band is 
the endogenous AML1 gene since the 10.8 kb Eco RV restriction fragment 
encompasses the exon 3 of AML  in mouse genome according the GeneBank data. 
The origin of the 6.5-7 kb band is not clear, but it may be either the AML2 or AML3 
gene fragment hybridised to the AML  probe. 
Figure 25 shows results of genotyping of the AML1A!EYFP mice. 3 out of 
10 genotyped mice are transgenics (samples 2, 9 and 10). Transgenic DNA is 
arranged into head-to-head tandems in all transgenic mice (5.74 kb hybridisation 
band) and into head-to-tail tandems in the mice 2 and 10 (4.05 kb hybridisation 
band). These bands were hybridised to both exon 3 AML1 and EYFP probes. All 
transgenic samples contain extra-bands of different lengths. This may be caused by 
integrants at margins of arrays which may give a hybridisation band of any length, 
several sites of integration that increases the number of marginal integrants and 
variability of extra-bands, (iii) integration of incomplete copies of the construct. 
Figure 27 shows results of genotyping of the AML1B/EYFP mice. 3 mice 
(83, 84 and 92) are transgenics. All of them contain the head-to-head tandems (6.94 
kb hybridisation band), and the mice 92 contains the head-to-tail tandem (4.65 kb 
hybridisation band). The 6.94 kb transgenic specific band coincides with the 6.5-7 kb 
common band when hybridised with the exon 3 AMLI probe. Therefore, re-
hybridization of the blots with the EYFP probe is necessary to detect the 6.94 kb 
transgenic specific hybridisation band. 
6.3.3. Doxycycline inducible EYFP expression in responsive mice 
All further test experiments with the AML I /EYFP responsive mice to detect 
functional activity of the transgene were performed and results were kindly provided 
by Drs Nicky Harker and Dimitns Kioussis (NJMR, London). The AML1/EYFP 
responsive mice were intercrossed with the CD2-rtTA regulatory mice containing the 
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rtTA transgene (Gossen et al. 1995) driven by the human CD2 promoter (Legname et 
al. 2000). The CD2 promoter is active in all T-cells beginning from the DN stage 
(reviewed by Springer 1990). Induction of the EYFP reporter expression by 
doxycycline in double transgenic mice was tested (see Figure 28). For this purpose, 
mice received 1 mg of doxycycline per I g of food for the duration of 4 days. After 
that, the mice were sacrified and single cell suspensions prepared from their thymi. 
Following staining with anti-CD4 and anti-CD8 antibodies the cells were analysed 
by flow cytometry. Administration of doxycycline induced the EYFP expression in 
all analysed cell populations (see Figure 28A); whereas no EYFP expressing cells 
were found in the absence of doxycycline (see Figure 2813). The difference in the 
levels of EYFP expression between cell populations presumably reflects changes in 
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Figure 28. Doxycycline induces EYFP expression in thymocytes of double 
transgenic mice 
(kindly provided by Dr. Nicky Harker) 
AIVIIL 1 A/EYFP-rtTA double transgenic mice got 1 mg of doxycycline per I g of food 
for 4 days (A) while the control group of mice got no doxycycline (B). Single cell 
suspension of the mouse thymocytes was stained with anti-CD4 and anti-CD8 
antibodies and analysed by flow cytometry. CD4/CD8 dot plot is shown for total 
thymus (center). Histograms demonstrate EYFP expression in DN (double negative), 
CD4/CD8 SP (single positive) and DP (double positive) thymic cell populations. The 
percentage of the EYFP positive cells in each cell population is indicated. 
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Chapter 7: RESULTS 
Inducible expression of the AMLI isoforms: 
Tet-On/HPRT gene expression system 
7.1. Introduction 
The AML1/rtTA regulatory ES cells were generated but difficulties in 
proving functionality of these cells were experienced. It became clear that generating 
a reliable regulatable system would be a problem and I started to search for an 
alternative solution. At that time, a paper describing an elegant regulatable system 
(Tet-On/HPRT system) was published (Kyba et al. 2002). Therefore, the strategy 
was changed and a new Tet-OnIHPRT system for inducible regulation of AML 1 
isoforms was designed based on this system. 
As other tetracycline inducible systems, the Tet-OnII-IPRT system consists of 
two genetic elements (regulatory and responsive) integrated in the genome. The 
original Ainv15 cells are designed to introduce any cDNA and make its expression 
tetracycline-inducible. The regulatory element of the Tet-On/HIPRT system is rtTA 
(NLS-rtTA) targeted into ubiquitously expressed ROSA26 gene locus of ES cells 
(Gossen et al. 1995; Zambrowicz et al. 1997) (see Figure 29). Therefore the system 
should be working in all cell lineages differentiated from ES cells. The responsive 
element of the Tet-OnIHPRT system consists of TRP followed by the lox? site, 
ANeo transgene and PGK (phosphoglycerate çinase) polyadenylation signal. They 
are integrated into the 5' end of the HPRT locus of the ROSA26-rtTA cells and form 
the HPRT homing site for the exogenous cDNA targeting. The ANeo transgene is a 
non-functional deletion mutant of the Ned gene. It lacks nucleotides encoding the 
first five N-terminal amino acids (including the initiator ATG) of the Neor  protein. 
Therefore, the original Ainv15 cells are G418 sensitive. 
A tetracycline regulatable transgene can be introduced into AinvlS cells using so-
called single lox? targeting strategy, based on the Cre-mediated recombination 
between chromosomal and extrachromosomal lox? sites (reviewed by Sauer 2002). 
In AinvlS cells loxP site is introduced into the HPRT homing site. A specially 
designed pLox plasmid which encodes the PGK promoter that is followed by a loxP 
site, ATG codon and cloned cDNA of interest is used for integration of the cDNA 
into the genome of Amy 15 cells. Cre catalyses recombination between the 
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Figure 29. Tet-On/HPRT gene expression system 
Ainvl5 ES cells contain the rtTA transgene targeted into the ROSA26 gene locus. 
They also contain HPRT homing site which consists of TRP, loxP site, ANeo 
transgene and PGK polyadenylation signal which are targeted upstream of the HPRT 
gene locus. Cre recombinase catalyses site-specific recombination between the loxP 
sites in the HPRT homing site and pLox plasmid. The pLox plasmid encodes the 
PGK promoter, initiator ATG, cDNA of interest and SV40 polyadenylation signal. 
Upon Cre-mediated DNA insertion of TRP driving cDNA into the I-IPRT homing 
site the functional Neor  gene is restored since the PGK promoter and initiator ATG 
are incorporated upstream the ANeo transgene. As a result Ainvl5 cells become 
G418 resistant and can be selected. 
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extrachromosomal (plasmid) and chromosomal loxP sites if the Ainv15 cells are 
coelectroporated with the pLox and Cre-expressing plasmids. As a result the cDNA 
integrates into the HPRT homing site (see Figure 29). In correctly recombined clones 
the functional Neor  gene restores and these cell clones can be selected in presence of 
G418. Since the cells also contain rtTA, the cDNA expression can be induced by the 
doxycycline. The Tet-On/HPRT gene expression system has been successfully 
employed to investigate the role of HoxB4 and STAT5 gene in the haematopoietic 
differentiation (Kyba et al. 2002; Kyba et at. 2003). 
The integrated cDNA is foxed and can be excised in presence of Cre-
recombinase. Excision of the cDNA is an intramolecular reaction and therefore may 
prevail over the intermolecular insertion reaction. However, once site-specific 
recombination restores the functional Ned gene selection of these rare G418 resistant 
clones becomes practically achievable. Both random integrants and non-transfected 
cells remain drug sensitive and disappear in presence of G418. The single loxP site 
targeting strategy has been successfully employed in both yeast and mammalian cells 
(Sauer and Henderson 1990; Fukushige and Sauer 1992). It has been shown that the 
complete elimination of random integrants may be achieved if the recombination 
event is necessary for the Neor  both transcription and translation restoration. Another 
important feature of the single loxP site targeting strategy is that one cDNA copy 
only is integrated into genome (Fukushige and Sauer 1992). This system ensures 
efficient and standard site-specific integration of exogenous cDNA of interest and 
therefore eliminates variability between clones. 
7.2. Generation of the gene targeting constructs 
Plasmids and Ainv15 cells for the Tet-OnIHPRT gene expression system 
were kindly provided by Dr. George Daley (USA). Before starting molecular cloning 
I sequenced functional regions of all plasmids and found two unexpected features of 
the pLox plasmid: (i) GC insertion in the loxP site and (ii) an ATG triplet upstream 
MCS (see Figure 30). In order to check the structure of the corresponding loxP site 
within the HPRT gene locus of Ainv15 cells I isolated genomic DNA and the 238 bp 
fragment encompassing loxP site was amplified by PCR and cloned into the pCR2. 1 
vector for TA cloning (Invitrogene). Bacterial colonies remaining white on the IPTG 
X-gal containing medium were picked up, propagated and their plasmid DNA was 
isolated and sequenced. All three clones showed no difference in the 238 bp insert 
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Figure 30. Sequence of the pLox plasmid 
Fragment of the pLox plasmid sequence is shown. The lox? site contains the GC 
insertion (red bracket). The ATG triplet is underlined (blue line). 
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structure and no mutation in the lox? site (see Appendix for the sequence). However, 
since the same GC insertion in the extrachromosomal lox? site employed in the 
single lox? site targeting strategy was previously described in the literature 
(Fukushige and Sauer 1992), it is conceivable that the mutation favours Cre-
mediated site-specific integration over excision and was introduced into the pLox 
plasmid deliberately. 
The upstream ATG triplet has no Kozak consensus sequence (Kozak 1987; 
Kozak 1989). However ATG codon without Kozak consensus sequence can be 
functional (Ho et al. 1995; Tucker et al. 2001). Therefore, the extra ATG in the pLox 
plasmid was substituted for the ATT codon in order to avoid competition with 
downstream AML1 translation initiating codon. For this purpose, the pLox plasmid 
was subsequently treated with the Sph I, T4 DNA polymerase and Kpn I enzymes 
(see Figure 31). The Sph I enzyme linearised the plasmid within the 3' end part of 
the lox? site. T4 DNA polymerase removed the 3' protruding ends. The Kpn I 
enzyme digested the plasmid MCS. Therefore, a linearised vector with the blunt and 
3' protruding Kpn I compatible ends was generated. An adaptor was ligated into the 
vector. The adaptor had the blunt and 3' protruding Kpn I compatible ends thereby 
ensuring its directional cloning. Furthermore, the adaptor contained the Sna BI 
restriction site used for the recombinant molecules screening. An original lox? site 
with the GC insertion was restored into the modified plasmid called pLoxm. The 
upstream ATG triplet was substituted for the ATT one. 
The constructs for the site-specific recombination were generated using two 
step cloning procedure (see Figure 32). First, the AML 1A and AML IB cDNAs were 
excised from the pLNSX vector using the Stu I and CIa I restriction enzymes which 
released 0.8 kb (AML1A) and 1.4 kb (AMIL1B) inserts (see Chapters 4.2 for the 
pLNSX-AMLI plasmids description). The inserts were ligated into the 3.6 kb pLoxm 
vector digested with the Sna BI and Acc I restriction enzymes. These restriction 
enzymes released the NeorEGFP  insert from the pLoxm vector. Sna BI generated 
blunt ends compatible with the Stu I ones, while Acc I generated the 5' protruding 
CIa I compatible ends. Therefore, the inserts were cloned directionally into the 
vector. Second, the 1.4 kb ECMV JIRES fragment was excised from the pPGK-Puro-
IRES-EGFP plasmid (kindly provided by Atif Suleman, University of Edinburgh) 
using the Not I restriction enzyme and ligated independently into the 4.4 kb 
(pLoxmAMLA) and 5 kb (pLoxmAMLlB) vectors linearised using the same 
enzyme. Not I digested the pLoxmAMLl vectors downstream the AMLI insert. 
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Figure 31. Modification of the pLox plasmid 
The pLox plasmid was digested using the Sph I restriction enzyme (the Sph I 
recognition site is shown by green), 3' protruding ends were removed using T4 DNA 
polymerase, and the plasmid was digested again using the Kpn I restriction enzyme 
(the Kpn I restriction site is shown by blue). An adaptor (shown by purple) with the 
blunt and 3' protruding Kpn I compatible ends was ligated into the linearised 
plasmid. The ATG triplet at the 3' end of the lox? site was substituted for ATT in the 
modified molecule. The lox? site is shown by bold. The GC insertion in the lox? site 
is shown by capital letters. The Sna BI recognition site is underlined. 
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Figure 32. Diagram of the two steps cloning of the constructs for site-specific 
recombination. 
Cloning of AML 1 cDNAs into the pLoxrn vector. 
Cloning of the IIRES-EGFP insert into the pLoxm-AML1 vector. 
Two constructs with different isoforms of AML 1 (A and B) were generated. 
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Recombinant molecules with the head-to-tail orientations of AML 1 and EGFP were 
selected. All functional regions of the constructs were sequenced before targeting. 
7.3. Targeting of the Ainv15 cells 
Ainvl5 cells were co-electroporated with the pLoxm-AML1A (or B) and 
pSALK-Cre plasmids. The pSALK-Cre plasmid encodes Cre recombinase driven by 
CMV promoter. Two days after electroporation G418 (final concentration 0.35 
mg/mL) was added to cells. Resistant clones were selected and split into two wells of 
a 12-well plate each. Doxycycline (final concentration 1 igImL) was added to one of 
two wells. 48 hours later, the EGFP expression was analyzed by flow cytometry (see 
Figures 33 and 34). In all 12 analysed clones EGFP expression was induced that 
demonstrated high efficiency of the single loxF targeting strategy. Two AML 1 A and 
two AML 1 B overexpressing clones were selected for further experiments. For these 
clones doxycycline induction was tested independently three times. 65-75% of cells 
expressed EGFP upon the doxycycline addition. A very small number of EGFP 
positive cells have been found in the absence of doxycycline. Thus, the Tet-
OnIHPRT gene expression system ensures low background expression which can be 
significantly induced by the doxycycline. 
7.4. Self-renewal abilities of Ainv15 cells and its derivatives 
In my initial experiments overexpression of AML1 cDNA isoforms using 
episomal vectors resulted in growth inhibition of undifferentiated ES cell colonies. 
Using the Tet-On!HPRT gene inducible system constructed on the basis of Amy 15 
cells the cytotoxic effect of AMILl can be more precisely addressed. For this 
purpose, the equal numbers of the AinvlS -AML IA (and B) and Ainvl5 control cells 
were plated at low density into 6-well plates with medium containing LIF and 
different amount of doxycycline (see Figure 35). Doxycycline was used at 
concentrations of 5, 10, 50, 100 and 1000 ng/mL. After 10-14 days of culture self-
renewal capacity of the ES cell was assessed using staining for alkaline phosphatase 
activity. Differentiated ES cells contain no alkaline phosphatase activity whereas the 
enzyme is highly active in undifferentiated ES cells (Berstine et al. 1973). This 
experiment was repeated three times. The size and number of the Ainvi 5 cell 
colonies were higher than those of the Ainvl5-AML1A (and B) cells both with and 
without doxycycline. Subsequent alkaline phosphatase staining showed that the 
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Figure 33. Flow cytometric analysis of EGFP expression in Ainv15-AML1A cells 
AinvlS-AML1A (A, B) and Ainvl5 (C, D) control cells were cultured with (A, C) or 
without doxycycline (lp.g/mL) (B, D) for 48 hours. Dead cells were stained with 
propidium iodide and gated out. Percentage of live EGFP positive cells is indicated. 
FL 1-H channel detects EGFP whereas FL2-H channel detects autofluorescence. The 
data are representative of three independent experiments. 
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Figure 34. Flow cytometric analysis of EGFP expression in Ainv15-AML1B cells 
Ainvl5-AML1B (A, B) and Ainv15 (C, D) control cells were cultivated with (A, C) 
or without doxycycline (ljiglmL) (B, D) for 48 hours. Dead cells were stained with 
propidium iodide and were gated out. Percentage of live EGFP positive cells is 
indicated. FL1-H channel detects EGFP whereas FL2-H channel detects 
autofluorescence. The data are representative of three independent experiments. 
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Figure 35. Self-renewal abilities of the Ainv15-AML1A (and B) and Ainv15 cells 
cultivated at different concentrations of doxycycline 
Amy 15 (A), Amy 15 -AML 1 A (B) and Ainvi 5-AML 1 B (C) cells were grown at 
different concentrations of doxycycline: 
well 1 - no doxycycline 
well 2-5 ng/mL doxycycline 
well 3 - 10 ng/mL doxycycline 
well 4— 50 ng/mL doxycycline 
well 5 - 100 ng/mL doxycycline 
well 6— 1000 ng/mL doxycycline 
Alkaline phosphate activity of the cells was assayed on the tenth (A) or fourteenth 
(B, C) day of growth. The data presented are representative of three independent 
experiments. 
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(and B) (see Figure 35). The reduced proliferation abilities of Ainvl5-AML1A (and 
B) cells might be caused by the following reasons: (i) the cells underwent more 
manupilation (including an extra-electroporation) in vitro, (ii) exogenous DNA 
inserted into the HPRT locus of Ainvl5-AIvIL1A (and B) cells might affect the cells 
growth abilities. Doxycycline induced overexpression of the transgenes affected the 
self-renewal abilities of the Ainvl5-AM1L1A (and B) cells. The number and size of 
the Ainvl5-AMLIB alkaline positive colonies were highly reduced if the cells had 
been cultured with high concentration of doxycycline. Similar but more moderate 
effect was observed in Ainvl5-AML1A cells in the presence of doxycycline. 
Doxycycline did not influence colony formation by the parental AinvlS cells. 
However, since the Ainvi 5 cells growth capacity was much higher than that of the 
Ainvl5-AML1A (and B) cells the moderate influence of doxycycline on the self-
renewal ability of the AinvlS cells could not be noticed in this experiment. 
7.5. AML1 overexpression does not induce apoptosis in ES cells 
I then tested to see if the growth inhibitory effect of the AML  
overexpression on the undifferentiated ES cells is caused by the AML 1-mediated 
apoptosis induction. To this end parental Ainvl5 cells and derivative AML1 cDNA 
containing clones were co-stained using the fluorochrome-conjugated annexin V and 
7-AAD (7-amino-actinomycin D). Aimexin V is a phospholipid binding protein 
which preferentially interacts with phosphatidylserine in the presence of calcium 
cations. Phosphatidylserine is usually located in the inner leaflet of the plasma 
membrane but is translocated to the outer layer during early stages of apoptosis 
(reviewed by Vermes et al. 2000). Co-staining using a fluorochrome-conjugated 
annexin V and 7-AAD allows discriminating between live, early and late apoptotic 
and necrotic cells. 7-AAD penetrates cells with damaged plasma membrane (dying 
or dead cells) and binds DNA (Schmid et al. 1992). Neither annexin V nor 7-AAD 
can stain viable cells. Plasma membranes of early apoptotic cells is not penetratable 
for 7-AAD, but their inner leaflets contain phosphatidylserine, these cells are annexin 
V positive but 7-AAD negative. Membranes of late apoptotic, necrotic and dead cells 
are damaged that results in staing by both annexin V and 7-AAD. 
Undifferentiated AinvlS, Ainvl5-AML1A and B cells were incubated with 
or without doxycycline (final concentration 1 .tg!mL) for three days. After that, the 
cells were co-stained using the PE (phycoerythrin) —conjugated annexin V and 7-
AAD in the presence of calcium cations and analysed by flow cytometry (see Figures 
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36, 37 and 38). The experiment was repeated three times. Doxycycline induced 
AML1 overexpression did not increase apoptosis in the cells. Furthermore, FACS 
analysis showed that the most of the AMIL1/EGFP positive cells were viable. 
7.6. Influence of the AML1 overexpression on the ES cells hematopoietic 
differentiation in vitro 
The original Ainv15 cells and AML1/EYFP containing derivative clones 
were assayed in haematopoietic differentiation assay (see Figures 39 and 40). ES 
cells hematopoietic differentiation in vitro is routinely performed in semi-solid 
medium (0.9% methylcellulose) with cytokines and growth factors (Wiles and Keller 
1991). For this purpose, undifferentiated ES cells or pre-differentiated EBs were 
plated into bacterial low adhesive dishes with differentiation medium in absence of 
LIF. The medium is supplemented with erythropoietin, IL-6, IL-3, SCF, transferrin 
and insulin. However, semi-solid medium is unsuitable for doxycycline induction, 
since addition and removal of the doxycycline is not easily achievable. Therefore, a 
modified in vitro hematopoietic differentiation assay has been set up (see Figure 39) 
(Kyba et al. 2002; Kyba et al. 2003). The ES cells were predifferentiated in hanging 
drops for 2 days. The cells descend to the nadir of the drop by gravity and form an 
aggregate. As a result a single EB is formed per drop. Equal number of cells in each 
drop ensures relative uniformity of EBs. After formation of EBs for two days the 
hanging drops were washed out and EBs were cultured in a liquid medium in 
absence of LIF for 6 days. During the culture period the EBs were rotated to prevent 
them from adhering to the plates. Doxycycline (final concentration 1 .tg/mL) was 
added to the liquid cultures on the fourth day, at the critical point when 
haemangioblasts are formed (Choi et al. 1998; Kyba et al. 2002; Kyba et al. 2003). 
After two days culture with doxycycline the EBs were harvested and disrupted with 
trypsin. The cells were plated into methylcellulose with cytokines and growth factors 
for hematopoietic differentiation. No doxycycline was added to the methylcellulose 
cultures. Haematopoietic colonies were scored on the fourteenth day of culture. The 
experiment has been repeated three times. 
The EGFP expression was observed in both Ainvl5-AML1A and Ainvl5-
AMIL1B EBs shortly after doxycycline addition (see Figure 3913). No green 
fluorescence was observed in any of the engineered cells without induction. All 
tested cell lines were capable of generating haematopoietic colonies (see Figures 39C 
and 40). All of them produced 30-50 hematopoietic colonies per 104 plated 
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Figure 36. AML1A overexpression does not induce apoptosis in undifferentiated 
Ainv15 cells 
Ainvl5-AML1A cells were incubated with (A, C, E) or without doxycycline (B, D, 
F) for 3 days. Live, early and late apoptotic and necrotic cells were discriminated 
using the annexin V and 7-AAD co-staining (A, B). Live cells are double negative, 
early apoptotic cells are aimexin V positive and 7-AAD negative, late apoptotic, dead 
and necrotic cells are double positive. EGFP positive cells were gated as RI (C, D) 
and distribution of live, early and late apoptotic and necrotic cells in the green 
fluorescent cell population was determined (E, F). Percentage of stained cells is 
shown in each quadrant of dot plots A, B, E and F. 
124 































Figure 37. AML1B overexpression does not induce apoptosis in undifferentiated 
Ainv15 cells 
All designations are as for Figure 36. 
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Figure 38. Annexin V and 7-AAD co-staining of Ainv15 cells 
All designations are as for Figure 36, but green cells were not gated since the Ainvl5 
cells do not express EGFP. 
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2 days 	 Liquid culture: 6 days Mtc culture: 14 days 
Figure 39. Scheme of the Ainv15 cell hematopoietic differentiation in vitro assay 
Embryoid bodies were formed in hanging drops for two days. After that they 
were transferred in liquid culture and doxycycline (1 jig/mL) was added on the 
fourth day. Two days later embryoid bodies were disrupted and the cells were plated 
into methylcellulose (mtc) containing medium with cytokines. No doxycycline was 
added into the methylcellulose containing medium. 
A microphotograph of Ainvl5-AML1A EBs incubated for two days with 
doxycycline. The scale bar represents 250 tm. 
A hematopoietic colony differentiated from the Ainvl5-AML1A cells by the 
fourteenth day of the methylcellulose culture. The scale bar represents 250 tm. 
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lilk iii: 
Ainv15-AML1A Ainv15-AMLIB 	Ainv15 
Figure 40. Overexpression of AML1 isoforms does not significantly influence ES 
cell hematopoietic differentiation in vitro. 
AML1A (or B) individual isoforms were overexpressed in EBs presumably during 
differentiation of haemangioblast. After that the cells were plated into the 
methylcellulose medium with cytokines and growth factors. Hematopoietic colonies 
were scored on the fourteenth day of culture. "+" and "-" designate whether 
doxycycline (1 .tg/mL) has been added to pre-differentiated cells. Note that in 
control Ainvl 5 cells doxycycline inhibits haematopoitic colony formation. Different 
bar colours demonstrate individual types of hematopoietic colonies: erythroid (red), 
myeloid (purple) and endothelial (yellow). Each bar represents the mean value of 
three independent experiments (n=3). Error bars show standards errors. 
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predifferrentiated cells. The total number of hematopoietic colonies did not vary 
significantly between cell lines. The number of Ainv15 and Ainvl5-AML1A 
hematopoietic colonies was slightly decreased if doxycycline was added. However, 
no difference between induced and uninduced cultures is observed in AML1B 
overexpressing cells. Erythroid, myeloid and endothelial colonies were scored 
independently. The number of colonies of each type did not vary significantly 
between induced and non-induced cell populations. Therefore, I concluded that the 
AML1B overexpression might slightly induce hematopoietic differentiation that 
abandons doxycycline inhibition. However, this requires further elucidation. 
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Chapter 8: DISCUSSION 
AIvIL1/Runxl is a Runt domain containing transcriptional regulator which is 
necessary for the development of the definitive hematopoietic system. However, a 
conditional knockout mouse model has shown that AMLI is not crucial to maintain 
haematopoietic stem cells (HSCs) in adult bone marrow. The mouse survives upon 
induced deletion of AML 1, only megakaryocytic and lymphoid differentiation are 
dramatically affected (Ichikawa et al. 2004). The human AML  genomic locus spans 
260 kb and contains 12 exons. It is regulated by two promoters: distal and proximal. 
Furthermore, this locus produces a number of splice isoforms of which short isoform 
which lacks the C-terminal transcription activation domain attracted special 
attention. 
In this study I concentrated on two AML1 isoforms. The long AML1B 
isoform contains both the Runt (DNA binding) and transactivation (TA) domains 
while the AML 1 A short isoform encodes the TA domain only. I hypothesised that 
while the AML 1B long isoform promotes haematopoietic differentiation the AML 1A 
short isoform plays a dominant-inhibitory role and perhaps promotes self-renewal of 
immature haematopoietic progenitors. The main goal of this project was to generate 
model ES cell lines and mouse strains overexpressing the AML1 isoforms and to 
carry out initial assessment of the AML1 overexpression influence on the 
haematopoietic development. 
First, an attempt to constitutively overexpress individual isoforms of AML 1 
in ES cells was undertaken. For this purpose, puromycin resistant episomal vectors 
which can replicate autonomously in eukaryotic cells harbouring polyoma large T 
antigen were used. The E14/T ES cell line constructed previously by Dr. Ian 
Chambers was used for this purpose (Aubert et al. 2002; Chambers et al. 2003). I 
found that these cells supertransfected with control vectors with or without an EGFP 
insert gave a large number of puromycin resistant undifferentiated colonies (see 
Figure 9). However, AML1A and AML1B supertransfected cells gave few or no 
colonies, respectively, indicating that AML1 has some cytotoxic effect in ES cells. 
The absence of puromycin resistant colonies cannot be caused by inhibitory effect of 
AML 1 on proper function of IRES which drives expression of Puror,  since the same 
design of the vector was successfully used for initiation of the EGFP translation in 
bi-cistronic vectors (see Figures 33 and 34). These data contrasted a previously 
published study which reported that overexpression of AML1 isoforms in ES cells 
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does not affect their growth (Aziz-Aloya et al. 1998). In this paper ES cells were 
stably transfected with AMLI cDNAs driven by a PGK promoter. Following drug 
selection resistant colonies were obtained and expression of isoforms was confirmed 
by Northern and Western blotting. However in my experiments AMLI is likely to be 
expressed at much higher level since (i) a strong composite CAG promoter was used 
and (ii) high number of copies of the episome which is not influenced by chromatin 
context due to lack of integration into genome is maintained in the cells. Indeed, 
episomal vectors which contain the CAG promoter give 10 times higher level of 
cDNA expression than analogous episomal vectors with the PGK promoter in ES 
cells (Niwa et al. 1998). In line with that it has been shown that the functional 
efficiency of Cre recombinase driven by the CAG promoter in recombination 
experiments was 3-4 times higher than in case when PGK promoter was used (Araki 
et al. 1997). Furthermore, it has been assessed previously that about 5-10 copies of 
the episomal vector per cell is normally maintained by supertransfected cells 
(Gassrnann et al. 1995). However, this number may be underestimated due to low 
efficiency of recovery of episomal vectors during the isolation procedure. It is likely 
that the number of copies of the AMLI expressing transgene in the previous study 
was not much higher than one copy due to specific conditions used for ES cell 
electroporation (Aziz-Aloya et al. 1998). Therefore, the level of AMLI expression 
might not be sufficient to inhibit ES cell growth. Therefore, it is likely that ES cells 
can tolerate relatively low levels of overexpressed AMLI but are inhibited by high 
levels of AMLI expression. Therefore, it would be useful to use regulatable AMLI 
expression system to analyse biological effects of this gene. This became next aim of 
this research. 
Over the last decade a few systems have been published which allow 
regulatable expression of genes of interest (Wang et al. 1994; Gossen et al. 1995; No 
et al. 1996). I choose the most advanced Tet-On inducible gene expression system to 
express AMLI in an inducible manner. The basic system consists of the chimaeric 
transcriptional transactivator rtTA2SM2  which binds TRP upon the doxycycline 
addition. This system is tightly regulated. It shows no background expression of the 
reporter gene in the absence of doxycycline which is upregulated up to 4-5 orders of 
magnitude upon doxycycline induction. Furthermore, working concentrations of 
doxycycline are below its cytotoxic level and the components of the system do not 
interfere with cellular metabolic pathways. 
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In order to overexpress AML I isoforms in haematopoietic progenitors in a 
regulatable manner in vivo the Tet-On double transgenic system was designed. 
rtTA2SM2 (further referred as rtTA) was targeted into the AML1 gene locus and 
TRP driving individual isoforms of AML1 were planned to be randomly integrated 
into genome. It was expected that fine tuning of the AIvIL1 expression can be 
achieved by variation of the doxycycline concentration. 
The first stage was generation of the regulatory ES cell line and the mouse 
strain. Unpublished data from our and other laboratories suggest that both proximal 
and distal promoters are active in hematopoietic progenitors though it is conceivable 
that the distal promoter turns on upon the proximal promoter activation (Fujita et al. 
2001). Therefore, I supposed that the proximal promoter would be adequate to drive 
AIvIIL 1 cDNA expression in early hematopoietic progenitors. Therefore, the rtTA 
gene expression cassette was targeted into the exon 3 of AML 1 which is the first 
coding exon in proximal transcripts. The cloning strategy was designed so that the 
rtTA gene expression cassette was inserted between the AML1 fourth and fifth 
coding nucleotide in-frame with the initiator ATG codon. The proximal 5' UTR and 
rtTA transgene only can be transcribed from the proximal promoter since 
transcription is designed to be terminated by exogenous SV4OpA and SPA signal 
sequences targeted downstream the rtTA transgene. Therefore, the rtTA targeted 
AML 1 locus cannot produce functional proximal transcripts. Translation of rtTA will 
presumably be initiated by endogenous 1RES located within the proximal 5' UTR 
(Pozner et al. 2000). Transcription from the distal promoter is also terminated by 
downstream exogenous signals following rtTA sequence. Aberrant distal transcript 
contains the exons 1, 2 and relevant introns. The last intron of the distal transcript 
encodes proximal promoter, proximal 5' UTR and the rtTA transgene. A splice 
acceptor site of the intron is located within the coding part of exon 3 downstream the 
exogenous polyadenylation signals and is not transcribed. Therefore, rtTA is unlikely 
to be spliced out from distal transcripts. rtTA encoded by the aberrant distal 
transcript may be translated via the IRES initiated mechanism. However, the real fate 
of the aberrant distal transcripts in a cell requires further investigations. Taken 
together, no functional AML 1 transcripts are expected to be transcribed from the 
rtTA targeted allele unless there is read through the SV40pA and SPA 
polyadenylation signals located downstream of the rtTA transgene. In contrast, at 
least proximal transcripts should encode functional rtTA. 
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rtTA was successfully targeted into the AML1 locus using standard gene 
targeting procedure in ES cells. The ES cells were injected into the blastocyst and 
chimaeric mice were generated. Germ line transmission of the mutant allele was 
further achieved by crossing these chimaenc mice with wild type mice. rtTA 
expression was studied in in vitro differentiating ES cells by RT-PCR (see Figure 
18). The AML1 gene expression was analysed using primers annealing to both distal 
and proximal transcripts. The amplified region was designed to be common for major 
proximal and distal transcripts. However, since distal transcripts are expressed at 
very low levels during the first 8 days of ES cells differentiation (Fujita et al. 2001), 
their expression may not be taken into account in this analysis. Both rtTA and AML 1 
had very similar dynamics of expression that further confirmed correct targeting of 
the AML  locus with rtTA. 
The dynamics of rtTA expression in targeted ES cells suggested that it can be 
used to activate the TRP expression in an AMIL1-specific fashion. I generated two 
series of AML1 responsive constructs to use in this system: (i) luciferase responsive 
constructs for transient transfection (see Figure 19) and (ii) EYFP responsive 
constructs for stable transfection (see Figure 23). The AMLI/rtTA regulatory ES 
cells were transiently transfected with luciferase responsive constructs in order to test 
functionality of rtTA. The reporter activity was determined after 56 hours of 
incubation with doxycycline. However, no induction of the firefly luciferase 
expression was detected despite testing different conditions of transfection and 
culture. This cannot be explained by failure of DNA to penetrate the cells, since high 
expression level of cotransfected Ren Ella luciferase could readily be detected. To 
check if the responsive constructs are functional I used B8 ES cell line with 
integrated functional rtTA generated by Dawn Fisher and Dr. Andrew Smith. In 
these cells the rtTA transgene is targeted into the house-keeping HPRT gene locus. 
Using transient transfection of B8 ES cells with luciferase responsive constructs I 
demonstrated that the firefly luciferase expression was induced 40 fold by 
doxycycline. Therefore, the reason why these responsive constructs were not 
inducible in AMLI/rtTA regulatory ES cells was associated most likely with low 
levels of AMLI/rtTA expression in undifferentiated ES cells. However, although I 
have shown by RT-PCR that dynamics of rtTA expression follows endogenous 
AML1 expression it cannot be entirely ruled out that rtTA protein is unfunctional. 
The analysis of the problem would be very laborious and time-consuming and 
therefore I started to look for an alternative system. By that time the Tet-On!HPRT 
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gene expression system was reported (Kyba et al. 2002; Kyba et al. 2003) and I 
decided to use it to overexpress AML I isoforms in a regulatable fashion. 
Ainvi 5 ES cells which have been used in these publications were provided to 
us by the authors. These cells contain fimctional rtTA targeted in a ubiquitously 
expressed ROSA26 locus. They also contain a homing site for the single loxP site 
targeting into a house-keeping HPRT locus. A specially modified pLox plasmid in 
which a cDNA of interest can be cloned also contains a loxP site. If the pLox and 
Cre-expressing plasmids are cotransfected recombination between chromosomal and 
plasmid loxP sites occurs which results in integration of cDNA into the HPRT 
horning site of Ainvi 5 cells. Although Cre-mediated excision is more favourable 
than Cre-mediated integration rare cells with integrated transgene can effectively be 
selected in presence of G418 since the correct integration results in generation of a 
functional Neor  gene. Therefore, no screening is necessary. 
However, during detailed analysis of the system I found an additional feature 
of these cells that is not described in the literature but can play an important role in 
high efficiency of integration of cDNA into the HPRT homing site in genome. 
Before designing strategy of molecular cloning I sequenced all functional regions in 
the pLox plasmid and found a two nucleotide insertion in the loxP site (see Figure 
30). Further literature search has shown that this mutant loxP site was previously 
used to bias the loxP recombination event towards integration (Fukushige and Sauer 
1992). This had not been described in the papers where the Tet-On!HPRT system 
generation was reported (Kyba et al. 2002; Kyba et al. 2003). Furthermore, contact 
with one of the authors showed that they were not aware of this feature of the system. 
In fact the original system was generated by another group (Wutz et al. 2002). 
Therefore, it may be that the efficiency of integration of cDNA is defined not only by 
restoration of the Ned transgene in correctly recombined cells but also by use of the 
mutant loxP site which favours integration over excision. This is in line with 
experience in our laboratory: an attempt to use a similar approach to integrate a 
sequence via Cre-mediated recombination using a wild type loxP sites failed. 
The analysis of the pLox plasmid has shown presence of an extra ATG 
codon. This codon has no Kozak sequence but still can be functionally active (Ho et 
al. 1995; Tucker et al. 2001). If so it can inhibit the downstream ATG codon 
initiating the cDNA translation. Therefore, before cloning the cDNA I mutated the 
upstream ATG site in the plasmid. 
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In order to monitor upregulation of the AML 1 eDNA the IRES EGFP 
reporter unit was cloned into the pLox plasmid. Therefore, transgene expression can 
be tracked in live cells. This also allows flow sorting of AML  expressing cells. The 
doxycycline induced EGFP expression was observed in all targeted Ainvi 5 cells 
which were selected in presence of G418. Thus, high efficiency of the single loxP 
targeting strategy has been readily observed. In order to test the putative cytotoxic 
effect of overexpression of AM1L1 isoforms, the cells were cultured at increasing 
concentrations of doxycycline. The alkaline phosphatase activity of colonies was 
assayed what allowed identification of undifferentiated colonies. Similarly to 
experiments with episomal vectors, overexpression of the long isoform AML 1 B was 
more toxic than overexpression of the short isoform AML IA. However the cytotoxic 
effect was observed only at high concentrations of doxycycline. 
It has been shown that AML 1 may be involved in regulation of senescence 
and/or apoptosis. AML1 overexpression in mouse embryonic fibroblasts induces 
senescence (Linggi et al. 2002). The AIVILI-mediated transcriptional activation of 
the pl4APF promoter has been demonstrated in human HeLa cells (Linggi et al. 
2002). pl4ARF is an important tumour suppressor gene controlling the function of p53 
which is an important regulator of cell growth and apoptosis. Loss of either p14' RF 
or p53 function prevents growth arrest and/or apoptosis (reviewed by Hiebert et al. 
2003). In order to check if overexpression of AML1 induces apoptosis I co-stained 
cells with Annexin V and 7-AAD upon induction with doxycycline during three 
days. FACS analysis has shown no difference between induced and uninduced cell 
populations. Moreover, the most part of EGFP positive cells was alive. Therefore, it 
is not likely that AML1 overexpression induces apoptosis in ES cells although its 
involvement in the senescence or cell cycle progression regulation is still 
conceivable. 
In order to test the influence of AML1 expression haematopoietic 
development in vitro differentiation of Ainvl5-AML1 cells was undertaken. The 
normally used ES cell differentiation protocol is not suitable for doxycycline 
induction due to technical reasons (addition and removal of an inducer are not easily 
achievable in the semi-solid medium). Therefore, a modified protocol which allows 
short tenTn induction was used. To this end the ES cells were initially plated in 
hanging drops to form embryoid bodies. Following that the EBs were plated in liquid 
differentiation culture in a shaking incubator to avoid adherence to the plate. Use of 
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liquid culture allowed precise exogenous AML 1 induction with doxycycline during 
putative differentiation of the haemangioblast (Choi et al. 1998; Kyba et al. 2002; 
Kyba et al. 2003). After that the EBs were plated in the haematopoietic 
methylcellulose differentiation medium. The AML 1 A overexpression does not 
influence the hematopoietic differentiation in vitro whereas the number of 
hematopoietic colonies appeared to be slightly elevated upon the AML 1B induction. 
Further research is necessary to investigate this issue. It may be that the effect can be 
achieved if AIvIL1 overexpression is induced at later stages of EB differentiation or 
during a more prolonged period of time. It also could be that only certain levels of 
AML 1 expression can cause deviation in haematopoietic differentiation. Such 
examples have been reported in the literature previously (Niwa et al. 2000). 
In addition to the aforementioned analysis a binary AML1 inducible system 
has been generated and undergone initial analysis. The AIMLI/rtTA regulatory mice 
were generated from targeted AML1/rtTA regulatory ES cells. The responsive 
AIvIL1A and AIVIIL1B mice have been generated by pronuclear microinjection in 
collaboration with the Dr. Dirnitris Kioussis laboratory (NIMR, Lodon). For this 
purpose, an EYFP series of the AMIL I bi-directional responsive constructs was used 
(see Figure 23). Therefore, AML1 induction can be monitored by expression of 
EYFP reporter in live cells. Several transgenics mouse lines were obtained by the 
pronuclear microinjections. These mice were intercrossed with the CD2-rtTA 
regulatory mice. Adding doxycycline in food induced EYFP expression in 
thymocytes of the double transgenic mice as expected since CD2 promoter drives 
expression in thymocytes. The double transgenic mice will be used in collaboration 
with D. Kioussis to investigate the role of AML1 role in T-cells development and 
differentiation. 
The use of AML1/rtTA regulatory mice in combination with responsive 
AIVIL1/EYFP mice in future will allow analysis of AML1 overexpression in 
haematopoietic stem and progenitor cells. 
The data obtained in the thesis do not support the original hypothesis stating 
that the AML1A short isoform may promote the hematopoietic progenitors self-
renewal whereas the AML1B long isoform may promote their differentiation. 
Although the number of hematopoietic colonies was slightly elevated upon the 
AMLIB long isoform overexpression in vitro the underlying mechanism (which may 
be promoting either self-renewal or differentiation) requires of further investigation. 
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This may include analysis of early hematopoietic progenitors in vitro in order to to 
determine the exact stage when the difference between induced and uninduced 
populations appears. Furthermore, transplantation of Ainv15 cells and its derivatives 
into lethally irradiated recipients may be done in order to investigate the role of the 
AML 1 isoforms in hematopoiesis in vivo. 
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